A Prospective Open Labelled Phase-II Non Randomized Clinical Trial Drug on Herbal Formulation of Nannari Ver Ooral Kudineer for the treatment of Vali Azhal Keel Vayu (Rheumatoid Arthritis) by Malarvizhi, E
A PROSPECTIVE  OPEN LABELLED PHASE
CLINICAL TRIAL 
“NANNARI VER OORAL KUDINEER
“VALI AZHAL KEEL VAYU
(RHEUMATOID ARTHRITIS)
THE TAMILNADU DR. M.G.R. MEDICAL 
For the partial fulfillment of the requirement for the degree of
 
DOCTOR OF MEDICINE (SIDDHA)
 
 
 
 
 
 
 
 
 
 
 
 
 
DEPARTMENT OF POTHU MARUTHUVAM 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
-II NON RANDOMI
DRUG ON HERBAL FORMULATION OF
” 
FOR THE TREATMENT OF 
” 
 
 
Dissertation submitted to 
UNIVERSITY, CHENNAI
 
(Branch-I Pothu Maruthuvam) 
 
& HOSPITAL
PALAYAMKOTTAI-627 002 
OCTOBER 2019 
 
 
 
ZED 
 
–32 
 
 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
PALAYAMKOTTAI, TIRUNELVELI - 627 002, 
TAMIL NADU, INDIA. 
Ph:0462-2572736/2572737 Fax: 0462 – 2582010 
gsmc.palayamkottai@gmail.com 
 
BONAFIDE CERTIFICATE 
This is to certify that the dissertation entitled “A PROSPECTIVE  OPEN 
LABELLED PHASE-II NON RANDOMIZED CLINICAL TRIAL DRUG ON 
HERBAL FORMULATION OF NANNARI VER OORAL KUDINEER FOR THE 
TREATMENT OF  VALI AZHAL KEEL VAYU (RHEUMATOID ARTHRITIS) ” is 
a bonafide work done by Dr. E.MALARVIZHI (Reg.No.321611004) Govt. Siddha 
Medical College, Palayamkottai in partial fulfilment of the University rules and 
regulations for award for MD (S), BRANCH-I POTHU MARUTHUVAM under 
my guidance and supervision during the academic year OCTOBER 2016-2019. 
 
 
 
Name and signature of the Guide 
Dr. G.SUBASH CHANDRAN, MD (S), Ph.D.,   
Lecturer (Grade II) 
Department of Pothu Maruthuvam, 
Govt. Siddha Medical College,   
Palayamkottai. 
 
 
 
Name and signature of the HOD      Name and signature of the Principal 
Prof. Dr. A.MANOHARAN,MD(S),(Ph.D). Prof. Dr.S.VICTORIA,M.D(S) 
HOD, Dept. of Pothu Maruthuvam,   Govt.Siddha Medical College, 
Govt. Siddha Medical College,   Palayamkottai. 
Palayamkottai 
 
CERTIFICATE-I 
 
Certified that I have gone through the dissertation entitled “A 
PROSPECTIVE  OPEN LABELLED PHASE-II NON RANDOMIZED 
CLINICAL TRIAL DRUG ON HERBAL FORMULATION OF NANNARI 
VER OORAL KUDINEER FOR THE TREATMENT OF  VALI AZHAL KEEL 
VAYU (RHEUMATOID ARTHRITIS)” submitted by Dr.E.MALARVIZHI (Reg. 
No.321611004) a student of final year MD (S), Branch-I, Department of Pothu 
Maruthuvam of this college and the dissertation work has been carried out by the 
individual only. This dissertation does not represent or reproduce the dissertation 
submitted and approved earlier. 
 
 
 
 
 
 
 
  
Head of the Department, 
P.G Pothu Maruthuvam (Branch-I) 
Govt. Siddha Medical College, 
Palayamkottai. 
 
 
 
 
 
 
 
 
 
 
CERTIFICATE II 
 
 This is to certify that this dissertation work titled “A PROSPECTIVE  OPEN 
LABELLED PHASE-II NON RANDOMIZED CLINICAL TRIAL DRUG ON 
HERBAL FORMULATION OF NANNARI VER OORAL KUDINEER FOR THE 
TREATMENT OF  VALI AZHAL KEEL VAYU (RHEUMATOID ARTHRITIS) ”   of 
the candidate Dr.E.MALARVIZHI with registration Number 321611004 for the 
award of M.D (Siddha) in the branch of Pothu Maruthuvam. I personally verified the 
urkund.com website for the purpose of plagiarism check. I found that the uploaded 
thesis file contains from introduction to conclusion pages and result shows percentage 
of plagiarism in the dissertation. 
 
 
 
 
 
 
 
 
Signature of the Guide   Signature of the Supervisor  
P.G Pothu Maruthuvam (Branch-I),  P.G Pothu Maruthuvam (Branch-I), 
Govt.Siddha Medical College,  Govt.Siddha Medical College, 
Palayamkottai.    Palayamkottai. 
 
 
 
 
 
 
 
DECLARATION 
 
I declare that the dissertation entitled “A PROSPECTIVE  OPEN LABELLED 
PHASE-II NON RANDOMIZED CLINICAL TRIAL DRUG ON HERBAL 
FORMULATION OF NANNARI VER OORAL KUDINEER FOR THE TREATMENT 
OF  VALI AZHAL KEEL VAYU (RHEUMATOID ARTHRITIS)” submitted for the 
degree of MD in Siddha Medicine of Government Siddha Medical College, 
Palayamkottai, Tirunelveli, Tamil Nadu (The Tamil Nadu Dr. M.G.R. Medical 
University, Chennai) the record of work carried out by me under the supervision of 
Prof.Dr.A.Manoharan, MD (S), (Ph.D.) Head of the Department of Pothu 
Maruthuvam, and guidance by Dr. G.Subash Chandran , MD (S), Ph.D., Lecturer, 
Govt. Siddha Medical College, Palayamkottai. This work has not formed the basis of 
award of any degree, diploma, associateship, fellowship or other titles in the 
university or any other university or institution of higher learning. 
 
 
 
 
Place : Palayamkottai     Signature of the candidate 
 
Date :       (Dr.E.MALARVIZHI) 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENT 
 
First of all I thank my Almighty God for his showered blessings upon me 
in performing my dissertation works. I express my gratitude to Vice-Chancellor, 
the Tamil Nadu Dr. M.G.R. Medical University, Chennai and Special 
Commissioner, Commissionerate of Indian Medicine and Homeopathy, 
Chennai for granting me to undertake this dissertation work. 
 
My sincere thanks to Prof. Dr.S.Victoria,M.D(S), Principal,  Govt. 
Siddha Medical College, Palayamkottai for permitting me to use all the facilities 
available in this institution. 
 
I extend my sincere thanks to Former Principal Prof.Dr.R.Neelavathi, 
MD(S),Ph.D, Govt. Siddha  Medical College, Palayamkottai for their approval 
and support provided as the for runner of the study. 
 
I also wish to express my sincere gratitude to my supervisor 
Prof.Dr.A.Manoharan,MD,(Ph.D) Head of the Department of Pothu 
Maruthuvam, Government Siddha Medical College, Palayamkottai, Tirunelveli 
for his encouragement, patience, guidance and his excellent supervision during my 
stay at the Department. 
 
I also wish to express my sincere thanks to the guide Dr. G.Subash 
Chandran, MD(S), Ph.D., Lecturer (Grade II) Department of Pothu 
Maruthuvam, Government Siddha Medical College, Palayamkottai, Tirunelveli 
for his encouragement and excellent guidance during my study. 
 
I would take this moment to signify my sincere gratitude to Associate 
Professors Dr.T.Komalavalli, MD(S), Ph.D., Dr.Thomas M Walter, MD(S), 
Lecturers Dr. S.Justus Antony, MD(S), Dr. S.Uma Kalyani, MD (S), Dr. 
P.Sathish Kumar, MD (S), Post Graduate Department of  Pothu Maruthuvam for 
their valuable suggestions for my dissertation work. 
 
I express my thanks to Dr. (Mrs). S.Sutha, M.Sc., Ph.D., Associate 
Professor in Department of Medicinal Botany, Govt. Siddha Medical College, 
Palayamkottai for her suggestions in the botanical aspect of my work. 
 
I thank Prof. Mrs. N.Naga prema, M.Sc., M.Phil., and other technical 
staffs, Department of Biochemistry for helping me in elicting biochemical 
analysis. 
 
I express my thanks to Mrs. T.Poonkodi, M.A., M.L.I.S., Librarian, 
Govt. Siddha Medical College, Palayamkottai for permitting me to utilize the 
college library. 
 
I express my thanks Dr.N.Chidambaranathan, M.Pharm, Ph.D, Vice 
principal, K.M.College of  Pharmacy, Madurai who helped me in carrying out the 
pharmacological Study  of the clinical  trial medicine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONTENTS 
CHAPTER 
NO 
TITLE 
PAGE 
NO. 
 
ABBREVIATIONS  
 
ABSTRACT  
I INTRODUCTION  
 1.1 BACKGROUND 1 
 1.2 AIM AND OBJECTIVE 3 
 1.3 JUSTIFICATION OF RESEARCH 4 
II LITERATURE REVIEW  
 
2.1 FROM SCIENTIFIC JOURNAL 5 
 
2.2 SIDDHA LITERATURE 12 
 
2.3 GUNAPADAM ASPECT OF NANNARI 12 
 
2.4 SIDDHA ASPECT  - VALI AZHAL KEEL VAYU 14 
 
2.5 MODERN ASPECT - RHEUMATOID ARTHRITIS 40 
III MATERIALS AND METHODS  
 
3.1 STUDY AREA AND SETTING 58 
 
3.2 STUDY DESIGN 58 
 
3.3 SELECTION OF PATIENTS  58 
 
       3.3.1 INCLUSION CRITERIA 58 
 
       3.3.2 EXCLUSION CRITERIA 59 
 
       3.3.3 DIAGNOSIS 59 
 
       3.3.4 INVESTIGATIONS 59 
 
3.4 THE PREPARATION OF TRIAL MEDICINE   
       (ANNEXURE-I) 
60 
 
3.5 COLLECTION AND AUTHENTICATION  OF   
       TRIAL MEDICINE (ANNEXURE - VI) 
60 
 
3.6 PRECLINICAL ANALYSIS OF TRIAL MEDICINE 61 
 
3.7 ETHICAL REVIEW  61 
 
3.8 STUDY ENROLMENT 61 
 
3.9 STATISTICAL ANALYSIS 62 
 
IV OBSERVATION AND RESULTS  
 
4.1 PRE CLINICAL STUDY OF NANNARI VER   
       OORAL KUDINEER 
63 
 
       4.1.1 BIOCHEMICAL ANALYSIS 63 
 
       4.1.2 ANTI MICROBIAL ANALYSIS 65 
 
       4.1.3 PHYTOCHEMICAL  STUDY 66 
 
       4.1.4 PHARMACOLOGICAL ACTIVITIES 68 
 
       4.1.5 TOXICITY STUDIES 79 
 
4.2 CLINICAL STUDY 85 
 
4.3 BIOSTATISTICAL ANALYSIS 125 
V DISCUSSION 126 
VI SUMMARY 131 
VII CONCLUSION 133 
 BIBLIOGRAPHY  
 ANNEXURES  
 
ANNEXURE-I        PREPARATION OF TRIAL MEDICINE i 
 
ANNEXURE-II      DEFORMITIES OBSERVED IN  
THE PATIENTS 
iii 
 
ANNEXURE-III     SCREENING COMMITTEE v 
 
ANNEXURE-IV      IEC CERTIFICATE vi 
 
ANNEXURE-V      IAEC CERTIFICATE vii 
 
ANNEXURE-VI BOTANICAL AUTHENTICATION viii 
 
ANNEXURE-VII    RESEARCH METHODOLOGY &   
BIOSTATISTICS 
ix 
 
ANNEXURE-VIII CTRI x 
 
ANNEXURE-IX    CME PROGRAMME CERTIFICATES xi 
 
ANNEXURE-X      JOURNAL PUBLICATIONS xiii 
 
ANNEXURE-XI     PLAGIARISM REPORT xvii 
 
 
 
 
 
LIST  OF  TABLES 
TABLE. 
NO TITLE 
PAGE. 
NO 
1  DISTRIBUTION OF SEX 86 
2  DISTRIBUTION OF AGE 87 
3 DISTRIBUTION OF KAALAM 88 
4 CONSTITUTION OF BODY 89 
5 DISTRIBUTION OF GUNAM 90 
6 DISTRIBUTION OF RELIGION 91 
7 DISTRIBUTION OF PARUVA KAALAM 92 
8 DISTRIBUTION OF THINAI 93 
9 SOCIO-ECONOMICAL STATUS 94 
10 FOOD HABITS 95 
11 FAMILY HISTORY 96 
12 OCCUPATION 97 
13 CLINICAL MANIFESTATION 98 
14 DURATION OF ILLNESS 100 
15 KANMENTHIRIYAM 101 
16 GNANENDRIUM 102 
17 CONDITION OF MUKKUTRAM 103 
 a) CONDITION OF VATHAM 103 
 b) CONDITION OF PITHAM 105 
 c) CONDITION OF KAPHAM 106 
18 INVOLVEMENT OF UDAL KATTUGAL 107 
19 CONDITIONS OF ENVAGAI THERVUGAL 108 
20 NEER KURI 110 
21 NEI KURI 111 
22 ASSESSMENT OF OUTCOME 112 
23 GRADATION OF RESULTS 114 
24 LABORATORY INVESTIGATIONS  
 a) OUT PATIENTS 115 
 b) IN PATIENTS 118 
25 DISEASES ACTIVITY PAIN SCORE  
 
a) OUT PATIENTS 121 
 
b) IN PATIENTS 122 
26 CASE SUMMARY  
 
a) OUT PATIENTS 123 
 
b) IN PATIENTS 124 
LIST  OF  FIGURES 
TABLE. 
NO 
TITLE 
PAGE. 
NO 
1  DISTRIBUTION OF SEX 86 
2  DISTRIBUTION OF AGE 87 
3 DISTRIBUTION OF KAALAM 88 
4 CONSTITUTION OF BODY 89 
5 DISTRIBUTION OF GUNAM 90 
6 DISTRIBUTION OF RELIGION 91 
7 DISTRIBUTION OF PARUVA KAALAM 92 
8 DISTRIBUTION OF THINAI 93 
9 SOCIO-ECONOMICAL STATUS 94 
10 FOOD HABITS 95 
11 FAMILY HISTORY 96 
12 OCCUPATION 97 
13 CLINICAL MANIFESTATION 99 
14 DURATION OF ILLNESS 100 
15 KANMENTHIRIYAM 101 
16 GNANENDRIUM 102 
17 CONDITION OF MUKKUTRAM  
 a) CONDITION OF VATHAM 104 
 b) CONDITION OF PITHAM 105 
 c) CONDITION OF KAPHAM 106 
18 INVOLVEMENT OF UDAL KATTUGAL 107 
19 CONDITIONS OF ENVAGAI THERVUGAL 109 
20 NEER KURI 110 
21 NEI KURI 111 
22 ASSESSMENT OF OUTCOME 113 
23 GRADATION OF RESULTS 114 
 
 
 
 
LIST OF ABBREVIATIONS 
% - Percentage 
i.e., - That is 
RA - Rheumatoid Arthritis 
ESR - Erythrocyte Sedimentation Rate 
ASO - Anti-Streptolysin ‘O’ factor 
TJC 28 - Tender Joints 28 
SJC 28 - Swollen Joints 28 
DAS 28 - Disease Activity Score 28 
VAS - Visual Analog Scale 
gms - Grams 
kg - Kilogram 
mg - Milligram 
dl - Decilitre 
Ml - Milli litre 
Cm - Centimeter 
S E M - Structural Equation Modelling 
ANOVA - Analysis Of Variance 
Hb - Haemoglobin 
TC - Total Count 
DC - Differential Count 
P - Polymorphs 
L - Lymphocytes 
E - Eosinophils 
CRP - C-Reactive Protein 
WBC - White Blood Corpuscles 
RBC -  Red Blood Corpuscles 
HLA -  Human Leukocyte Antigen 
MHC -  Major Histo Compability Complex 
ACPA -  Anti-Citrullinated Peptide Anti bodies 
TNF -  Tumour Necrosis Factor 
IL -  Interleukin 
Anti-CCP -  Anti-cyclic Citrullinated peptide 
MMPs -  Matrix Metalloprotases 
ANA -  Anti Nuclear Anti body 
PIP -  Proximal Interphalangeal Joint 
DIP -  Distal Inter Phalangeal Joint 
MCP -  Metacarpo Phalangeal Joint 
MTP -  Metatarsal Phalangeal Joint 
CMC -  Carpometacarpal Joint 
Ref -  Reference 
CT -  Computerized Tomography 
MRI -  Magnetic Resonance and Imaging 
SLE -  Systemic Lupus Erythematous 
NVOK -  Nannari Ver Ooral Kudineer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ABSTRACT 
 
Vali Azhal Keel Vayu (Rheumatoid Arthritis) is now becoming a common 
disease now-a-days with numbers of suffers increasing day by day. The evidence of 
the disease was derived from  “Sabapathy Manuscript” Noi Naadal Noi Mudhal 
Naadal Thiratu Part-II” 2nd Edition, compiled by Dr. M. Shanmugavelu, B.H.I.M 
[Page No: 623]. The signs and symptoms mentioned in the Literature of Siddha  
closely resembles with “Rheumatoid Arthiritis” in modern medicine. Totally 40 
patients were selected and treated with the trial medicine “NANNARI VER OORAL 
KUDINEER” 90 ml Thrice a day for 30 days.  Reference for trial medicine was taken 
from Gunapadam Mooligai Vaguppu, Pg.No.562,Dr.K.S.Murugesa Mudaliyar. The 
trial drug was subjected to biochemical, anti-micribial, phytochemical , 
pharmacological & toxicological analysis. At the end of the  trial study, the majority 
of the cases showed good clinical improvement. All the relevant reports were 
statistically analysed and found to be significant. 
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CHAPTER  I 
INTRODUCTION 
1.1 BACKGROUND:           
The Siddha medicine is one of the traditional medical system originated 
during pre-vedic period in Southern India. It was founded by a set of people with 
tremendous supernatural powers called “Siddhars”. This system had been developed 
with “Philosophy” or ‘’Thathuvam’’ as its base. Siddhars had given equal importance 
to ‘Vedhanta’ and ‘Sidhanta’. The siddha system includes various sciences such as 
philosopy, yoga, astrology, anatomy, physiology & psychology. The treatment goal 
focusses on body and the mind simultaneously. 
Health is the state of complete well being of physical, psychological, social 
and spiritual components of the body. But onset of diseases causes intervention to this 
state of well being. 
“clk;gh uopapd; capuh uoptu; 
jplk;gl nka;QhdQ; NruT khl;lhu; 
clk;ig tsu;f;Fk; Kgha kwpe;Nj 
clk;ig tsu;j;Nj Dapu;tsu;j; NjNd”  
- jpU%yu; jpUke;jpuk; 
The ultimate aim of Siddhars was to attain eternal bliss. Human body is 
considered to be the media for that purpose. Thus the media must be protected from 
undesired effects such as degenerative changes, diseases and untimely death .For that 
sole purpose, siddhars followed specific type of life style including dietary habit 
which was also clearly mentioned in this system medicine.  
According to siddhars theory, human body is constituted by 5 basic elements 
which also constitute the universe viz .Earth,fire,air,water and ether.  The three 
humors are derived from pancha bootham. By the combination of earth and water, 
kabham is produced. Fire alone forms pitham and  union of air and ether forms 
vatham .The normal functioning  of human body is based on homeostasis of 3 forces 
or 3 humors called Vatham,Pitham And Kapham. 
Among these three ,vatham is placed first .It can be provided by the following 
line,                               
“thjkyhJ Nkdp nflhJ” 
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Any derangements in this homeostasis lead to pathological condition called 
PINI Or NOI.  This is what that Thiruvalluvar  says, 
“kpfpDk; FiwapDk; Neha; nra;Ak; E}Nyhu;  
tspKjyh vz;zpa %d;W” 
By observing the signs and symptoms of the patient we could find the 
disordered humor and the particular aliment could be diagnosed through the specific 
sets of diagnostic methods called Envagai thervugal in which the naadi examination 
is the principal method. According to Yugimunivars Vaidhya Chindamani-800, vatha 
diseases were classified into 80 types . Some authors say that there are 84 vatha 
diseases .Keel vayu comes under of 80 types of vatha diseases . Keel vayu was further 
divided into 10 types in the text of  Siddha Maruthuvam. Vali azhal keel vayu is one 
among the 10 sub division. The Vali azhal keel vayu [Noi Nadal Noi Muthal Nadal 
Thirattu-II  ( Pg No .623) can be correlated in modern medicine as Rheumatoid 
Arthritis (RA). 
RA is a chronic inflammatory multi systemic disease characterized by 
symmetric polyarticular joint involvement in association with extra articular 
manifestation .The disease affects approximately 1% of the world wide population 
and occurs in women 2 to 3 times more frequently than in men.The most common age 
of onset is between 30 and 50 years. The inflammation of the synovium typically of 
the small joints of the hands [MCP and PIP],wrists and feet. The symptoms includes  
pain, swelling, stiffness and can lead progressive joint damage resulting in deformities 
and loss of function, associated organ damage also contributes to severe disability.In 
the management of RA, herbs contribute approximately 50% of currently used crude 
drugs and another 25% is derived from chemically altered natural products. Thus, 
Siddha medicines possess a potential role as the definite alternative therapy in curing 
rheumatoid arthritis. 
So, I have chosen my clinical trial drug as ‘’NANNARI  VER  OORAL  
KUDINEER’’, mentioned in Gunapadam Mooligai Vaguppu Pg.NO.562, 
Dr.K.S.Murugesa Mudaliyar in the management of VALI AZHAL KEEL VAYU 
[Noi Nadal Noi Muthal Nadal Thirattu-II  (Pg No .623)]. 
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1.2 AIM AND OBJECTIVE   
AIM: 
To document the clinical therapeutic efficacy of NANNARI VER OORAL 
KUDINEER  [Internal] in the treatment of VALI AZHAL KEEL VAYU. 
 
OBJECTIVE 
Primary Objective  
To evaluate the clinical therapeutic efficacy of NANNARI VER OORAL 
KUDINEER  [Internal] in the treatment of VALI AZHAL KEEL VAYU 
(RHEUMATOID ARTHRITIS) 
Secondary objective 
1. To adjudge the Bio-chemical, Phyto chemical, Anti microbial analysis of the 
trial drug.. 
2. To evaluate pharmacological parameters such as Analgesic, Anti-
inflammatory and Immunomodulatory actions. 
3.  To evaluate acute and sub-acute toxicity activities of the trial medicine. 
4.  To evaluate additional effects and siddha parameters [Envagai  Thervugal] 
changes   in Vali Azhal Keel  Vayu. 
5. To explore the apt definition, aetiology, clinical features, pathology, diagnosis,   
complication and treatment for Vali Azhal Keel Vayu in Siddha literatures and 
correlation with modern science. 
6. To survey the incidence of the diseases according to age, occupation, socio 
economic status, habits, family history, paruva kaalangal, thinai  and three 
vital humours. 
7. To divulge how the mukkutram and seven udal kattugal are deranged in this 
disease. 
8. To have a detailed clinical investigations. 
9. To use modern parameters to confirm the diagnosis and prognosis of the 
disease. 
10. To rule out any adverse effect of the drug. 
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1.3 JUSTIFICATION OF RESEARCH: 
Over the past two decades, the treatment of RA has been revolutionized by 
advances in the understanding of its pathologic mechanism and the development of 
drugs which target them.These newer medications have shown great promise at 
improving disease outcomes but they come up with notable side effects which can 
pose  long term treatment, difficulties in the perioperative arena and also with 
significant financial cost, of which medication has been a major contributor.As a 
disease that affects primarily women, RA has a major impact on family life and child 
rearing. So consideration for strategies to improve diagnosis, treatment and implement 
more cost effective care was taken before and during the trial.Therefore, current 
therapy of “NANNARI VER OORAL KUDINEER” for RA served the role which 
reduced the impact of diseases in a way by extending the benefits beyond the patient 
himself/herself.  
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CHAPTER II 
LITERATURE REVIEW 
    2.1 FROM SCIENTIFIC JOURNAL:  
TAXONOMY: 
Kingdom  : Plantae 
Division  : Magnoliophytina 
Sub-division  : Magnoliophytina 
Class  : Magnoliopsida 
Sub-class  : Magnoliodae 
Order  : Gentianales 
Sub-order  : Gentianineae 
Family  : Asclepiadiaceae 
Genus  : Hemidesmus 
Species  : Hemidesmus indicus 
 
Macroscopic features of Nannari : 
The roots are dark brown in color with 30 centimeter length and 3-8 
millimeter in diameter on average. Usually,it is thick cylindrical, hard, sparsely 
branched and are provided with few thick rootlets along with secondary roots. 
Cortical layer is present in the wood. Bark is light brownish and showed the 
transverse crack & longitudinal fissure and highly aromatic in nature.(Bonvicini et al. 
2018). 
 
Microscopic features of Nannari : 
Transverse section of roots shows periderm consisting three layers of tissues, 
secondary cortex cork and cork cambium. 
 Cork cells are rectangular, filled with dark brown contents and radially 
flattened. 
 Cork cambium is 2 or 3 layered is filled with deep brown contents which are 
compressed. 
 Secondary cortex contains little 3-4 layers of cells. 
 Secondary phloem ray cells along with several scattered laticiferous ducts and 
sieve elements are also present. 
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 Parenchyma cells contain prismatic crystals of calcium oxalate which are 
filled with starch grain.  
 Cambium is extremely narrow.  
 Xylem is tranverse with narrow medullary rays. 
 Patted marks are seen in vessels and trachieds with absence of piths in central 
area which is occupied by woody tissues (Parthipan et al. 2011). 
 
Chemical constituents : 
Roots of H.indicus are reported to contain chemical constituents like 
 Pregnane glycoside viz.Hemindicusin 
 Coumarinolignoids viz.Hemidesmin-1 and H-hemidesmin-2 . 
 Others – β-amyrin acetate ,α-amyrin, β-amyrin, lupeol acetate,β-sitosterol, 
hexadecanoic acid, hexatriacontane, lupeol octasonate. 
 
Essential oil founds to contain the following constituents: 
 80% of crystalline matter. 
 Glucose 
 Hemidesmol. 
 Hemidesterol. 
 2-hydroxy 4-methoxy benzaldehyde. 
 Others - resin acid, glucoside, α-amyrin triterpene, β-amyrin triterpene, and 
benzaldehyde.(Sethi A et al, 2006 &Austin A 2008) 
 
Pharmacological screening:  
Hemidesmus indicus is a widely used shrub in Indian traditional medicines. 
For wide range of medicinal properties of the H.indicus, considerable efforts have 
been made to verify its efficacy as a curative agent through pharmacological 
investigations. Different experiments in vitro and vivo models convincingly 
demonstrated the ability of H.indicus exhibiting various actions due to its remarkable 
biological activity and bioactive constituents  are as follows(Sneha Dandekar et 
al.(2018), Lalrinpuia et al.(2017) 
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 Analgesic 
 Anti-arthritic  
 Anti-inflammatory 
 Antipyretic 
 Antioxidant 
 Hepatoproductive 
 Immunomodulatory 
 Diuretic 
 Anti-carcinogenic    activities  
 Anti-hyperlipidaemic 
 Anti-ulcer 
 Anti-leprotic 
 Antimicrobial 
 Anti-diabetic 
 
Analgesic activity: 
Farook SM et al.(2011), study showed the hydro-alcoholic extract of 
H,indicus at different doses (100,200 and 300 mg/kg,p.o) in swiss albino mice 
significantly inhibitis writhing response,decrease the licking response in acetic acid 
induced writhing response and Eddy’s hot plate method.A maximal effect was 
observed at 300mg/kg which was comparable to 10 mg of piroxicam per kg body 
weight [b.w] . Gupta et al.(2011 )studies of the aqueous extract of above preparation 
found to possess analgesic property with very low ulcerogenicity and toxicity in 
animal model.  Magaji MG et al. (2008) evaluated the hydro –alcoholic extract of  
100,200 and mg/kg b.w in adult wister rats showed significantly reduces the licking 
response in Eddy’s hot plate method [55-56ºc]. The analgesic effect of the extract 
may therefore be due to either its action on the inhibition of the production of 
algogenic substance or the inhibition at the central level of the transmission of painful 
message. Verma PR et al.(2005), studied Oral administration of ethanolic extract 
[25,50,100 mg/kg ],prior to pain induction ,produced dose-dependent antinociceptive 
effects and blocked neurogenic eand inflammatory pain in the acetic acid 
(writhing),formalin (paw licking) and hot plate tests in mice. 
 
Anti arthritic activity: 
Mehta A et al.(2012), found that H.indicus root has protective activity against 
arthritis and the activity is might be attributed by presence of terpens,sterols and 
phenolic compounds in hydroalcoholic root extract as well as in ethyl acetate 
fraction.The protective effects of hydroalcholic (450mg/kg BW,p.o),ethyl acetate 
(75mg/kg,BW,p.o),Chloroform (60 mg/kg BW,p.o) extact and residual fraction 
(270mg/kg BW,p.o)from roots of H.indicus on arthritis in vitro model in rats were 
studied.There was significant decrease in physical and biochemical parameters 
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supported by good tissue architecture in histopathological analysis. The 
hydroalcoholic extract and ethyl acetate fraction protective effects were coparable 
with methotrexates which were used as positive control. 
 
Anti-inflammatory activity: 
A.Guerrini et al.(2014) Anantamul has demonstrated anti-inflammatory 
activity in laboratory studies mediated by the inhibition of the transcription factor,NF-
kB ,reduction of pro-inflammatory IL-8 exprssion. Shaikh (2011) determined 
ethanolic extracts (100,200 mg/kg) exhibited dose dependent inhibition in various 
subchronic and chronic models of inflammation,and delayed type hypersensitivity 
using egg white iysozyme as an antigen. Vijayalakshmi K et al.(2010) Study 
observed a hydro-alcoholic extract of anantamul at a dose level of 100mg/kg/b.w 
demonstrated good anti-inflammatory activity than indomethacin (a non-steriodal 
anti-inflammatory drug) in a carrageenan –induced hind paw rodent model.   
Lakshman K et al.(2006) observed in carragenan induced paw odema method that 
methanolic roots extract also exhibited significant reduction in volume between 2-4 hr 
after treatment. Periyanayagam K et al.(2004) aqueous extract of H.indicus showed 
significant anti-inflammatory activity when compared to diclofenac sodium gel. Jain 
and Basal et al. (2003), reported that polymorphonuclear leukocytes (PMNL) and 
monocytes treated with Propionnibacterium acnes in the presence or absence of H. 
indicus (5-50 µg/ml) showed a significant suppression of ROS and pro- inflammatory 
cytokines ,two inflammatory mediators in acne pathogenesis. Joseph P et al.(1918), 
studied a saponin from the H.indicus and found to have anti inflammatory activity 
against formalin induced edema. Dutta MK et al.(1982),  revealed that ethyl acetate 
extract of H. indicus root shows much anti-inflammatory effect in acute and subacute 
inflammation .Oral administration of H.indicus root extract blocked both neurogenic 
and inflammatory pains.  
 
Anti –pyretic activity: 
Farook MG (2011) , study showed the anti-pyretic [brewer’s yeast induced 
pyrexia] effect in Wister albino rats (measured as % reduction in body temperature) 
was compared with paracetomol [100 mg/kg orally] .Hydro –alcoholic extract of 
Hemidesmus indicus at the dose of 300 mg/kg caused significant decrease in body 
temperature of rats. Lakshman et al.(2006) determined the standard drug 
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paracetamol 100 mg/kg b.w and H.indicus extract at a dose of 100,200 and 400 mg/kg 
BW reduced the yeast elevated rectal temperature compared to control group. Gupta 
M et al.(2010),observed that aqueous extract of root showed anti-pyretic –analgesic 
property with very low ulcerogenicity and toxicity in animal model. 
 
Antioxitant activity: 
 Zarei M and Javarappa K.M et al. [2012] ,determined H.indicus root extract 
for  its antioxidant properties & found out significant reduction in the oxidative stress 
and thereby toxicity induced by doxorubicin. Santheesh Kumar D et al.(2013), paper 
revealed the aqueous extracts of whole plant of H.indicus showed significant free 
radical scavenging activity which indicates that the plants extracts has antioxidants. 
Kumar G et al.(2008) ,observed that administration of H. indicus extract 500 mg/kg 
/day for 30 days of experiment significantly reduced the level of serum –urea,uric 
acid, creatinine and kidney –thiobarbituric acid reacting substances [TBARS],lipid 
peroxidase and conjugated dienes. Nadana S et al.(2007), studied and postulated that 
in rats with ethanol induced nephrotoxicity, ethanolic extract of H. indicus showed 
potent antioxidant effect and provided protection against free radical mediated 
oxidative stress in kidney.    
 
Hepatoprotective activity: 
Ashaa S et al.(2011), Observed Methanolic root extract of H.indicus (500 
mg/kg ,p.o) showed a remarkable hepatoprotuctive activity against paracetamol 
induced hepatotoxicity. Mookan P et al.(2000), observed that Ethanolic extract of 
H.indicus roots showed protective effect against Rifampicin and Isoniazid [INH] 
induced liver toxicity. Prabakaran M et al.(2000), reported that Oral administration 
of 50% ethanolic extract of H.indicus significantly prevented rifampicin and isoniazid 
induced hepatotoxicity in male wister rat. 
 
Immunomodulatory effects : 
  Kainthla RP et al.(2006), reported that H.indicus extract (1 mg/ml) 
stimulated the proliferation and viability of peripheral blood lymphocytes (PBLs) 
,increased IgG production and adenosine deaminase activity ,and suppressed both 
cell-mediated and humoral components of the immune system. 
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 Diuretic activity: 
Kotnis M.S et al.(2004), reported that aqueous extract of H. indicus root 
extract to diabetic rats,reduced level of glycogen content in muscle tissues was 
significantly improved. Gadge and Jalapure (2011), reported that the aqueous 
extract (400 mg/kg), which caused a marked increase in urinary Na+ and k+ levels 
over 5 hr,was comparable to that of frusimide and hydrochlothiazide.   
 
Anti –cancerous activity: 
Zarei M and Javarappa KM (2012) observed it significantly enhanced 
antitumor activity of three commonly used chemotherapeutic drugs –methotrexate ,6-
thioguanine,cytarabine.  Hiremath SP et al since (1997), study showed the roots 
decoction of H.indicus showed cytotoxic on HepG2 cells.Pasumarthi S et al.(2011), 
The roots methanolic extractsshowed inhibition on colon adenocarcinoma cell line 
with IC 50 60 µg /ml by MTT assay and this may be due to the presence of saponins 
,tannins steroids.Zarei M and Javarappa K.M [2012], reported that H.indicus have 
remarkable anticancer potentials against MCF7 Breast cancer cell lines.H. indicus 
methanolic root extract showed a significant cytotoxic activity against Ehrlich 
Ascities Tumor too. Sultana S et al.(2003) studied extract inhibited tumor growth in 
mouse skin and hence can be considered as a potent chemopreventive agent. 
 
Anti hyperlipidaemic activity: 
            Bopanna KN et al.(1997) ,evaluated Cell culture extracts of H.indicus [CCH] 
administered at a dose of 16 mg/kg showed decreased low density lipoproteins [LDL] 
and very low dencity lipoproteins [VLDL] ,Cholesterol and significantly increased 
high density lipoproteins [HDL] :cholesterol ratio. Saravanan and nalini (2007), 
HMBA (200 µg/kg) showed antihyperlipidaemic activity in ethanol (5 g/kg p.o) 
induced antihyperlipidaemia significantly decreasing plasma and hepatic lipids ,and 
increasing plama Low –density lipoprotein (LPL) concentrations.  
 
Anti- ulcer activity: 
Austin A et al.(2008), studied  established the anti ulcer activity of H. indicus. 
It acts by mucoprotective action and selectively inhibiting prostaglandins .Even 
standard drugs,like- omeperazole, rantidine have less mucoproductive activity than 
H.indicus have.Vishali et al.(2011), the ethonal extract (200,400 mg/kg ) showed 
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ulcer production comparable to that of omeprazole in the indimethacin (20 mg/kg) 
induced ulcer in rat ,possibly due to cytoproductive action or strengthening of vgstric 
mucosa. Nadana S et al (2007),observed Aqueous ethanolic extracts decreased 
formation of gastric and duodenal ulcers by various ulcerogenic procedure and 
cytodestructing agent. 
 
Anti leprotic activity: 
Gupta PN et al.(1981), paper revealed that aqueous extract of H.indicus root 
orally administered at 2% concentration in mice infected with Mycobacterium leprae 
showed delayed in cutaneous hypersensitivity stimulation. 
 
Antimicrobial activity: 
Pandey KK and Dwivedi M et al.(2001),determined  that the drug was found 
to be safe and effective against E.coli ,Bacillus sp ,proteus sp,Klebsiella sp and 
Pseudomonas sp. Hiremath SP et al.(1997), study  showed that chloroform and 95% 
ethanolic extracts of roots of H. indicus posses antifungal activity against Aspergillius 
niger. Das and Devaraj (2006), was  evaluated the chloroform and methanol extracts 
(500-1000 µg/ml) were effect against S.flexineri and other enterobacterial 
strains,except for Shigella dysenteriae. 
 
Anti diabetic activity: 
Subramaniyan et al.(2012), study have reported antihyperglycemic, 
antioxidant and anti dyslipidemic properties of H,indicus root extract in Alloxan –
induced experimental diabetic in rats.The dry powdered roots were extracted with 
petroleum,ether,then soxhletted with ethanol. The level of lipid peroxides in the 
plasma and pancreatic tissues of diabetic rats were elevated significantly and were 
normalized by the administration of the extract. Banerjee and Ganguly et al.(2014) , 
paper revealed upon treatment with H.indicus root extract to diabetic rats ,reduced 
level of glycogen content in muscle tissues was significantly improved. Treatment 
with H. indicus root extract showed a significant decrease in the glycosylated 
hemoglobin level, which could be due do improvement in glycemic control. 
Mahalingam and Kannabiran (2009), studied the crude aqueous extract (500 
mg/kg),and HMBA (500µg/kg),produced hypoglycemic and hypocholesterolemic 
effects in steptozotocin-induced diabetic rats. 
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2.2 SIDDHA LITERATURE: 
               As per the below verse, a physician  can plan the line of treatment accurately 
and will be able to provide maximum benefit to the patient 
           “$u;ghU jhjdpyf; fzKk; ghU 
      Nfhs;ghU ehs;ghU; FzKk; ghU 
     Neu;ghU NjrNg jq;fs; ghU 
      epiyghU fpufTr;r ePrk; ghU 
     Ngu;ghU ,tideP gpwF ghU 
      NgujpNy fP;u;j;j;papd; wd;ik ghU 
     Ntu;ghU jioghU kpQ;rpdf;fhy;; ; ; ;; ; ; ;; ; ; ; 
      nky;ynky;y gw;gnre; J}uk; ghNu; ; ; ; ;; ; ; ; ;; ; ; ; ; ” 
- rpj;j kUj;Jthq;fr; RUf;fk; (473)  
- f.R.cj;jkuhad; 
It is clearly evident that physician should preferrably start with herbal 
medications initially using underground part like root,then by aerial parts like 
leaves/flowers/fruits etc.If these medications does not yield any result, it is advised to 
use higher order medicines like parpam or chendooram. 
The underground part like root absorbs the various nutrients and minerals 
from the land it grows. So collection of roots in correct time is required to maintain 
the quality of roots. Such roots with active phyto-chemicals after processing into 
finished drugs found to be more beneficial in the management of Vali azhal keel 
vayu. 
 
2.3 GUNAPADAM ASPECT OF NANNARI: 
Botanical name  : Hemidesmus indicus 
Tamil   : Nannari,Ankari mooli, Chariyam,Krishnavalli,  
Paathala mulli 
English  : Indian sarsaparilla 
Hindi   : Salsa 
Telugu  : Suganthi 
  Bengali  : Anantmul 
     Sanskirit  : Dhawala Shariva, Gopavalli  
      Part used  : Root 
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Properties of nannari 
 Suvai   : Inippu  
 Thanmai  : Tatpam  
 Pirivu   : Inippu 
 
Action : 
 Alternative 
 Tonic 
 Demulcent 
 Diuretic, 
 Diaphoretic 
 
Ingredients and Medicinal uses of Nannari Ver Ooral Kudineer:      
(Gunapadam Mooligai vaguppu Muthal pagam pg no.562 , 
(Pathartha gunapadam pg no.210) 
TAMIL   
NAME 
PHARMACOLOGICAL 
ACTIONS 
THERAPEUTIC USES IN SIDDHA 
Nannari • Analgesic,  
• Anti-inflammatory 
• Immunomodulatory   
• Anti pyretic 
• Anti oxitent 
• Anti ulcer 
• Anti canceros  
• Diuretics  
• Chronic rheumatism 
• Fever 
• Edema 
• Loss of appetite, 
• Diseases of the vatham and pitham 
• Syphilis 
• Skin diseases  
• Leucorrhoea 
• Diabetes, 
• Indigestion 
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2.4 SIDDHA ASPECT - VALI AZHAL  KEEL VAYU:  
According to the siddha system, the individual is a microcosm of the 
universe.The human body consists of the five primordial elements & the three 
humours. In state of imbalance, they vitiate the structural and functional elements 
known as Udal Thathus. The equilibrium of humours is considered as health and its 
disturbance or imbalance leads to a diseased state. 
Reflecting this theory of cosmic oneness, the five senses are said to 
correspond with the five elements. 
 Ether [veli] is responsible for hearing 
 Air [katru] for sense of touch 
 Fire [thee] for sight 
 Water [neer] for taste 
 Earth [mann] for the sense of smell. 
 
VATHAM: 
Vatham is the primal constituent of the living body whose structure is 
Vayu+Agayam. Among the three humours, vatham is called as king of all sort of 
ailments . Vayu plays a relavant role in the function of joints. Features of increased 
vatham in the body are as follows. 
“uikl<!uf<Kx<x!OhiK!ubxK!ohiVlq!ogit<Tl< 
kikuqp<f<kqMh<H!jggiz<!sf<Kgt<!gMh<Hk<!Okie<Xl<!
sQokiV!lzLl<!fQVf<!sqXk<Kme<!gMk<K!uqP!
likuljv!Olz<!uf<k!uikk<kqe<!G{lqkiOl” 
.!B,gq!Lequv<!ohVF~z<!juk<kqb!giuqbl<!)2111*!
• Abdominal discomfort  
• Pain in the hip joint and in the joints of upper and lower limbs  
• Decreased quantity and painful voiding of  urine 
• Constipation  
The Vatha dosha quoted in various Siddha Literature are as follows 
 
According to Agasthiyar, 
“fhzg;gh thjkPwpy; fhy;iffs; nghUj;J NehTk;  
G+zg;gh Fly; Gul;Lk; kyryk; nghUkpf;fl;Lk;” 
          mfj;jpaH itj;jpa fhtpak; 150; ; ;; ; ;; ; ;  
(ghly; vz;.10> gf;fk; vz;.2)             
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According to Thirumoolar, 
‘vwpa ey;thjk; vwpf;Fk; Fzq;NfS  
Fwpnadf; iffhy; Fisr;R tpyhr; re;J 
Gwpnad nehe;Jly; gr;irg;Gz; MFNk ;” 
       jpU%yH fUf;fpil itj;jpak;; ; ;; ; ;; ; ;-600 
      (ghly; vz;.36>gf;fk; vz;.11) 
 
CHARACTERS OF VATHAM: 
 Hardness 
 Dryness 
 Lightness 
 Coldness 
 Mobility 
 Subtleness 
 
OPPOSITE QUALITIES OF VATHAM: 
 Softness 
 Unctuousness 
 Heaviness 
 Hotness 
 Stability 
 Solid 
 
DWELLING PLACES OF VATHAM: 
“cz;b rikj;Jlw; $l;Lq; Flw;gFjp 
jpz;bnyd;G nrtpFwq;F tpz;l 
njhLzu;T Njhw;Wtpf;Fk; NjhypUg; gpt;thWk; 
 tLtpyplkhk; tspf;F”  
“mwpe;jpLk; thjk; mlq;F kyj;jpdpy;” 
“ehnkd;w thjj;jpw;F fpUg;glNk Nfsha; 
ehgpf;Ff; fPnod;W etpy yhFk;” 
            (Neha; ehly; Neha; Kjy; ehly; Kjy; ghfk;) 
  
Abanan Idaikalai 
Undhiyin Keezh moolam Bones 
Ear Thigh 
Skin Hip region 
Muscle Nerve 
Joints Hair follicles 
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FUNCTIONS: 
“xOq;Fld; jhJ Vo; %r;Nrhq;fp ,aq;f 
      vOr;rpngw vg;gzpAkhw;w – vOe;jpupa 
Ntfk; Gyd;fSf;F Nktr; RWRWg;G 
      thfspf;Fk; khe;ju;f;F thA” 
       lVk<Kuk<keqh<!himz<!
 Giving briskness 
 Respiration 
 Maintenance of body and mind in a balanced state 
 Regulation of reflexes[14 urges] 
 Enhancement of functioning of seven Udal Thathukal 
 Protection and strengthening of sense organs 
 
DISTURBANCE IN VATHAM: 
 Body ache 
 Pricking pain 
 Nerve weakness 
 Shivering 
 Numbness in feet 
 Joint pain 
 Cramps in calf muscles  
 Increased thirst 
 Weakness of organs 
 Breaking pain in the joints 
!
 Pain in the leg and thigh 
 Unable to do flexion &  
extension of the limbs 
 Pilo-erection 
 Dryness 
 Polydypsia 
 Excess salivation 
 Anuria and constipation 
 Astringent taste perception in all food 
 Darkness of skin, eyes and urine 
RELATIONS WITH FIVE ELEMENTS: 
Vatham – Air + Sky 
Pitham – Fire 
Kabham  - Water + Earth 
Vatham has ‘’Air’’ and ‘’Sky’’ as its elemental constituents. If ‘’Air’’ and 
“Sky’’ or any one of them is decreased [or] increased from the normal level, it will 
surely lead to pathological state of vatham.Regarding diet, bitter,pungent and 
astringent taste contain air and bitter alone contains sky. So if these are consumed in 
large amounts ,they result in the vitiation and eventually vatha diseases. 
17 
 
VATHAM & SUVAIGAL: 
Siddha system explains about six types of tastes, which are formed by the 
combination of two boothams. They are sweet, salt, sour, bitter, pungent and 
astringent. some tastes will aggrevate vatham and some tastes will neutralize vatham. 
Futher if the thodam (thodam) is increased, it will cause an alteration of taste in 
tongue, which is appreciable by the patient. So suvaigal holds a separate place in 
diagnosing. 
“khj;jpa Gspg;G kPwpy; te;jpLk; thjkhFk;”  
- mfj;jpa ehb 
“thjNk Gspg;G Ntz;Lk; td;gpj;jk; frg;G Ntz;Lk;” 
-,uj;d RUf;f  ehb 
“GspJtu; tpQ;Rq;fwp ahw;G+upf; Fk;thjk;” 
The above versions denotes that sour, astringent and pungent tastes hold its 
part in raising vatham 
“thjk; Nkypl;lhy; kJuk; Gsp cg;G” 
- fz;Zrhkpak; 
Exaggerated vatham can be neutralized by tastes like sweet ,sour and salt. The 
basic concept behind this is,among the panchabootham, Vin and Vayu forms vatham. 
So tastes formed by other boothams are advisable to neutralize it. It is noted that, in 
the formation of sweet tastes vayu and vin doesn’t takes part.      
 
KEEL VAYU 
rpj;j kUj;Jtj;jpy; vz;gJ tif tsp Neha;fs; gw;wpf; $wg;gl;Ls;sJ. 
tsp moy; fPy; thA vd;gJ> fPy; thA vd;w jiyg;gpd; fPo;f; $wg;gl;l gj;J 
tiffSs; xd;W. fPy;thA vd;gJ %l;L kw;Wk; mjidr; Rw;wpAs;s 
gFjpfspy; Vw;gLk; Neha;f isf; Fwpg;gjhFk;. 
 
According to Agasthiar in Agasthiyar Gunavagadam,  
jhdhf fPy;thj Nuhfk; Ngiu 
.........Neha; jdf;F ghfpaha; thjNuhf nkd;ghH 
El;gKs;s thjNuhf nkz;gJe; jhd; 
Ma;e;njLj;J ,jw;Fs;Ns mlf;fk; ghU…………. 
- mfj;jpaH Fzthflk;; ;; ;; ; 
From this we understood Keel Vayu is one the Vatha Disease. 
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NtW ngaHfs ;:; ;; (Synonyms)
 
Santhuvali, Muttuvali, Megasoolai, Mudakku vayu, Santhu vatham, Soolai 
kattu, Vayu rogam, Santheega silaeshma rogam , Aamavatham  .
 
‘jhdhd fPy;thj Nuhf Ngiu 
rhw;WfpNwd; ePawpa tpgukhf 
khdhd tha;TNuhfk; thj Nuhfk;  
kfj;jhd Klf;FthA Klf;F thjk; 
Njdhd re;jPf rpNyl;Lk Nuhfk; 
njspthd iffhypy; gpbg;G Nuhfk; 
Cdhd urthjk; #iyf;fl;L 
cj;jkNd re;jpthjk; thj#iy ahNk  
Mnkd;w ,j;jidAk; mjw;Fg; Nguhk;” 
- mfj;jpaH Fzthflk;; ;; ;; ; 
Thus the terms of the diseases are named according to the Cause, Tridhosa 
principle ,kurigunam, site of lesion, complication etc. 
Cause    : Mega Soolai 
Tridhosa principle :   Vatha soolai,Santheega silaeshma rogam 
Kurigunam  :   Soolai kattu 
Site of lesion  : Muttu vali ,Santhu vali ,Aama vatham,  
Santhu vatham 
Complication  : Mutakku vatham 
 
Description of the nomenclature: 
Vali Azhal Keel Vayu      = Vali+ Azhal+ Keel+ Vayu 
           Vali     = Vatham 
Azhal     = Pitham 
Keel     = Joint 
Vayu     = Vatham 
 
Initially the joints are affected by the vitiated Vatham. Then, other two 
Humours will be affected. Mostly it is affected in Pitha Kaalangal (Middle 1/3 of the 
life span). 
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DEFINITION:(,ay;);;;  
‘tspA ikAe; jd;dpiy nfl;L 
typAld; tPf;fr; RuKk; fha;e;J 
%l;Lf NlhWk; KLf;fpNa nehe;J 
%l;Lf ld;dpd; ePUk; Rue;J 
jhq;nfhzh typAld; nehe;jpL kk;Nk” 
- rghgjp ifNaL 
Keel vayu is a vatha diseases characterized by pain and swealing of the joint 
stiffness of the muscles and joints with tenderness frequently associated with 
fever,anorexia,insomnia etc.It may be accompanied by emaciation ,anemia and 
restriction of joint movements can also occur. 
 
AETIOLOGY: (Neha; tUk; top); ;; ;; ;   
According to Siddha system, any modifications (or) disturbances in Uyir 
thathugal, especially Vatham which plays a major role to produce Keel Vayu. There 
are various number of factors that can play its role in modification of Vatham. They 
are: 
1. Environmental factors 
2. Physical factors 
4/ Factors of kanmam!
!
1) Environmental factors: 
‘Mbahjpaha; Ig;grp <wha; 
Mdpykjw; Nfhuurpay; fhyk;” 
                   rjfehb (Neha; ehly;) ; ;; ;; ;  
(ghfk;.1> gf;fk; vz;.167>168) 
Sathaganaadi describes that the Vatha diseases are predominant in the months of 
Aadi to Iypasi (July to November). 
‘thj tHj;jid fhyNkNjh ntd;dpy; 
kUTfpd;w Mdp fw;flfkhFk; 
Mjitg; grpNahL fhHj;jpif jd;dpy; 
mUlNk...............................................”   
- a+fp itj;jpa rpe;jhkzp; ;; ;; ; -800 
                 (ghly; vz;.245> gf;fk; vz;.76) 
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In Yugi Chinthamani, Yugimuni says that the Vatham provokes in its own site 
in Aani and Aadi (jd;dpiy tsHr;rp). But it provokes and spread beyond its site in 
the month of Iypasi and Karthigai (Ntw;Wepiy tsHr;rp) and reassumes normal in 
the rest of the months
 (jd;dpiy miljy;). 
According to this Poem, 
‘gJkj;ijg; g+f;f itf;Fk; ghDkpf;f fhAk; 
KJNtdp ypw;G tpePH Kw;Wk; - fJnkd 
tw;Wk; fgFk; thAkpFk;.........................................” 
- kUj;JtH jdpg;ghly;; ; ;; ; ;; ; ; 
KJNtdpw; fhyj;jpy;> #hpa ntg;gj;jpd; fhuzkhf ngUthhpahf ePH 
Mtpahf;fg;gl;L g+kpapy; twl;rp epyTk;. mJNghy; ekJ clypy; twl;rp 
Vw;gl;L tspNeha; tUtjw;F VJthfpwJ. 
 
2. Physical factors: 
1.   According to Sabapathy Manuscript, 
‘tspjU fha;fpoq;F tiutpyh japyy; Nfhio 
KspjU Nghd;kpFf;F Kiwapyh tz;b Nfhly; 
Fspu;jU tspapw; Njfq;Fdpg;Gw Tyty; ngz;bH 
fspjU kaf;fk; ngw;NwhH fbnray; fUtpahkhy;” 
        rghgjp ifNaL - rpj;j kUj;Jtk; (nghJ) ; ; ;; ; ;; ; ;  
(gf;fk; vz;.624); ; ;; ; ;; ; ;  
Excessive intake of rhizomes and vegetables that can increase Vatha 
diseases. Irregular food intake, prolonged exposure to cold air, staying in hilly area, 
excessive sexual activity and hereditary factors produce Keel Vayu. 
 
2.According to Agasthiyar in Agasthiyar Gunavagadam, 
‘ ;jhdhd fPy; thj Nuhfk; Ngiu………………. 
NghNk jhd;ur J}~paj; jpdhNy  
nghy;yhj ,e;j Neha; fhZk; ghU” 
- mfj;jpaH Fzthflk;; ;; ;; ;  
Keel Vayu occurs due to dietary substances which degrade the quality of chyle 
(md;durk; – chyle). 
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3.According to Yugi Muni in Yugi Vaithya Chinthamani, 
‘gfuNt thjkJ Nfhgpj;jg;Ngh 
gz;ghf ngz;Nghfk; mJjhd; nra;apy;  
efuNt ntFJ}u topelf;fpy; 
espuhd fhw;WNk gdpNky; gl;lhy;  
kpfuNt fha;fs; fdpfpoq;F jd;id 
kpftUe;jp kPwpNa japHjhd; nfhz;lhy;  
KfuNt KJnfYk;ig KWf;fp nehe;J 
Koq;fhYk;> fZf;fhYk; fLg;Gz;lhNk” 
a+fp itj;jpa rpe;jhkzp; ;; ;; ; -800  
(ghly; ;;; vz;.215> gf;fk; vz;.89); ; ; ;; ; ; ;; ; ; ;  
Excessive sexual activity (or) desire, walking for a long distance, prolonged 
exposure to cold, harmful consumption like taking excessive curd after eating fruits, 
vegetables and tubers produces toxic factors which affects bones and muscles, 
produce Vatha disease. 
 
4.According to Theraiyar in Theriyar Vagadam text, 
‘nta;apypy; elf;ifahYk; kpfj; jz;zPH Fbf;ifahYk;                 
Nra;apio kfspiur; NrHe;jd gtpf;ifahYk; 
igaNd cz;ikahYk; ghfw;fha; jpz;ifahYk;    
 ijaNy thjNuhfk; rdpf;F nkd;wwpe;J nfhs;s” 
                       NjiuaH thflk;;;; 
(ghly; vz;.16> gf;fk; vz;.5); ; ; ; ;; ; ; ; ;; ; ; ; ;  
Excessive walking in hot Sun, excessive intake of water, excessive sexual 
activity, intake of bitter guard etc…, may disturb the normal functions of Vatham. 
 
5. According to Pararasa sagaram, 
Improper Dietary habits and Sleep pattern causes Vatha disease. 
‘njhopy;ngW ifg;Gf; fhHj;jy; JtHj;jy; tpQ;RfpDQ; NrhWk;         
 gioajhk; tuF kw;iwg; ige;jpiz aUe;jp dhYk; 
vopy;ngwg; gfY wq;fp ,utpdp ywq;fh jhYk; 
kioepfH Foyp dhNs thjq;Nfh gpf;Fq; fhNz” 
                                     - guuhr Nrfuk;;;; 
‘fhyq;fz; khwp Az;Zq; fhhpaj; jhYe; jz;zPh; 
 rhyNt aUe;jp dhYQ; re;jpap Yl;fhHe;jhYk; 
thythH Kiyey; yhNs thjKw; gtpf;Fq; fhNa” 
                                - guuhr Nrfuk;;;; 
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3. Factors of Kanmam (Genetics): 
In Siddha system, many diseases are said to be precipitated by Kanmam, 
which means the deeds good (or) bad committed, by an individual in his / her 
previous and the present births. According to Agasthiyar Kanma Kandam-300, 
Vatha diseases may also be precipitated by Kanmam. 
 
Vatha Kanma Varalaru says, 
‘E}nyd;w thjk; te;j tifjhNdJ  
Jz;ikaha;f; fd;kj;jpd; tifiaf; NfS 
fhypNy Njhd;wpaJ fLg;gNjJ 
iffhypy; Kof;fpaJ tPf;fkJ 
NfhypNy gLfpd;w tpUl;rkhd 
Foe;ij kue;jid ntl;ly; Nky;Njhy;rPty;  
E}ypNy rPt[e;J fhy; Kwpj;jy; 
ey;ynfhk;G jioKwpj;jy; eypj;jy; jhNd” 
                    mfj;jpaH fd;kfhz;lk; ; ; ; ;; ; ; ;; ; ; ;  
(ghly; vz;.56> gf;fk; vz;.23; ; ; ; ;; ; ; ; ;; ; ; ; ; ) 
Psychological factors such as removing the bark of living trees, injuring the 
animals, cutting the branches in the living trees and plucking the leaves may produce 
Vatha disease. 
 
As per Karmic Law: 
‘me;jzH fw;G khjH mUspa rhgj;jhYk; 
Ke;jpa tpidahYk; KjpHfHg;g Nkfj;jhYk; 
rpe;ijapw; nfhLikahYk; rptFU epe;ijahYe; 
njhe;jkhk;tpahjpahYk ;Njhd;wpLk; #iyjhNd” 
- mfj;jpaH;;;  
Soolai may occur by the curse of well characterized people and ladies or due 
to evil deeds in the previous births or due to megam produced by their parents or due 
to bad thoughts and curse of Guru. 
 
Prodromal symptoms of Keel Vayu:(Lx<GxqG{r<gt<*< < << < << < <   
Nasal block, running nose, hoarseness of voice, low grade fever, painful 
arthralgia are prodromal symptoms of Keel vayu. 
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Individual derangements in Mukkutram : 
• Abanan and Viyanan were affected in Vatham. 
• In Pitham, Sathaga Pitham is affected. 
• In Kapham, Santhigam is affected. 
 
Classification of Keel vayu: 
According to Sabapathy manuscript the Keel vayu is classified into 10 
types.They are: 
1. Vali keel vayu 
2. Azhal keel vayu 
3. Iya keel vayu 
4. Vali azhal keel vayu 
5. Vali iya keel vayu 
6. Azhal vali keel vayu 
7. Azhal iya keel vayu 
8. Iya vali keel vayu 
9. Iya azhal keel vayu 
10. Mukkutra keel vayu 
 
General clinical features of keel vayu: 
1. Painful joints 
2. Swelling 
3. Restricted joint movements 
4. Stiffness 
5. Fever 
6. Loss of appetite 
7. Synovial effusion 
 
 
VALI AZHAL KEEL VAYU: 
• Vali Azhal Keel Vayu is one among the ten of keel vayus. 
• When the Vatha dosham is in vitiated condition, some untold activity, food 
stuffs, kanmam provoke the Pitha dosham which is the causative factor of Vali 
Azhal Keel Vayu. 
The normal structure and functions of Vatham (tbtj;jd;ik) 
• Dry (uxm<sq*!!!!!<<< !
• Cold (FspHr;rp);;; !
• Rough (fbdk;);;;
    
!
• Motion (mirjy;);;;  
• Light)zG* 
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The normal structure and functions of Pitham )ucuk<ke<jl* is: 
• Heat (ntg;gk;); ;; ;; ;  
• Sharpness )%Ijl* 
• Lubrication )ofb<h<H*< << << < !
• Relaxation (nefpo;r;rp); ;; ;; ;  
• Motion (,af;fk;); ;; ;; ;  
 
thj kpF Fzk;:;;;  
‘mwpatpk; %d;wpd; jd;ik nrhd;dhHee;jp 
Vwpa ey;thj nkwpf;Fq; Fzq;NfS 
Fwpnadf; iffhy; Fisr;R tpyhr;re;J...” 
- jpU%yH fUf;fpil itj;jpak; 600; ; ;; ; ;; ; ;  
‘thjtPW md;dkpwq; fhJ fLg;Gz;lhk; tz;zKz;lhk; 
       NkhJfl;F Nuhfk; RuKz;lh kpUkYkh Kwq;fhnjd;Wk; 
XJjhpa thjkdyhF eLf;fKz;lhk; nghUs; fsaHe;j 
jPnjdNt euk;gpj;J re;Jfs; NjhWq; fLf;Fe; jpdKe;jhNd” 
           NjiuaH thflk;;;; 
(ghly; vz;.210> gf;fk; vz;.58) 
‘jf;f thA Nfhgpj;jhy; re;Jisj;J #iyNehth  
kpf;f nfhl;lhtp tpl;lq; nfhpA kyq;nfl;Lk; 
xf;f euk;G jhd; Klq;F kyHe;J tha; eP&wptUk; 
kpf;f FspUk; eLf;fkha; Nkdp Fd;wp tUq;fhNd” 
- NjiuaH thflk;;;;  
(ghly; vz;.43> gf;fk; vz;.13) 
thjk; kpFk;NghJ grpapd;ik> cly; fLg;G> Ruk;> ,Uky;> cwf;fkpd;ik> 
cly; eLf;fk;> euk;Gj; jsHr;rp> re;Jfs; NjhWk; Filjy;> tpyhr;re;Jfs; 
Nehjy;> tapW nghUky;> Flypiwr;ry;> kyr;rpf;fy;> kpFe;j nfhl;lhtp Nghd;w 
Fwp Fzq;fs; Njhd;Wk;. 
 
gpj;jk; kpF Fzk;:; ; ;; ; ;; ; ;  
fz;> kyk;> rpWePH> Njhy; ,itfs; kQ;rs; epwk; miljy;> grp> 
ePHNtl;if kpFjpg;gly;> cly; Kw;Wk; vhpr;ry; cz;lhjy;> Fiwe;j J}f;fk; 
Nghd;w Fwp Fzq;fs; Njhd;Wk;. 
So, thus Vali Azhal Keel Vayu is the deranged Vatha Pitha dosham which 
produce stiffness, swelling, restriction of movements in the affected joints. 
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‘jhdhd fPy;thj Nuhfk; Ngiu 
............................................................................... 
nghy;yhj ,e;j Neha; fhZk; ghU 
ehNkjhd; Koq;fhy; nghpafPy;fs; 
ed;ikAld; mijr; Rw;wp ,Uf;Fk; rt;tpd; 
...............................................................................” 
- mfj;jpaH Fzthflk;; ;; ;; ; 
According to Agasthiyar Gunavagadam, keel vayu affects all joints and their 
periarticular surface. So, I compared Vali Azhal Keel Vayu, the disease affecting 
major, minor joints and produce disability. 
 
CLINICAL FEATURES OF VALI AZHAL KEEL VAYU: 
According to Sabapathy Manuscript, 
‘thj gpj;jf; fPy; thAtpd; 
tUq;Fwpr; rhw;wf; Nfsha; 
VjkhH ke;j Nkg;gk; 
,iur;rYk; tapw;wpw; fhZk; 
XjUq; Fj;jy; tPf;fk; 
Xa;jypy; vhpr;r Yz;lhk; 
fhjW Kwf;f kpd;ik 
fha;r;rYq; fhZq; fz;lha;” 
• czT nrhpahky; GspNag;gk; (Dyspepsia). 
• mbf;fb fhw;Wg; ghpjy; (Flatulence). 
• kyr;rpf;fy; (Chronic constipation). 
• cly; ngUj;jy; (Morbid obesity) 
• kzpf;fl;L> fZf;fhy;> tpuy;fs; ,tw;wpy; fPy;fs; rpte;J 
vhpr;riyAk;>typiaAKz;lhf;Fk; (Painful proximal interphalangeal joints,  
• distal inter phalangeal joints). 
• mf;fPy; fuL fl;b ePl;lTk;> ed;wha; klf;fTk; Kbahky; epiyj;J 
epw;fTk; nra;Ak;. J}f;fkpd;ik> gLf;ifapw; Gusy;> rpWRuk; Mfpait 
Vw;gLk; (Stiffness, insomnia, low grade fever). 
Review of literature about the disease of joints implies that the clinical 
features more or less correlates with Vali Azhal Keel Vayu. 
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i) According to Yugi Muni, 
‘itfpjkha;f; fizf;fhY Koq;fhy; jhD  
kw;flQ; re;JGw tbAk; tPq;fpr; 
nra;fpjkhQ; rpWtpuy;fs; kpfT nehe;J 
rpe;ijjL khwpNa rypg;Gz;lhFk; 
igfpjkha; gapj;jpaj;jpy; thj kpQ;rpg; 
ghukh Aw;gtpj; joYz;lhFk; 
ca;fpjhk krdkJ jhDk; Ntz;lh 
      cjputhjr; RNuhzpjj;jp DzHr;rp ahNk” 
rpj;jkUj;Jtk; (nghJ) ; ; ;; ; ;; ; ; (gf;fk; vz;.609) 
Uthira Vatha Surothinam, one of the 80 Vatha disease characterized by 
swellings especially in ankle, knee and in all major and minor joints. Secondarily it 
can produce depression, fatigueness, anorexia. This is due to the deranged (or) altered 
Vatha and Pitha dosham. 
 
ii)  According to Theriyar in Theriyar Vagadam, 
‘nkhop thjk; nkhopfNlhWq; fuizfl;Lk; 
........................................................kprpe;J NehFk;” 
         NjiuaHthflk; %yKk; ; ;; ;; ; ciuAk; ;;;   
(ghly; vz;.215> gf;fk; vz;.59) 
Theriyar, here defines Mozhi Vatham the one among 81 Vatham, has a 
characteristic features of joint pain, erosion and fusion of joints, causing deformity 
leading to inability to use the joints. 
 
iii). According to  Panditharathna Dr. S. Chidambarathanu Pillai,  Siddha 
Medical Literature Research Centre, 
‘clyJ ntJk;gp if fhy;fs; 
cisTld; fLj;J nehe;J 
flyiy jhd; gpuz;lhg; NghNy 
fdj;JNk maHe;J fhZk; 
rlkJ tpOe;J jhfk; 
rQ;ryk; Njh~k; cz;lha; 
Klkjhk; iffhy; jd;id 
Klf;fpa thjnkd;Nw” 
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NkYk;> 
‘Kwpe;j thjk; te;jhy; 
vOe;jJNk elf;f nthl;lhJ” 
thjNeha; kUj;Jtk; ; ; ;; ; ;; ; ; (gf;fk; vz;.164) 
 
                ‘thhpePH ngUFk; NghNy cyHe;jpLk; %lLk;> fhYk;  
               ghFw re;J NjhWk; gue;Jly; Rspj;Jf; Fj;Jk; 
        fhhpif cjpunky;yhk; eae;JNk tUe;jpthLk; 
               $hpa thjnkd;W nfhw;wtH tUj;jhH jhNk...” 
                                                                - thjNeha; kUj;Jtk;; ; ;; ; ;; ; ;(gf;fk; vz; .168) 
Kooriya Vatham is one among the 80 types of Vatha disease. It is 
characterized by painful interphalangeal joints and swelling. All the above features 
described in various texts closely resembles the clinical features of Vali Azhal Keel 
Vayu (Rheumatoid Arthiritis). 
 
DIAGNOSIS IN SIDDHA: 
a) Piniyari Muraigal (Methods of Diagnosis) is based upon three main topics 
namely, 
• Poriyal Aridhal (Physical Examination, Perception) 
• Pulanal Aridhal (Palpation) 
• Vinnadhal (Interrogation) 
 
1.Poriyal Aridhal (Inspection) 
Poriyal Aridhal means examining the “Pori” of the patient by the “Pori” of the 
physician for proper diagnosis. Pori is considered as the five sensory organs of 
perception namely. 
 Mei (Skin) 
 Vai (Tongue) 
 Kan (Eye) 
 Mooku (Nose) 
 Sevi (Ear) 
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QhNde;jphpaq;fspd; Ma;T; ; ; ;; ; ; ;; ; ; ;   
 
fd;Nke;jphpaq;fspd; Ma;T; ; ; ; ;; ; ; ; ;; ; ; ; ;  
 
2. Pulanal Aridhal (Palpation): 
The five sense are given below: 
• Smell 
• Taste 
• Vision 
• Sensation of touch  
• Hearing 
By examining the  Pulan of the patient the physician can diagnose the disease. 
 
3. Vinnadhal (Interrogation): 
Vinnadhal is questioning and gathering information regarding the previous 
history of disease and clinical features which is much essential for diagnosis. 
 
b) Envagai Thervugal (Eight Diagnostic Tools): 
The excellent and unique method in the Siddha system is the Envagai 
Thervugal. They are, 
‘ehb ];ghprk; eh epwk; nkhop top 
   kyk; %j;jpuk; kUj;JtuhAjk;” 
             Neha; ehly; Neha; Kjy; ehly; ; ; ; ; ;; ; ; ; ;; ; ; ; ;  
      Kjy; ghfk; (gf;fk; vz;.270) 
Gyd;fs;; ;; ;; ; njhopy;fs;; ;; ;; ; tsp moy; fPy; thA Nehapy; ghjpg;G; P ; ; ;; P ; ; ;; P ; ; ;  
1.nrtp xypia mwpa nra;jy; ,ay;G 
2.nka; clypy; Cw;iw mwpjy; %l;Lf;fspy; typ> tPf;fk; 
3.fz; xspia mwpar; nra;jy; ,ay;G 
4.ehf;F Ritia mwpar; nra;jy; ,ay;G 
5.%f;F thridia Efur; nra;jy; ,ay;G 
Gyd;fs;; ;; ;; ; njhopy;fs;; ;; ;; ; tsp moy; fPy; thA Nehapy; ghjpg;G ; P ; ; ;; P ; ; ;; P ; ; ;
1.tha; Ngrr; nra;Ak; ,ay;G 
2.if ,LjYk;> Vw;wYk; nra;Ak; ghjpg;G 
3.fhy; elf;fr; nra;Ak; %l;Lf;fspy; typ>  elf;fr; rpukk; 
4.vUtha; kyj;ijf; fopf;Fk; kyr;rpf;fy; 
5.fUtha; fU> Rf;fpyj;ijf;  fopf;Fk; ,ay;G 
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1.Naadi (Pulse): 
Among the Envagai Thervugal Naadi is most important. Naadi is felt as 
Vatham, Pitham and Kapham with the tip of the index, middle and ring fingers 
respectively over the end of the radius. 
Normally Vatham, Pitham and Kapham are held in the ratio of 1:1/2:1/4. 
Derangement in this will reflect as disease. Naadi Nadai in Keel Vayu is, 
‘jpUj;jkhk; thjj; NjhNl jPq;nfhL gpj;jQ; Nrhpy; 
      nghUj;J fs;NjhWk; nehe;J NghjNt gpbf;Fk; 
         Nehapd; rhuk; ; ;; ;; ; - rpj;jkUj;Jtk; (nghJ); ; ;; ; ;; ; ;  
      (gf;fk; vz;.634) 
‘fhzg;gh thj kPwpy;    
fhy;iffs; nghUj;J NehFk;” 
fhtpaehb - rpj;j kUj;Jtk; (nghJ) ; ; ;; ; ;; ; ;  
(gf;fk; vz;.634) 
 ‘nrhy;ypa itaj;NjhL gpj;jKq; $bw;whdhy; 
ty;ypak; Nghyf; Fj;Jk; ike;jNd vYk;G NjhWk;” 
            fhtpaehb - rpj;j kUj;Jtk; (nghJ) ; ; ;; ; ;; ; ;  
(gf;fk; vz;.634) 
 ‘mwpe;JghH thjNk jdpj;jhdjhy; 
rhpe;jplNt fhy; Klf;Fk;” 
mfj;jpaH uj;jpdr; RUf;fk; ; ; ; ; ;; ; ; ; ;; ; ; ; ;  
(gf;fk; vz;.634) 
‘thjj;jpy; Nrj;Jkkhfpy; typNahL tPf;fKz;lhk;”  
               - mfj;jpaH ehb;;;  
In Vali Azhal Keel Vayu the following Naadi nadai are commonly felt. 
• Vatham 
• Vatha Pitham 
• Pitha Vatham 
2. Sparisam (Sensation to touch): 
In Vali Azhal Keel Vayu heat is noticed over the affected joints. 
3. Naa (Tongue):  
In Vali Azhal Keel Vayu no abnormality is seen in Naa. 
4. Niram (Color): 
In Vali Azhal Keel Vayu some skin colour changes seen in affected area due 
to   inflammatory mechanism. 
30 
 
5. Mozhi (Voice): 
In Vali Azhal Keel Vayu no abnormality is seen. 
6. Vizhi (Eyes): 
In Vali Azhal Keel Vayu Eye pallor is reported in some cases. 
7. Malam (Faeces): 
 In Vali Azhal Keel Vayu Constipation is reported in some cases. 
8.  Moothiram (Physical appearance of Urine): 
In urine, Neer kuri and Nei kuri examinations are done. 
Nei kurai : 
“mUe;J khwpujKk; mtpNuhjkjha; 
 m/fy; myu;jy;  mfhyCz; jtpu;e;jow; 
 Fw;wstUe;jp cwq;fp itfiw 
 Mbf; fyrj; jhtpNa fhJ nga; 
 njhU K$u;j;jf; fiyf;Fl;gL ePupd; 
 epwf;Fwp nea;f;Fwp epUkpj;jy; flNd”            - Njiuau; 
Prior to the day of urine examination the patient is instructed to take a 
balanced diet and quantities of food must be proportionate to his / her appetite. The 
patient should get good sleep. After waking up in the morning, the first urine voided 
is collected in a clear wide mouthed glass dish or china clay bowl and is subjected to 
analysis of “Neer kuri’’ and “Nei kuri’’ within one and a half an hour of its collection. 
The collected urine specimen is kept in a glass dish or china clay container and 
observed under direct sunlight without shaking the vessel. Then add one drop of 
gingelly oil and observe the spreading pattern and conclude as follows: 
Character of vatha neer:  
‘muntd ePz;bd m/Nj thjk;’ 
When the drop of oil lengthens like a snake, it indicates ‘Vatha Neer’. 
Character of pitha neer :  
‘MopNghw; gutpd; m/Nj  gpj;jk;’ 
When the oil drop spreads like a ring , it indicates ‘pitha Neer’ 
Character of kabha neer : 
‘Kj;njhj;J epw;fpd; nkhopt njd; fgNk’ 
When the oil drop remains that of pearl, it indicates ‘Kabha Neer’ 
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Character of Thontha neer: 
‘mutpyhopAk; Mopapy; muTk; 
mutpd;Kj;Jk; Mopapy; Kj;Jk; 
Njhw;wpy; njhe;j Njhlq;fshNk’ 
Thontha neer appears as the combination of above patterns. 
When the oil drop gets immersed in urine,it indicates ‘Mukkutra Neer’.  
In ‘Vali Azhal Keel Vayu’ ,the  Neikuri appears to be thontha neer indicating 
patterns of aravil aazhi and aazhiyil aravu . Few cases showed patterns that the snake 
indicating vatha neer. 
Thinai : (land and place) 
The geographical distribution of land is classified into the five groups. Vatha 
diseases is predominantly affected in peoples who are living in Mullai & Neidhal 
places. 
 Kurinji  -  Mountain and its surroundings 
 Mullai  - Forest and its adjacent areas 
 Marutham - Field and its surroundings 
 Neithal - Sea and its surroundings 
 Paalai  - Desert and its surroundings 
 
Paruvakaalam (Seasonal variations): 
State of Kuttram                                   Kaalam 
Vaatham thannilai adaithal       - Munpani Kaalam 
  
Pinpani Kaalam 
  
Koothir Kaalam 
  
Elavenil Kaalam 
Vatham thannilai valarchi          - Muthuvenil Kaalam 
Vatham vetrunilai valarchi   - Karakalam 
KJNtdpw; fhyj;jpy; ekJ clypy; twl;rp Vw;gl;L tspNeha; tUtjw;F 
VJthfpwJ. 
 
WP!dmz<!kiKg<gtqe<!Nb<U< < < << < < << < < <   (Seven Udal Thathukal Examinations):  
Seven Thathus  
Saaram - Strenthens the body and mind 
Senner - gives power, knowledge and boldness to the mankind 
32 
 
Oon - It strengthens the body 
Kozhuppu - It lubricates the joints 
Enbu - 1. It protects all the internal organs and gives the structure 
to the body 
Moolai - It is present in the bones 
Sukkilam and 
suronitham 
- Mean for reproduction ( male and female respectively ) 
 
Table: Seven Udal Thathukal Examinations  
SI. 
No. 
Udal  
Thathukal 
Increased conditions Decreased condition 
1 Saaram Loss of appetite  
excessive salivation 
Tiredness, fatigue, 
diminished activity of 
the sense organs. 
2 Senneer Boils and tumours in different parts of 
the body, spleenomegaly, colic pain, 
increased blood pressure, reddish eyes 
and skin, jaundice, leprosy, 
Tiredness lassitude, 
anemia. 
 
3 Oon Tumours or extra growth around the 
neck, face, abdomen, thigh, genitalia 
etc., with dyspnoea. 
 
Muscle wasting 
4 Kozhuppu Tumours or extra growth around the 
neck, face, abdomen, thigh with 
dyspnoea and loss of activity 
Joint Pain, 
Emaciation, 
Spleenomegaly 
5 Enbu Extra growth of bone and teeth Weak bones , teeth , 
nails and hair. 
6 Moolai Heaviness, swollen eyes, swollen 
phalanges, oliguria and non healing 
ulcers. 
Osteoporotic changes, 
Blurred vision. 
7 Sukkilam or 
Suronitham 
Increased sexual activity and 
symptoms as that of urinary calculi. 
Infertility, pain in 
genitalia. 
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In Vali Azhal Keel Vayu:  Saaram, Seener, Kozhuppu, Enbu, Moolai 
thathukal are commonly affected.    
• Saaram   :     Weakness, pain in all major and minor joints  
• Seneer : Tiredness, anemia 
• Kozhuppu : Early morning stiffness occurs in affected joints 
• Enbu : Joint space narrowing, marginal erosions and deformities 
• Moolai : Joint effusion and oedema are seen in the joints. 
 
MUKKUTRAM:   
Uyir thathukal i.e., Vatham, Pitham and Kapham responsible for normal 
physiological conditions of the body. Vatham is mainly responsible for proper 
locomotor functions.  Bones and joints are the major site of Vatha. 
Vatham:- 
Locations : ln abana vayu , faeces , idakalai , spermatic cord , pelvic bone , 
skin nerves, joints etc., 
Types of vatham  
1. Piranan (uyirkkal)  
This controls knowledge mind and five objects of senses which are helpful for 
breathing and digestion  
2. Abanan (Keezh Nokkukal) 
This is responsible for all downward movements such as passing of urine 
stools, sperm menstrual flow etc.,  
3. Samanan (Nadukkal)  
This Aids for proper digestion  
4. Viyanan (Paravukkal)  
   Responsible for movements of all parts of the body   
5. Uthanan (Mel Nokukkal) 
Responsible for all upward visceral movenments such as cough, hiccup,     
vomiting, nausea etc., 
6. Nagan 
    Responsible for opening and closing of the eyes  
7. Koorman 
Responsible for vision and yawning  
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8.Kirukaran 
Responsible for salivation, nasal secretion and appetite  
9. Dhevathathan 
Responsible for laziness, sleep and anger 
10.Dhananjeyan  
Produces bloating of body after death and escapes on the third day bursing the 
cranium 
In vali azhal keel vayu abanan, viyanan, samanan, koornan and kirukaran are 
affected and they produce symptoms as follows  
 Affected abanan produces constipation, 
 Affected samanan produces loss of appetite and indigestion 
 Affected viyanan produces pain and restriction of movements of the affected 
joints 
 Affected koorman produces disturbed sleep 
 Affected kirukaran produces loss of appetite 
 
Pitham 
Locations of Pitham: In pirana vayu, bladder, molakini, heart, umbilical, 
region, abdomen, stomach, sweat glands. Eyes, saliva, blood etc., 
Types of pitham 
1) Anilapitham  - It gives appetite and helps digestion  
2) Pirasagapitham  - It gives complexion to the skin 
3) Ranjagapitham  - It gives colour to the blood 
4) Alosagapitham - It brightens the eye 
5) Sathagapitham - it controls the whole body 
In vali azhal keel vayu, anilapitham, Pirasagapitham, Ranjagapitham, and 
Sathagapitham maybe affected. 
 Affected anilapitham produces loss of appetite  
 Affected ranjagapitham produces anemia 
 Affected sathagapitham produces disability to carry out regular works  
 Affected  Pirasagapitham produces pallor of skin 
 
 
 
35 
 
Kabam  
Locations: In samana vayu , sperm, head, tongue, vulva etc., 
Types of Kabam 
1. Kilethagam – Lies in stomach, makes food soft and helps in digestion 
2. Avalambagam – Lies in lungs, controls the heart and other kabas, 
3. Pothagam – responsible for indentifying tastes  
4. Tharpagam – present in the head and responsible for the coolness of both eyes 
5. Santhigam – responsible for the lubrication and free movement of the joints. 
In vali azhal keel vayu, kilethagam and santhigam may be affected  
 Affected kilethagam causes loss of appetite   
 Affected santhigam causes pain in the joints 
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In Vali Azhal Keel Vayu, the Vatha kutram and Pitha kutram is mainly 
affected.  This produces the following signs and symptoms.  
 Deranged Viyanan leads to painful stimuli and difficulty in movements with 
early morning stiffness.  
 Deranged Abanan leads to constipation.  
 Inflammatory changes of the joints, heat, redness and swelling are developed 
due to altered Pitham.  Ranjaga Pitham – reduced haemoglobin level.  Sathaga 
Pitham –hindering of the locomotor functions. 
 Along with Vatham, Kapham is also deranged, Santhigam is affected and this 
leads to abnormality in joint movements. 
 Erosion, loss of joint space, increased secretion of synovial fluid may lead to 
synovial effusion due to increased Kapham.  
 
S.NO Name Location Physiological function 
1 Abanan Lower abdomen 
and extremitis 
Responsible for urination, defecation, 
parturition, menstruation and ejaculation of 
the sperm.  
 2 Viyanan Heat Responsible for movements of all parts of the 
body and sensation.  
3 Samanan Stomach Responsible for proper digestion.  
 
NOI KANIPPU VIVATHAM (Differential Diagnosis):   
 Vali Azhal Keel Vayu is differentiated from the following diseases,  
!!sf<K!uikl<)< << << < Santhu Vatham*!!
“osb<jg!kie<!sf<KgT!lqgk<!kqlqi<f<K!
smolr<Gl<!ofik<KOl!lqgu!px<xq!
jfjgbib<!fZk<KOl!lbqi<g<!%s<szqm<M!
! fi{qOb!Le<Ohiz<!fjm!ogimiK!
jljgkie<!lbg<goliM!uib<!fqVXl<!
! uv{<cMOl!fiUkiecg<g!cg<Gg<!
jggiz<kie<!kv{qkeqx<!xvqg<!ogi{iK!
! sR<siqg<GR<!sf<Kuil<!uikr<!OgOt”/!
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Pain in joints, body pain, pilo erection, inability to walk, giddiness, dryness of 
togue, excessive salivation and unable to keep the limbs in floor are the features of the 
disease.  
npz<!gQz<!uiB!)< Q << Q << Q < Azhal Keel Vayu):    
 “hqk<kg<gz<!uib<U!ke<eix<!hqxr<GgQe<!&m<M!uQr<gqs<!
! sqk<kI!osb<!lVk<K!uk<KR<!sQvhmik<!ke<jlk<!kigqk<!
kk<kX!gib<s<sz<!g{<M!sizOu!kjekie<!kf<Ok!
! olk<kX!sqgqs<js!ke<eiz<!ole<Olz<!fQr<G!lh<hi”!
.!shihkq!jgObM!sqk<k!lVk<Kul<!)ohiK*!!!!!< < << < << < < !
!!!!!!!!!!!!!!!!!!!! )hg<gl<!w{</737*!< < << < << < < !!
It is characterized by swelling of joint associated with severe pain and fever. 
In later stages joints gets fused to one another and result in inability to using joints 
leading to deformities.  !
 
Jb!gQz<!uiB!)Q <Q <Q < Iya Keel Vayu):   
“gVkVr<!ghg<gqz<!uiB!g{<cce<!dmzqjtg<Gl< 
dVolzquig<Gr<!ogit<Tl<!d{<cjbs<!SVg<G!lqehf<!
kVKbqz<!fQr<G!Lm<cx<!xir<ogi{i!uZjubig<Gl<!
! -VlOz!uqg<gz<!uif<kq?!Osijh!hi{<omPh<Hl<!hiOv”!
shihkq!jgObM!sqk<k!lVk<Kul<!< < << < << < < (ohiK) 
(hg<gl<!w{</738< < << < << < < )! 
It is characterized by severe pain in the joints associated with loss of weight, 
anorexia, insomnia, cough, hiccough, vomiting, anemia and dropsy. The common 
sites are spinal cord, hip joint and knee joints.     
!
fiqk<kjz!uikl<< << << <!)Narithalai Vatham*!
 “Li<g<glib<!Lbe<X!Lpr<giz<kie<!uqr<gq!
! Lkqi<f<Kvk<k!Lf<kqv{<M!Lbx<sq!bigq!
fqg<glib<!kqe<xqmoui!{ilx<!xiEl<!
! fqlqi<f<kqMgqz<!sf<Kf<kie<!Lmg<!ogi{ilz<!
kQv<g<glib<k<!K{<ck<K!lqg!sqg<oge<X!
! osPjl!fiqk<!kjz!Ohiz!lqgOu!uQr<gq!
fii<g<glib<!ficBOl!hmhmg<Gl<!
! fiqk<kqjzbqe<!uikole<Ox!fuqz!ziOl”/!
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Swelling of the knee joint with hyperemia, difficulty to stand, palpitation will 
be seen, the swelling looks like the head of the fox are the features of this disease. 
 
utq!Jbg<!gQz<!uiB!)< Q << Q << Q < Vali Iya Keel Vayu):    
“ubr<!uikg<!ghg<gQz<!uiBuie<!uzq!lqGf<Ok!
! dbr<G!fQI!Ogik<K!gQz<gt<!yiqbqe<!kjzOhix<!gi[l<!
fbr<ogit<t!Lmg<gz<!fQm<mz<!f{<{qmiolb<!Br<giBl<!
! lbg<GX!Lxg<glqe<eil<!le<eqb!ofiqg<gm<!miOl”!
shihkq!jgObM!sqk<k!lVk<Kul<!)ohiK*< < << < << < < !
)hg<gl<!w{</739*!< < << < << < < !
It is characterized by pain in the joints associated with effusion of joint, 
swelling, restricted joint movements, pyrexia, fainting, insomnia, asymmetrical 
presentation lymphadenopathy, generalized malaise, atrophy of the affected limb etc.,  
 
TREATMENT : (Pini neekkam / parikaram) 
   The aim of pini neekam is, 
 To bring the three doshas in equilibrium  
 Treatment of disease and topical application of medicated oils, ottradam 
(Fomentation) thokkanam (Message) etc. 
 Diet and prevention of the diseases. 
Since siddha system of medicine is based on mukkutra theory ,the treatment is 
mainly aimed to bring down the increased dosha to its equilibrium state and 
thereby restoring the physiological condition of various thathus. 
“tpNurdj;jhy; thje; jhOk;” 
Vali Azhal Keel Vayu is a vatha diseases. Therefore laxatives or mild 
purgatives are to be administered on the first day or in the early morning respectively 
according to patient’s tolerance to the drug . 
Thokkanam may be advised in case of atrophy or wasting of muscle. 
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PATHIYAM : 
During the course of treating according to the drug administered to the patient 
and nature of the diseases, the patient is advised to follow certain precautions 
regarding diet and physical activities. This form of medical advice in siddha system of 
medicine is termed as ‘pathiyam’. 
Pathiyam for vatha diseases as mentioned in ‘Patharthaguna Chinthamani’ is 
as follows  
“nrq;fO ePu;Nfhl;le; Njd;kpsF ey;nyz;nza; 
 jq;FngUq; fhae; jOjhio – vq;nfq;Fk; 
$l;LrpW Kj;Jnea; Nfhjpy; cOe;jpitfs; 
 thl;Lkzp yj;ij kjp” 
Root of water lily, costus root, honey collected on branches of trees, black 
pepper, gingelly oil, asafoetida, leaves of clerodendron phlomoides, caster oil black 
gram etc cure vatha diseases. 
ePf;f Ntz;bait:P ; ;P ; ;P ; ;  
Gspg;G> Jtu;g;Gr; RitAs;s czTfs;.  
In Theraiyar venba, under the heading Itcha pathiyam mentioned to avoid  
ghfw;fha;> khq;fha;> fj;jhpf;fha;> nfhj;jtuq;fha;> fy;ahzg;g+rzpf;fha;> 
mfj;jpf;fPiu> ke;jKs;s gjhHj;j tiffs; and also underground tubers , 
coconut, mustard and sexual intercourse should be avoided. 
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2.5. MODERN ASPECT: 
RHEUMATOID ARTHRITIS 
Definition : 
Rheumatoid Arthritis is a chronic inflammatory systemic disease characterized 
by persistent inflammatory synovitis, usually involing peripheral joints in a symmetric 
distribution. The potential after effect of the synovial inflammation includes cartilage 
damage, bone erosions and subsequent changes in joint integrity which are the 
hallmarks of the disease. 
Epidemiology: 
In worldwide, the annual incidence of RA is approximately 3 cases per 1000 
population and the prevalence rate is approximately 0.8-1.0% increasing with age. It 
peaks between the age of 35 and 50 years. Women are affected 3 times more often 
than men but sex differences diminish in older age groups (Pg.No.2083) 
Causes and Risk factors: 
The cause of rheumatoid arthritis is unknown. The risk factors may be: 
 Infectious agents. 
 Hereditary 
 Environmental factors 
∗ Smoking 
∗ Tobacco chewing 
∗ Exposure to Silica Mineral 
 Periodontal diseases 
The tendency to develop rheumatoid arthritis may be genetically (hereditary) 
related. Certain genes have been identified that increase the risk for rheumatoid 
arthritis. It is also revealed that various environmental factors might trigger the 
activation of the immune system in susceptible individuals. The misdirected immune 
system acts as self antigens and leads to inflammation in the joints and sometimes in 
various organs of the body. 
In RA, immune cells called lymphocytes gets activated and chemical 
messengers (cytokines, such as tumor necrosis factor/TNF, interleukin-1/IL-1, and 
interleukin-6/IL-6) are expressed in the  inflammed areas. 
PATHOGENESIS: (https://images.app.goo.gl/fcomp
 
Changes in Synovium : 
The synovium is a thin delicate lining that serves as an important source of 
nutrients for cartilage since cartilage itself is avascular.Synovial cells also synthesize 
joint lubricants  that constitute the structural f
1. Synovial lining or intimal layer: 
 This layer is only 1
 In RA, this gets highly hypertrophied (8
populations includes fibroblasts and macrophages.
2. Subintimal area of synovium: 
• The synovial blood vessels are located here & this area normally has very few 
cells.  
• In RA, the area is heavily infiltrated with inflammatory cells that differentiate 
into multinucleated osteoclasts.
41 
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• The intense cellular infiltrate is accompanied by new blood vessel growth 
(angiogenesis).  
• The hypertrophied synovium (also called pannus) invades and erodes 
contiguous cartilage and bone.  
Changes in Cartilage: 
Composed primarily of type II collagen and proteoglycans, this is normally a 
very resilient tissue that absorbs considerable impact and stress. 
 In RA, cartilage damage appears to be due to action of proteolytic enzymes 
(collagenase, stromelysin) in synovial lining cells and by chondrocytes 
themselves. 
 Cytokines including IL1, 6 and TNF generates reactive oxygen & nitrogen 
species , increases chondrocyte catabolic pathways and matrix destruction.It 
also inhibit new cartilage formation.  
 Polymorphonuclear leukocytes in the synovial fluid may also contribute to 
this degradative process. 
Changes in Bone: 
Primarily composed of type I collagen.  
 Bony destruction is a characteristic of RA occuring by the activation of 
osteoclasts.  
 Osteoclasts differentiate under the influence of cytokines especially the 
interaction of RANK with its ligand.  
 The expression is done by the action of cytokines including TNF and IL1, IL-
17 & mediators derived from activated synovial cells. 
Changes in Synovial Cavity: 
The synovial cavity is a space with 1-2ml of highly viscous fluid with few 
cells. In RA, large effusions occur which are filtrates of plasma. In synovial fluid the 
predominant cell is neutrophil. 
Disease Initiation: 
a) Genetic Susceptibilities: 
 Class II MHC on the surface of an antigen presenting cell interacts with a T 
cell receptor in the context of a specific antigen. The hypervariable region of 
HLA-DR4 remains the largest genetic risk factor described for RA.It is 
43 
 
estimating that 30% of the genetic risk accounts by HLA-DR4 for this 
disease.  
 A triggering peptide (or peptides)  formed by these residues is an early event 
leading to the activation of T lymphocytes. Modified citrullinated peptides 
also have significant binding specificity for shared epitope alleles. 
Citrullinated sequences from different proteins are associated with allelic 
restriction. 
 Other genetic susceptibilities include peptidyl arginine deiminase-4 (PAD-4) 
which may lead to increased citrullination, PTNP22, STAT4, and CTLA4 
which may be involved in T cell activation & TNF receptors. 
 In research studies the concordance rates between twins were higher in 
monozygotic twins ranging from 15-35% compared with dizygotic twins in 
which the concordance was in the 5% range. Even the dizygotic RA 
prevalence was higher than the general population estimates of approximately 
1%. It is important to emphasize however that even in twins with nearly 
identical DNA, there was far from perfect correlation of the development of 
RA, implicating many other factors related to the development of disease 
than genetic factors. 
b) Citrullination: 
 Citrullination is a normal process required for normal skin formation and 
other physiologic functions. The triggering factors of RA results in increase 
citrullination of Proteins. However, in rheumatoid arthritis an autoimmune 
response develops against citrullinated peptides detected as anti-citrullinated 
peptide antibodies (ACPA). 
 A polymorphism in the PAD4 gene leads to increased citrullination. In RA 
patients, autoantibody responses also develop against the PAD4 protein, 
associated with a more aggressive disease course. 
 One species of oral bacteria Porphyromonas gingivalis has a PAD enzyme. 
Given the relationships described with periodontal disease and RA, it has 
been hypothesized that these bacteria may also serve to initiate citrullination 
in the preclinical phases of RA. 
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c) Propagation of Disease: 
 T cell activation 
Upon encounter with antigen in the context of MHC on an antigen presenting 
cell, a T lymphocyte is positioned for 3 possible fates: 
• Activation 
• Anergy /Tolerance 
• Apoptosis (Death). 
T cell activation is only possible if the T cell receives a “second signal” 
through engaging additional cellular receptors. The second signal is delivered through 
the CD28 molecule on the surface of the T cell but many other second signals are also 
involved. Upon engagement of these receptors, a T cell usually becomes activated. 
Failure to engage the stimulatory receptors, or engagement of a down-regulator 
receptor will cause the cell to become tolerant to the antigen or to undergo 
programmed cell death through apoptosis. 
Activated T cells will proliferate and begin to secrete additional cytokines  
which furthers their proliferation depending on exposures to cytokines such as IFN-γ, 
TNF, and IL-4. Due to effect of the cytokines that additional cells become activated. 
T cells also directly interact through surface receptors with other cells to generate 
additional activation signals. 
 B Cell Activation and Autoantibodies 
 B cells become activated through interactions with T cells and through  
cytokines that enhance their proliferation and differentiation. B cells express a number 
of receptors on their surfaces during their differentiation, including the molecule 
CD20. B cells and plasma cells can be found in rheumatoid synovium sometimes as 
lymphoid aggregates in the subsynovium. 
The B cells plays roles in forming plasma cells including cytokine production, 
direct cellular interactions and they themselves serve as antigen-presenting cells to T 
lymphocytes.  
Autoantibodies known as rheumatoid factors (RF) and anti-citrullinated 
peptide antibodies (ACPA)  present in RA are directed against native antibodies most 
classically described as IgM antibodies that recognize the Fc portion of IgG 
molecules. RF may also be of the IgG or IgA isotypes. 
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 Effector Cell Activation 
Most of the damage from the disease occurs through effector cells and their 
products. The synovial lining in RA represents an expansion of fibroblast like cells 
and macrophages.                          
Macrophages are one of the principal factor for the effector damage in RA. 
Macrophages are  major producers of pro inflammatory cytokines including TNF,               
IL-1, IL-6, IL-8, and GM-CSF. These cytokines further stimulate the macrophage, 
fibroblastsand osteoclasts. Macrophages are also producers of prostaglandins and 
leukotrienes, nitric oxide, and other pro-inflammatory mediators with local and 
systemic effects. The synovial fibroblast also secretes cytokines including IL-6, IL-8 
and GM-CSF, and other mediators including destructive proteases and collagenases. 
Neutrophils are present abundantly in rheumatoid cavity & can be confirmed 
by examing the synovial fluid. The recruitment of neutrophils to the joint is carried by 
IL-8, leukotriene B4, and  localized complement activation through C5a. Neutrophils 
in the synovial fluid are in an activated state, releasing oxygen-derived free radicals 
that depolymerize hyaluronic acid and inactivate endogenous inhibitors of proteases. 
So it leads to damage of the joint. 
Chondrocytes like synovial fibroblasts, are activated by IL1 and TNF to 
secrete proteolytic enzymes. They may contribute to the dissolution of their own 
cartilage matrix, thus explaining the progressive narrowing of joint spaces seen 
radiographically in this disease. 
d) Inflammatory Mediators in RA: 
e) Cytokines: 
 One of the most important group of mediators in RA are cytokines. The most 
prominent of these are TNF, IL-1, and IL-6. These cytokines, released in the 
synovial microenvironment have  autocrine, paracrine, and endocrine effects .It 
accounts for many systemic manifestations of disease. There are many shared 
functions of TNF, IL-1, and IL-6, and these cytokines in turn upregulate the 
expression of the others. Among the important effects of these cytokines are: 
• Induction of cytokine synthesis 
• Upregulation of adhesion molecules 
• Activation of osteoclasts 
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• Induction of other inflammatory mediators including prostaglandins, nitric 
oxide,  matrix metalloproteinases 
• Induction of the acute phase response  
      (Increased C-reactive protein, increased ESR) 
• Systemic features ( Fatigue, fever, Cachexia) 
• Activation of B cells (IL-6) 
Soluble mediators of inflammation that may diffuse in from blood and/or be 
formed locally within the joint cavity include prostaglandins, leukotrienes, matrix 
metalloproteinases. Prostaglandins are involved in pain sensitization, localized 
inflammation and some effects on bone. Leukotrienes play roles in vascular 
permeability and chemotaxis. Matrix metalloproteinases (MMPs) are potent in their 
ability to enzymatically degrade the collagen matrix of cartilage. Kinins cause release 
of prostaglandins from synovial fibroblasts, and are also potent algesic (pain-
producing) agents.Complement may be available for interaction with immune 
complexes to generate additional chemotactic stimuli. The neuropeptide substance P 
is a potent vasoactive, pro inflammatory peptide that has also been implicated in RA. 
 
SIGNS AND SYMPTOMS: 
RA symptoms come and go, depending on the degree of tissue inflammation. 
When body tissues are inflammed, the disease is active. When tissue inflammation 
subsides, the disease is inactive (in remission). Remissions can occur spontaneously 
or with treatment and can last weeks, months, or years. During remissions, symptoms 
of the disease disappear, and people generally feel well. When the disease becomes 
active again (relapse), symptoms return. The return of disease activity and symptoms 
is called a Flare. The course of rheumatoid arthritis varies among affected individuals, 
and periods of flares and remissions are typical. 
       When the disease is active, RA symptoms can include 
 Fatigue 
 Insomnia 
 Lack of appetite. 
 Low-grade fever 
 Muscle and joint pain 
 Stiffness 
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Muscle and joint stiffness are usually most notable in the morning and after 
periods of inactivity. This is referred to as morning stiffness and post-sedentary 
stiffness. Arthritis is common during disease flares. Also during flares, joints 
frequently become warm, red, swollen, painful, and tender. This occurs because the 
lining tissue of the joint (synovium) becomes inflammed, resulting in the production 
of excessive joint fluid (synovial fluid). The synovium also thickens with 
inflammation (synovitis) Rheumatoid arthritis usually inflammes multiple joints and 
affects both sides of the body. In its most common form, therefore, it is referred to as 
a symmetric polyarthritis. Early RA symptoms may be subtle. The small joints of both 
the hands and wrists are often affected. Symptoms in the hands with rheumatoid 
arthritis include difficulty with simple tasks of daily living, such as turning door 
knobs and opening jars. The small joints of the feet are also commonly involved, 
which can lead to painful walking, especially in the morning after arising from bed. 
Chronic inflammation can cause damage to body tissues, including cartilage 
and bone. This leads to a loss of cartilage and erosion and weakness of the bones as 
well as the muscles, resulting in joint deformity, destruction, and loss of function. 
Rarely, rheumatoid arthritis can even affect the joint that is responsible for the 
tightening of our vocal cords to change the tone of our voice, the cricoarytenoid joint. 
When this joint is inflammed, it can cause hoarseness of the voice. Symptoms in 
children with rheumatoid arthritis include limping, irritability, crying, and poor 
appetite. 
 
ARTICULAR  MANIFESTATIONS: 
HANDS AND WRISTS: 
There is a predilection for: 
• PIP and MCP joints (especially 2nd and 3rd MCP) 
• Ulnar –Styloid Process 
• Triquetrum 
• As a rule, the DIP joints are spared. 
Late changes include: 
• Subchondral cyst formation: Destruction of cartilage presses synovial fluid 
into the bone 
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• Subluxation causing: Ulnar deviation of the MCP joints 
• Deformities    
 Boutonniere deformity 
 Swan neck Deformity  
 Hitchhiker‟s thumb deformity or “ Z ” deformity 
• Carpal instability: Scapholunate dissociation, Ulnar translocation 
• Ankylosis 
FEET: 
Similar to the hands, there is a predilection for the PIP and MTP joints 
(especially 4th and 5th MTP). 
• Involvement of Subtalar joint 
• Posterior Calcaneal tubercle erosion 
• Hammer toe deformity 
• Hallux valgus 
SHOULDER: 
• Erosion of the distal clavicle 
• Marginal erosions of the Humeral head: The superolateral aspect is a typical 
location 
• Reduction in the Acromiohumeral distance: "High-riding shoulder" due to 
Subacromial-Subdeltoid bursitis and high incidence of rotator cuff tear 
HIP: 
• Concentric loss of joint space where there is a tendency for superior loss of 
joint space 
• Acetabular protrusion 
  KNEE: 
• Joint effusion 
• Typically involves the lateral or non-weight bearing portion of the joint 
• Loss of joint space involving all three compartments 
• Lack of subchondral sclerosis and osteophytes, compared with OA 
• Baker’s cyst (Popliteal cyst) - rare 
• Prepatellar bursitis  
• Vulgus deformity 
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 IN SPINE: 
The Cervical spine is frequently involved in RA , where as a Thoracic and 
Lumbar involvement are rare. Findings include 
• Erosion of the dens 
• Atlantoaxial subluxation-atlantoaxial distance in more than 3 mm on a flexion 
radiograph Atlantoaxial impaction (cranial settling): cephalad migration of C2 
• Erosion and fusion of uncovertebral (apophyseal joints ) and facet joints 
• Osteoporosis and osteoporotic fractures 
• Erosion of spinous processes 
 
EXTRA  ARTICULAR  MANIFESTATIONS: 
SYSTEMIC: 
1.Fever     3. Weight loss 
2.Fatigue   4.Susceptability to infection 
MUSCULO SKELETAL  
1.Muscle Wasting  3.Tenosynovitis 
2.Bursitis     4.Osteoporosis 
HAEMATOLOGICAL 
1.Anemia   3.Thrombocytopenia 
2.Eosinophilia 
LYMPHATIC 
1.Splenomegaly  2.Felty’s syndrome 
NODULES 
1.Sinuses   2.Fistulae 
OCULAR: 
1.Scleritis   3.Scleromalacia 
2.Episcleritis   4.Keratoconjuctivitis Sicca 
VASCULITIS: 
1.Digital Arteritis  4.Visceral Arteritis 
2.Mononeuritis Multiplex 5.Pyoderma  gangrenosum 
3.Venous ulcers 
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CARDIAC: 
1.Pericarditis   4.Conduction defect 
2.Myocarditis   5.Coronary Vasculitis 
3.Endocarditis   6.Granulomatous Aortitis 
PULMONARY: 
1.Nodules   4.Caplan’s syndrome 
2.Bronchiolitis  5.Fibrosing alveolitis 
3.Pleural Effusion 
NEUROLOGICAL 
1.Cervical cord compression 
2.Peripheral neuropathy 
3.Compression neuropathies 
4.Mononeuritis Multiplex 
Amyloidosis is a rare complication of prolonged active disease and usually  
presents with Nephrotic syndrome. 
 
Subcutaneous  Rheumatoid  Nodules  
Subcutanneous and intracutaneous nodules are the hall mark of the disease.  It 
develop in 20 to 30% of patients with Rheumatoid Arthritis.  
They are usually found on peri articular structures, extensor or other areas  
subject to Mechanical pressure.  
Common locations include a olecranon bursa, the proximal ulnar, the achilles  
tendon, the occipital bone etc., They are also found in the flexor tendon,the  
scalar,with in the aortic value,myocardium,larynx and vocal cord.  
Histologically, the nodules consist of a central zone of necrotic 
material,including  collagen fibrils,non-collagenous filaments and cellular debris,mid 
zone of palisading  macrophages that express HLA-DR antigens and an outer zone of 
granuloma tissue. 
Rheumatoid vasculitis 
It can affect nearly any organ system and is seen in patients with severe from 
and high titres of circulating rheumatoid factors.  Neurovascular disease presenting 
either as distal sensory neuropathy or as mononeuritis multiplex may be the only sign 
of vasculitis.  Custaneous vasculitis usually presents as crops of small brown spots in 
the nail bed, nail folds and digital pulp,large ischaemic ulcers especially in the lower 
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extremity may also develop. Vasculitis also involves the lungs, bowel, liver, spleen, 
pancreas, lymphnodes and testes. 
Renal Involvement   
Renal papillary necrosis and interstitial nephritis occasionally occur IgA  
nephropathy associated with elevated serum levels of IgG and IgA is described in RA. 
Liver Involvement  
This is evident in about 10% of patients with active disease.  
There may be mild hepatospleenomegaly and asympatamatic elevation of the 
serum alkaline phosphatase.  
Kupffer cell hyperplasia and lymphocytic infilteration of the portal tracts may 
be seen. 
Pulmonary Manifestations   
Pleuro pulmonary nodule may occur as singly or in clusters when they appear  
in individual with the pneumoconiosis and diffuse nodular fibrotic nodules 0.5-5 cm  
in diameter are seen mainly in the periphery of the lung fields. This association is  
known as Caplan’s syndrome. These nodules may produce pneumothorax or  
broncho pleural fistula.  
Interstitial fibrosis.  
• Pleurisy and pleural effusion produce frank synovitis. 
• Pulmonary fibrosis is common in rheumatoid arthritis but is often subclinical. 
• Pulmonary hypertension due to vasculitis.   
• Obliterative bronchiolitis is a rare but rapidly progressive and fatal process 
• Cardiovascular  Manifestations 
• Asymptamatic pericarditis  
• Pericardial effusion  
• Constructive pericarditis  
• Cardiomyopathy 
• Coronary artery occlusion 
• Acute aortic regurgitation  
• Valvulitis  
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STAGES OF RHEUMATOID ARTHIRITIS 
The American College of Rheumatology has developed a system for 
classifying rheumatoid arthritis that is  based upon the X-ray appearance of the joints. 
It describes the severity of rheumatoid arthritis with respect to cartilage, ligaments, 
and bone. 
Stage-I 
• No damage seen on X-rays, although there may be signs of bone thinning 
Stage-II 
 On X-ray, evidence of bone thinning around a joint with or without slight bone 
damage 
 Slight cartilage damage possible 
 Joint mobility may be limited; no joint deformities observed 
 Atrophy of adjacent muscle 
 Abnormalities of soft tissue around joint possible 
Stage-III 
 On X-ray, evidence of cartilage and bone damage and bone thinning around 
the joint 
 Joint deformity without permanent stiffening or fixation of the joint 
 Extensive muscle atrophy 
 Abnormalities of soft tissue around joint possible 
Stage-IV 
 On X-ray, evidence of cartilage and bone damage and osteoporosis around 
joint 
 Joint deformity with permanent fixation of the joint (referred to as ankylosis) 
 Extensive muscle atrophy 
 Abnormalities of soft tissue around joint possible. 
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CRITERIA:  
JOINTS AFFECTED SCORE 
1 Large joint    0 
2-10 Large joints 1 
1-3 Small joints 2 
 4-10 Small joints 
 
5 
 
 
SEROLOGY  
Negative RF and ACPA     0 
Low Positive RF or ACPA     2 
High Positive RF or ACPA     3 
DURATION OF SYMPTOMS  
<6 weeks     0 
>6 weeks     1 
ACUTE PHASE REACTANTS  
Normal CRP and ESR     0 
Abnormal CRP or ESR     1 
 
 
Patient with a score greater than or equal 6 are considered to have definite 
Rheumatiod Arthritis. 
Criteria for the Diagnosis of Rheumatoid Arthritis: 
1. Morning Stiffness for more than  1 hour 
2. Arthritis of  3 or more joint  
3. Arthritis of hand joints 
4. Symmetrical distribution of  arthritis 
5. Rheumatoid Nodules 
6. Rheumatoid Factor 
7.Radiological findings 
Dignosis of Rheumatoid Arthritis made with 4 or more criteria 
By using the above criteria Rheumatoid Arthritis can be differentiated from  
other types of arthritis. 
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INVESTIGATIONS 
HAEMATOLOGICAL INVESTIGATIONS: 
 Haemoglobin Concentration 
 Total WBC count 
 Differential count 
 Polymorphs 
  Lymphocytes 
 Eosinophils 
 Monocytes 
 Basophils 
 ESR 
 Blood sugar 
 Total Cholesterol 
 Urea 
 Creatinine 
 Uric acid                . 
URINE 
• Albumin 
• Sugar 
• Deposits 
SPECIFIC INVESTIGATIONS 
• CRP 
• ASO Titre 
• Antinuclear antibody (ANA) 
• Rheumatoid factor (RF): Designed to detect and measure the level of an 
antibody that acts against the blood component gamma globulin, this test is 
often positive in people with Rheumatoid arthritis. 
• Anti-cyclic citrullinated peptide (anti-CCP): Also called anti-citrullinated 
protein antibodies (ACPA) 
• HLA tissue typing – This test, which detects the presence of certain genetic 
markers in the blood, can often confirm a diagnosis of ankylosing 
spondylitis (a disease involving inflammation of the spine and sacroiliac 
joint) or reactive arthritis (a disease involving inflammation of the urethra, 
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eyes and joints). The genetic marker HLA-B27 is almost always present in 
people with either of these diseases. 
• Lyme serology – This test detects an immune response to the infectious agent 
that causes Lyme disease and thus can be used to confirm a diagnosis of the 
disease. 
• Skin biopsy 
• Muscle biopsy 
• Joint fluid tests 
RADIOLOGICAL INVESTIGATIONS: 
The radiographic hallmarks of Rheumatoid arthritis are: 
• Soft tissue swelling: Fusiform and Periarticular; it represents a combination of 
Joint Effusion, Oedema and Tenosynovitis 
• Osteoporosis: initially juxta-articular, and later generalised. 
• Joint space narrowing: Symmetrical or Concentric 
• Marginal Erosions: Due to erosion by pannus of the bony “bare areas” 
Ultrasound: 
Sonography can assess the soft tissue manifestations of RA. In particular: 
• Synovial proliferation and inflammation of the superficial joints 
• Tenosynovitis: Extensor carpi ulnaris tendon involvement is common in early 
disease and may lead to erosion of the ulnar styloid 2 
• Bursitis 
CT: 
CT is not routinely used in the evaluation of peripheral RA. It has 
applications in imaging of the spine, and peri-operative assessment. 
MRI 
MRI is particularly sensitive to the early and subtle features of RA.                   
Features of RA best demonstrated with MRI include: 
• Synovial hyperaemia: indication of acute inflammation 
• Synovial hyperplasia (rice bodies) 
• Pannus formation 
• Decreased thickness of cartilage 
• Subchondral cysts and erosions 
• Juxta-articular bone marrow oedema 
• Joint effusions 
56 
 
DIFFERENTIAL DIAGNOSIS 
The differential for the skeletal manifestations of RA includes 
• Osteoarthritis involving the: DIPs, PIPs, 1st CMC joints, Nonuniform joint 
space loss, subchondral sclerosis and osteophyte, soft tissue swelling, 
Heberdon’s node (DIPs) and Bouchard node (PIPs), no Erosions and no 
anklylosis. 
• Erosive osteoarthritis: Clinically an acute inflammatory attacks (swelling, 
erythema, pain) in postmenopausal woman typically includes the DIPs, PIPs 
1st CMC joint 6, but not the metacarpophalangeal (MCP) joints and large 
joints. Classic central erosions, possible ankylosis. 
• Psoriatic arthritis (PsA): Commonly  involves the hands and there is  an 
interphalangeal predominant distribution in  PsA . MCP joint  predominance 
in Rheumatoid arthritis (RA) starts with erosions in the margins and 
eventually   involves the whole joint.  
Classic: “pencil in cup” and bone proliferation (unlike RA).  
Osteoporosis not a feature in PsA. MRI dynamic enhancement pattern may 
differentiate PsA from RA at 15 minutes 
• Reactive arthritis (Reiter’s syndrome): Predilection for the lower limb 
Osteopenia and then Osteoporosis, uniform joint space loss, subchondral cyst 
formation, subluxations, marginal erosions but no bone formation, 
symmetrical involvement of the: PIPs, MCPs, and carpal bones. 
• Systemic lupus erythematosus (SLE)/Jaccoud arthropathy: Joint space 
loss, subchondral sclerosis, osteophyte, and ulnar deviation of the phalanges 
without erosions 
• Calcium pyrophosphate dihydrate (CPPD) arthropathy:  usually 
only affects the MCP's: symmetric joint space narrowing, subchondral cysts, 
and    osteophytes. unlike RA: chondrocalcinosis and no erosions. 
• Gout usually in older men : Punched out erosions usually with a sclerotic 
border and overhanging edges, tophi, most commonly involves the 1st MTP 
known as podagra. 
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COMPLICATIONS: 
Since rheumatoid arthritis is a systemic disease, its inflammation can affect 
organs and areas of the body other than the joints. 
Inflammation of the glands of the eyes and mouth can cause dryness of these 
areas and is referred to as Sjögren's syndrome. Dryness of the eyes can lead to 
corneal abrasion. Inflammation of the white parts of the eyes (the sclerae) is referred 
to as scleritis and can be very dangerous to the eye. Rheumatoid inflammation of the 
lung lining (pleuritis) causes chest pain with deep breathing, shortness of breath, or 
coughing. The lung tissue itself can also become inflammed and scarred, and 
sometimes nodules of inflammation (rheumatoid nodules) develop within the lungs. 
Inflammation of the tissue (pericardium) surrounding the heart, called 
pericarditis, can cause a chest pain that typically changes in intensity when lying 
down or leaning forward. Rheumatoid arthritis is associated with an increased risk for 
heart attack. Rheumatoid disease can reduce the number of red blood cells (anemia) 
and white blood cells. Decreased white cells can be associated with an enlarged 
spleen referred to as Felty's syndrome and can increase the risk of infections. 
The risk of lymph gland cancer (lymphoma) is higher in patients with 
rheumatoid arthritis, especially in those with sustained active joint inflammation. 
Firm lumps or firm bumps under the skin, subcutaneous nodules called rheumatoid 
nodules can occur around the elbows and fingers where there is frequent pressure. 
Even though these nodules usually do not cause symptoms, occasionally they can 
become infected.Nerves can become pinched in the wrists to cause carpal tunnel 
syndrome.  A rare, serious complication, usually with longstanding rheumatoid 
disease, is blood vessel inflammation (vasculitis). Vasculitis can impair blood supply 
to tissues and lead to tissue death (necrosis) leading to leg ulcers. 
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CHAPTER-III 
MATERIALS AND METHODS 
3.1 STUDY AREA AND SETTING   
The study period was covered from June 2017 to July 2019 at the Govt. 
Siddha Medical College and Hospital, Palayamkottai- 627 002, Tirunelveli, Tamil 
Nadu. All procedures were carried out before getting the permission from Institutional 
Ethical Committee (GSMC-IV-IEC/2017/Br.-I/04/29.05.2017). 
 
3.2 STUDY DESIGN: 
STUDY TYPE        :   A open  labelled Phase II non - randomized clinical trial  
STUDY PLACE      :   OPD & IPD of Govt.Siddha Medical College and Hospital, 
   Palayamkottai. 
STUDY PERIOD    :   24 Months  
SAMPLE SIZE       :   40 Patients (20 OPD &20 IPD) 
 
3.3  SELECTION OF PATIENTS 
 Patients with symptoms mentioned in inclusion criteria reported in P.G.Dept 
of Pothu Maruthuvam, GSMC, Palayamkottai was subjected to screening test and 
documented using screening proforma.  
 
3.3.1 INCLUSION CRITERIA  
• Age :  18 – 50 years 
• Sex :  Both male and female 
• Symmetrical joint involvement 
• Arthritis of  3 or more joints 
• Florid Morning stiffness and swelling that lasts for few hours or days 
• Pain, Joint swelling especially in the interphalangeal joint. 
• Patients who are willing for admission and stay in IPD for minimum 20 – 30 
days or willing to attend OPD. 
• Patient who are willing to undergo radiological investigation and give blood 
and urine samples for laboratory investigation. 
• Pain criteria score should be greater than or equal to 6. 
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3.3.2 EXCLUSION CRITERIA  
• Age :  Below 18 and above 50 years 
• Gouty arthritis 
• Psoritatic arthritis 
• Mixed Connective Tissue Disorders (MCTD) 
• SLE  
• Extra pulmonary Tuberculosis  
• Other auto-immune disease  
• Chronic kidney disease 
• Pregnant women and lactating mothers 
 
3.3.3  DIAGNOSIS 
The Siddha diagnostic procedure were included this study, which are,                  
• Poriyal Arithal 
• Pulanal Arithal 
• Vinathal 
• Mukkutra nilaigal 
• Envagai thervugal 
• Nilam 
• Kaalam & Udal kattugal 
 
3.3.4 INVESTICATIONS: 
The following investigations were done in modern medicine aspects. 
Haematological aspects 
• Total RBC count 
• Hb% 
• Total WBC count 
• Differential count 
• ESR 
• Blood sugar 
• Serum cholesterol 
• Serum urea  
• Serum creatinine 
• Serum uric acid 
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Urine analysis: 
• Albumin 
• Sugar 
• Deposits 
 
Specific investigations: 
1. CRP 
2. RA factor 
3. ASO titre 
4. Anti-CCP (In selective cases) 
Radiological investigations (for selected cases): 
 X-ray of affected joints (AP and lateral view) 
Assessment of results: 
The results were assessed on the basis of symptomatic relief and DISEASE 
ACTIVITY SCORE OF 28 JOINTS (DAS 28).The difference in the score before and 
after treatment represents the improvement in the treatment. 
           
3.4 The preparation of Trial Medicine (Annexure I) 
          The selected clinical trial drug was NANNARI VER OORAL KUDINEER 
            Reference   :  Gunapadam Mooligai Vaguppu, Pg. No. 562 
            Author        :  Dr. K.S. Murugesa Mudaliyar     
            Dose            :  90 ml (thrice a day) 
            Duration     :  30 days.     
All the paients admitted for the study were provided with regular                    
hospital diet. 
After discharge all the patients were advised to attend the Out patient 
Department of Pothu Maruthuvam, Government Siddha Medical College and 
Hospital, Palayamkottai for further follow–up. 
 
3.5. Collection and authentication of trial medicine (Annexure VI):  
The required drug for preparation of NANNARI VER OORAL KUDINEER 
(Internal) was purchased from a well reputed country shop and authenticated by 
Botanist, Department of Medicinal Botany, Govt. Siddha Medical College, 
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Palayamkottai. The drug was purified and the medicine was prepared in the 
Gunapadam practical hall of Govt.Siddha Medical College, Palayamkottai. 
 
3.6  Preclinical analysis of trial medicine 
All the preclinical studies of the study drug including bio-chemical and 
pharmacological studies were carried out and results were cross checked before 
starting the treatment.The bio-chemical analysis was carried out in Dept. of 
Biochemistry, GSMCH, Palyamkottai.. 
The relevant pharmacological activities - Anti inflamatory, Analgesic, 
Immunomodulatory Activity, Anti microbial, Phytochemical and Acute and sub-acute 
toxicity activities were  carried out in this study.  Studies were done in  K.M. College 
of Pharmacy, Madurai -625107. 
 
3.7 Ethical review 
The study was conducted in accordance with the ethical principles that are 
consistent with Good Clinical Practice guidelines and obtained prior approvals before 
start of the trial from the Institutional Ethical Committee of GSMCH, Palayamkottai 
(GSMC-IV-IEC/2017/Br.-I/04/29.05.2017) and Institutional animal ethical 
committee (IEAC) of K.M. College of Pharmacy, Madurai 
(TNMGRMU/KMCP/IEAC/26/2018).  The trial was applied and approved by the 
Clinical Trial Registry of India (CTRI/2018/06/014450[Registered on: 07/06/2018]). 
Trial was registered prospectively as per the norms. 
 
3.8 Study enrolment   
Patients reported at the OPD & IPD of Pothu Maruthuvam Govt. siddha 
medical college and hospital, palayamkottai with the clinical symptoms of pain in 
three or more joints, swelling of small joints, morning stiffness was examined 
clinically for enrollment in the study based on the inclusion and exclusion criteria.  
The patients who were to be enrolled were informed about the study, trial 
drug, possible outcomes and the objectives of the study in the language and terms 
understandable to them. 
During the visit, various parameters like body weight, blood pressure, 
cardiovascular, neurological and respiratory system were clinically recorded. During 
the treatment any adverse reaction or side effects of patients, immediately to inform 
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patient and pharmacovigilence committee. At the end of the study period, all the 
patients were instructed to follow diet control, and to monitor relevant parameters. 
They were also advised to pursue the further treatment in the PG, Pothu Maruthuvam 
OPD for the follow up study. 
 
WITHDRAWAL CRITERIA: 
• Intolerance to the drug and development of adverse reactions during drug trial.  
• Poor patient compliance and defaulters.  
• Patient turned unwilling to continue in the course of clinical trial.  
• Occurrence of any serious illness. 
 
3.9 Statistical Analysis 
All data were analysed using the SPSS 20.0 (IBM). Data were expressed as 
means and standard deviation. The significance of the difference between the means 
of the baseline and the final examinations was tested using the paired ‘t’ test. A 
probability value of <0.05 was considered to be statistically significant. 
                                                       
 
 
 
 
 
 
 
 
 
  
63 
 
CHAPTER-IV 
OBSERVATION AND RESULTS  
4.1.PRE CLINICAL STUDY OF NANNARI VER OORAL KUDINNER 
4.1.1.BIO-CHEMICAL ANALYSIS OF  NVOK 
PREPARATION OF THE EXTRACT: 
5 gm of the drug was weighed accurately and placed in a 250ml clean beaker. 
Then 50ml of distilled water was added and dissolved well. It was boiled well for 
about 10 minutes and allowed to cool. Mixture was filtered in a 100ml volumetric 
flask and then it is made into 100ml with distilled water and taken for analysis. 
 
QUALITATIVE ANALYSIS 
Table;4.1.1.a.BIO-CHEMICAL ANALYSIS OF NVOK 
Sl. 
No. 
EXPERIMENT OBSERVATION INFERENCE 
1. TEST FOR CALCIUM 
2ml of the above prepared extract is 
taken in a clean test tube. To this add 
2ml of 4% Ammonium oxalate solution 
A white 
precipitate is 
formed 
presence of 
calcium 
2. TEST FOR SULPHATE 
2ml of the extract is added to 5% 
Barium chloride solution. 
A white 
precipitate is 
formed 
presence of 
sulphate 
3. TEST FOR CHLORIDE 
The extract is treated with silver nitrate 
solution 
No white 
precipitate is 
formed 
Absence of 
Chloride 
4. TEST FOR CARBONATE 
The extract is treated with concentrated 
Hcl. 
No brisk 
effervescence is 
formed 
Absence of 
Carbonate 
5. TEST FOR STARCH 
The extract is added with weak iodine 
solution 
Blue colour is 
Formed 
presence of 
starch 
6. TEST FOR FERRIC IRON 
The extract is acidified with Glacial 
acetic acid and potassium ferro 
cyanide. 
No blue colour is 
formed 
Absence of 
ferric iron 
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7. TEST FOR FERROUS IRON 
The extract is treated with concentrated 
Nitric acid and Ammonium thiocyanate 
solution 
Blood red colour 
is formed 
presence of 
ferrous Iron 
8. TEST FOR PHOSPHATE 
The extract is treated with Ammonium 
Molybdate and concentrated nitric acid 
No yellow 
precipitate is 
formed 
Absence of 
Phosphate 
9. TEST FOR ALBUMIN 
The extract is treated with Esbach’s 
reagent 
No yellow 
precipitate is 
formed 
Absence of 
Albumin 
10. TEST FOR TANNIC ACID 
The extract is treated with ferric 
chloride. 
No blue black 
precipitate is 
formed 
Absence of 
tannic acid 
11. TEST FOR UNSATURATION 
Potassium permanganate solution is 
added to the extract 
It gets 
decolourised 
presence of 
unsaturated 
compound 
12. TEST FOR THE REDUCING 
SUGAR 
5ml of Benedict’s qualitative solution 
is taken in a test tube and allowed to 
boil for 2 minutes and add 8-10 drops 
of the extract and again boil it for 2 
minutes. 
No colour change 
Occurs 
Absence of 
reducing 
sugar 
 
13. 
TEST FOR AMINO ACID 
One or two drops of the extract is 
placed on a filter paper and dried well. 
After drying, 1% Ninhydrin is sprayed 
over the same and dried it well. 
Violet colour is 
Formed 
presence of 
amino acid 
14. TEST FOR ZINC 
The extract is treated with Potassium 
Ferrocyanide. 
No white 
precipitate is 
formed 
Absence of 
Zinc 
 
Inference: 
  Indicates the presence of calcium, sulphate, starch, ferrous iron, unsaturated 
compound and amino acid. 
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4.1.2.ANTIMICROBIAL ANALYSIS OF NANNARI VER OORAL KUDINEER 
Figure .4.1.2.1.ANTIMICROBIAL ANALYSIS OF NVOK 
    
   fig. 4.1.2.1.a. Staphylococcus aureus     fig.4.1.2.1.b. E.Coli 
 
 
 
 
 
 
 
 
 
      fig.4.1.2.1.c. Bacillus subtilius         fig.4.1.2.1.d. Klebsiella pneumoniae  
 
 
 
 
 
 
 
 
 
Fig.4.1.2.1.e. Streptococcus mutans 
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ANTIMICROBIAL  RESULTS 
Sample 
Code 
Bacteria  Strains Name 
Staphylococcus 
aureus (G+) 
Streptococcus 
mutans (G+) 
Bacillus 
subtilis 
(G+) 
Klebsilla 
pneumo
nia (G-) 
E – coli  
(G-) 
NVOK 12 - - 10 11 
PC 22 16 26 28 18 
NC - - - - - 
     
Keys 
PC - Positive Control (Streptomycin) 
NC - Negative Control 
-   - No Zone 
Mm - Millimetre  
G+  - Gram Positive Organism 
G- - Gram Negative Organism 
Trial drug  showed the anti- microbial activity against (MIC) both Gram 
positive (Staphylococcus aureus) and Gram negative bacteria (Klebsiella 
pneumoniae, E.coli) 
 
4.1.3.PHYTOCHEMICAL STUDY OF NANNARI VER OORAL KUDINEER  
The word “phytochemicals” are generally used to describe plant compounds 
that are under research with unestablished effects on health and are not scientifically 
defined as essential nutrients. These are chemicals produced by plants through 
primary or secondary metabolism. For the standardization purpose, islosation of 
specific compounds, determining their structures and identifying what specific 
phytochemical is primarily responsible for specific biologic activity should be carried 
out.  
The Nannari Ver Ooral Kudineer was subjected to qualitative phytochemical 
investigation. Details of the various test performed for the presence of the phyto 
constituents is shown in Table.4.1.3.a. 
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Table 4.1.3.a: Phytochemical Results of Nannari ver ooral kudineer. 
Phytochemical tests 
for NVOK 
Tests Inference 
Alkaloids Mayer’s test Positive 
Dragendroff’s test Positive 
Hager’s test Positive 
Carbohydrates and 
glycosides 
Molisch test Positive 
Legal’s test Positive 
Borntrager’s test for anthraquinones Positive 
Phytosterols Liebermann-Burchard test Positive 
Salkowski test Positive 
Flavanoids Shinoda test  
Magnesium turnings and hydrochloric  
acid (Presence of red color) 
Positive 
Fluorescence test Positive 
Tannins Ferric chloride test Positive 
Potassium dichromate test Positive 
Lead acetate test Positive 
Proteins Millon’s test Positive 
Biuret test Positive 
Ninhydrin test Positive 
Fixed oils and fats Spot test Negative 
Saponification test Negative 
Lignin  Phloroglucinol test Positive 
Saponins Frothing test Negative 
Positive indicates the presence of phyto-chemical constituents.  
Negative indicates the absence of phyto-chemical constituents . 
Results:  
The qualitative phytochemical analysis of nannari ver ooral kudineer has 
showed the presence of flavonoids, Carbohydrates, glycosides, alkaloids, 
phytosterols, Tanins, proteins and lignin. Fixed oils and saponins are absent .  
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4.1.4. PHARMACOLOGICAL ACTIVITIES: 
4.1.4.1 Analgesic activity: 
Acetic acid - induced writing test: 
The acetic-acid writhing test was performed as per the following procedure: 
24 adult male albino mice (25-35g) were divided into 4 groups. Groups of rats 
(n=6) were administered with 100 mg/kg and 200 mg/kg of nannari ver ooral 
kudineer, 10 mg/kg/. Diclofenac was taken for positive control group and 1ml 
distilled water as negative control group respectively. After 30 minutes , the animals 
were administered with i.p injection of 0.1ml acetic acid  0.6 % .Then the count of 
abdominal contractions of animals during 30 minutes after acetic acid injection was  
reported and the percentage activity (PAA) was calculated by  using the  following 
formula  
PAA = (C-CD)/ CD) X 100 
 
C=mean of contractions count in animals treated with different doses of  
Nannari Ver Ooral Kudineer and diclofenac sodium 
 
lCD=Mean of contractions count in animals served as negative control. 
 
Table 4.1.4.1.a  Effects of Nannari Ver Ooral Kudineer on acetic acid induced 
writhing response (N-6 in each group) 
Groups Treatment 
(Number of writhing  
movements) (Mean ±SEM) Percentage % 
Group I Distilled water  34.00±2.75  
Group II Diclofenac Sodium  
100 mg / kg 
6.55±1.02*b 80.73% 
Group III 100mg/kg NVOK 15.30±1.68*b 55.00% 
Group IV 200mg/kg NVOK 13.15 ± 1.28*b 61.32% 
 
Values are expressed as mean ± SEM 
*(b) Values are significantly different from Toxic control G2 at P<0.01 
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Discussion 
Acetic acid increases the PGE2 and PGEα in peritoneal fluid. The results of 
Nannari ver ooral kudineer when administered at the  doses  of 100 and 200 mg / kg 
showed significant antinociceptive activity in mice models and comparable with the 
effect of diclofenac sodium in analgesic activity. The analgesic activity shown in 
models of pain is indicative that nannari ver ooral kudineer might possess centrally 
and peripherally mediated antinociceptive properties. 
 
4.1.4.2Anti-inflammatory activity  
I. Carrageenan induced paw edema assay:  
Paw swelling or footpad edema, is a convenient method for assessing 
inflammatory responses to antigenic challenges and irritants. 
The Albino Wister rats (180 + 5g) were used. The rats were divided into 5 groups of 5 
animals each. 
• Rats of group I were given normal saline and treated as negative control.  
• Rats of group II were treated with carrageenan (1%w/v) in saline in the sub-
plantar region of the right hind paw.  
• Rats in group III were administered Indomethacin( 10 mg/kg, bw) and 
considered as standard.  
• Rats from group IV and V were given two doses siddha formulation (100 and 
200 mg/kg bw) respectively.  
Method: 
Acute paw edema was induced by injecting 0.1 ml of 1% (w/ Carrageenan 
solution, pre-pared in normal saline. After 1 hr, 0.1ml, 1 % Carrageenan suspension in 
0.9% NaCl solution was injected into the sub-plantar tissue of the right hind paw.The 
linear paw circumference will be measured at hourly interval for 4hr.The perimeter of 
paw was measured by using vernier callipers. Measurements were taken at 0-4hr after 
the administration of carrageenan. 
The anti-inflammatory activity was calculated by using the relation 
%inhibition of edema = T-T0           X100 
  T 
T= Thickness of paw in control group 
T0= Thickness of paw edema in the test compound treated group. 
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Table 4.1.4.2.a. Effect of NVOK on  carrageenan induced rat paw edema. 
Treatment 
Dose 
(mg/kg, p.o.) 
Mean increase 
in paw volume (ml) 
% Decrease 
in paw 
volume 
Normal control 10ml/kg saline 1.12 ± 0.11  
Toxic control 0.1 ml. 1% 
Carrageenan 
3.48 ±0.32*a 
 
 
Standard control 10 mg/kg 
Indomethacin 
1.25 ±0.14*b 
 
64.08% 
Treatment  
control 
100mg/kg NVOK 1.46 ± 0.19*b 58.04% 
Treatment  
control 
200mg/kg NVOK 1.36 ±0.16*b 60.91% 
 
Values are expressed as mean ± SEM. 
Values were compared by using analysis of variance (ANOVA) followed by 
Newman-Keuls multiple range tests 
(a) Values are significantly different from normal control G1 at P<0.01 
(b) Values are significantly different from Toxic control G2 at P<0.01. 
Results 
The results obtained indicate that the Nannari ver ooral kudineer had 
significant anti-inflammatory activity in rats. The kudineer reduced  carrageenan  
induced edema by 58.04% and 60.91% on oral administration of 100 and 200 mg/kg, 
as compared to the untreated control group .Indomethacin at 10 mg/kg inhibited the 
edema volume by 64.08%. 
 
II. Carrageenan Induced Pleurisy In Rats 
The animals were divided into five groups of five rats each as described in the 
carrageenan induced paw edema model and each were pretreated with siddha 
formulation (100 and 200 mg/kg. p.o.), Indomethacin (10 mg/kg, p.o.) or normal 
saline (0.1 ml).One hour later all the animals were received 0.25 ml of an intra-pleural 
injection of carrageenan on the right side of the thorax.  
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The animals were sacrificed 3 h after carrageenan injection by ether 
inhalation. One ml of heparinized Hank's solution was injected into the pleural cavity 
and gently massaged to mix its contents. The fluid was aspirated out of the cavity and 
the exudates were collected. The number of migrating leukocytes in the exudates was 
determined with Neubauer chamber . The values of each experimental group were 
expressed as mean SEM and compared with the control group. 
 
Table4.1.4.2.b.Effect of NVOK on carrageenan induced pleurisy in rats. 
Treatment Dose(mg/kg, p.o.) Pleural 
exudates (ml) 
Leukocytes 
(X103cells / ml) 
Normal control 10ml/kg saline 0.17 ±0.07 0.39 ± 0.06 
Toxic control 0.1 ml. 1% carrageenan 0.45 ±0.16*a 
 
4.23 ±0.39*a 
Standard 10 mg/kg Indomethacin 0.18 ±0.08*b 0.48 ±0.08*b 
Treatment  
control 
100mg/kg Nannari ver 
Ooral kudineer 
0.23 ±0.10*b 0.56 ± 0.11*b 
Treatment  
control 
 
200mg/kg Nannari ver 
Ooral kudineer 
0.19 ± 0.09*b 0.52 ± 0.10*b 
Values are expressed as mean ± SEM. 
Values were compared by using analysis of variance (ANOVA) followed by 
Newman-Keuls multiple range tests 
(a) Values are significantly different from normal control G1 at P<0.01 
(b) Values are significantly different from Toxic control G2 at P<0.01. 
 
Results 
The volume of pleural exudates in the toxic control group was 0.45+0.16 ml. 
Animals treated with the nannari ver ooral kudineer (100 and 200 mg/kg, p.o.) 
decreased the pleural exudates to 0.2340.10 ml and 0.19 0.09.Treatment with 
Indomethacin (10 mg/kg,p.o.) produced the exudates of 0.18+0.08 ml. The leukocyte 
count for the control group was found to be 4.23+0.39x103 cells/ml. Animals treated 
with the Nannari ver ooral kudineer and standard produced a leukocyte migration of 
0.56+0.11x103,0.52+0.10X103and 0.48+0.08X103cells/ml, respectively. 
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4.1.4.3 IMMUNOMODULATORY ACTIVITY 
The immunomodulatory study of Nannari ver ooral kudineer was conducted in 
wistar albino rats (180-220g) of either sex. It was tested on cyclophosphamide-treated 
immune suppressed rat models. The wistar albino rats were divided into seven groups 
and each group contained 6 animals. 
The groups are as follows: 
 Group I served as a control, which received saline solution. 
 Group II served as an immunosuppressant group, which received 
cyclophosphamide at the dosage of (30 mg/kg, i.p.) 
 Group III served as a parse control which received  Nannari  ver ooral 
kudineer (100 mg kg, i.p.) 
 Groups IV and V served as the test groups which were immune-suppressed 
with cyclophosphamide (30 mg/kg, i.p) and treated with  Nannari ver ooral 
kudineer (50 and 100 mg/kg, i.p), respectively. 
Group VI served as the positive control which received cyclophosphamide 
(30 mg/kg,i.p) along with Standard drug-levamisole hydrochloride (LH) (10 mg/kg 
bw, i.p) All the groups treated with Siddha Preparation Nannari ver ooral kudineer 
and levamisole hydrochloride were injected on daily basis for 11 days, while 
cyclophosphamide was given on 4, 5 and 6th days of the experiment.  
At the end of the experiment, the animals were sacrificed by cervical 
dislocation and the blood was collected using heart puncher in 3% citrate containing 
tubes. The organs namely liver, spleen, heart and kidney were immediately collected, 
weighed and stored at 8°C.  
Body weight and relative organ weight determination: -  
Body weight and relative organs (Spleen, liver, Heart, Kidney) weight were 
measured for all animals and the results were expressed as mg of organ weight/g body 
weight of animal,  
Organ weight index= W1/W0 × 100,  
where W1 is the weight of Organ and W0 is the weight of body  
Hematological analysis 
The level of WBC, RBC, platelet and heamoglobin level were determined 
using an automatic cell counter  
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Delayed type Hypersensitivity reaction 
The cell mediated immune response was assessed by footpad reaction test. On 
the 10th day, 5µg of hepatitis B vaccine was injected in the right paw and saline was 
injected in the left paw. On the 11th day after 24hr, the paw volume was measured 
using plethysmometer and the results were expressed as % of increase in the paw 
volume.  
Phagocytic response   
The phagocytic response was determined according to the method of Wang et 
al (2012). On the 7th day of the experiment, the animals were injected with 100 µl of 
Indian ink via intravenous injection. 50µl of blood was collected with 5µl of 3% 
citrate by retro-orbital puncher at an interval of 2 and 30 minutes after the injection of 
ink. Then 25 µl of citrated blood was added to 3 ml of 0.1% sodium carbonate 
solution to lyse the RBC. The concentration of ink in the blood was read at A675nm 
using spectrophotometer.  
The carbon clearance rate (κ) and phagocytic index (α) were calculated by 
using the following formula:  
Rate of carbon clearance (κ) = (1−log2)/(1−2)  
where OD1 is the absorbance at 2 minutes; OD2 is the absorbance at 30 
minutes; T1 is the time of blood collection at 2 minutes; T2 is the time of blood 
collection at 30 minutes  
Phagocytic index α =( ∛×	)/(
+)  
where A is the body weight, B is the liver weight, and C is the spleen weight.  
Total glutathione level  
Estimation of the reduced glutathione (GSH) level was done according to the 
method of Ellman (1959). Briefly, 400µl of the tissue homogenate was treated with 
400µl of 5% sulphosalicylic acid and mixed well with vortex. Then the mixture was 
centrifuged at 1000 x g for 10 minutes at 4°C. 100 µl of the supernatant was mixed 
with 400 µl of 0.3 M phosphate buffer (pH 8.4) and 400 µl of distilled water. Then 
100 µl of 0.001 M freshly prepared DTNB (5,5-dithiobis (2-nitrobenzoic acid)) was 
added and kept in room temperature for 10 minutes. The formation of yellow coloured 
product was measured at 412nm. The amount of glutathione present in the tissue 
homogenate was calculated by constructing standard graph with glutathione and the 
results were expressed as µM/mg of protein.  
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Lipid peroxidation  
The amount of lipid peroxide present in the tissue was estimated according to 
the method of Stocks and Dormandy (1971). Briefly, 400 µl of the tissue homogenate 
was mixed with an equal volume of 10 % Trichloro acetic acid and kept in 4°C for 30 
minutes. The proteins were removed by centrifugation at 2000 × g for 10 minutes at 
4°C. 500 µl of of 1% thiobarbituric acid was added to 500 µl of the supernatent and 
the mixture was kept in boiling water bath for 30 minutes. The reaction mixture was 
cooled and centrifuged at 2000 × g for 10 minutes at 4°C. The absorbance of the 
supernatant was measured at 532 nm using a spectrophotometer. The concentration of 
lipid peroxide was calculated using molar extinction coefficient of MDA-
thiobarbituric chromophore (1.56 x 10-5/M/cm) and the results were expressed in 
terms of nmoles MDA/mg of protein.  
Carbonyl protein  
The level of protein damage was determined by carbonyl protein estimation 
according to the method of Reznick and Packer (1994). Briefly 200µl of the tissue 
homogenate was treated with 200µl of 1% trichloro acetic acid and was kept at 4°C 
for 30 minutes. The mixture was centrifuged at 2000 x g for 15 minutes and the pellet 
was re-suspended in 10 mM 2,4-dinitrophenylhydrazine in 2N HCl or with 2N HCl as 
a control blank. This mixture was kept in room temperature for 1 hour and then 
centrifuged at 2000 x g for 10 minutes. 
The pellet was washed three times with 1:1 ethanol/ethyl acetate solution. 
Finally, the carbonyl protein containing the pellet was dissolved in 6 M Guanidine. 
The protein hydrazones were measured at A370 nm using spectrophotometer. The 
amount of carbonyl protein was calculated from molar extinction coefficient of 
22,000 M−1 cm−1 and the results were expressed as µg/mg of protein.  
Superoxide Dismutase activity  
The level of superoxide dismutase in the tissue was estimated according to the 
method of McCord and Fridovich (1969). This method is based on the ability of the 
enzyme to inhibit the auto-oxidation of pyrogallol. Briefly, 100µl of the tissue 
homogenate was added to 700 µl of 100 mm of Tris-HCl buffer (pH 8.2) containing 
30 mm EDTA. Then, 200µl of 2 mm of pyrogallol was added to the solution and 
measured at 420nm for 60 sec using spectrophotometer. A blank was run without the 
addition of homogenate. One unit of SOD activity is the amount of enzyme capable of 
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inhibiting 50% of the rate of autoxidation of pyrogallol compared with the blank and 
are expressed as units’/mg protein/min  
Catalase activity  
The catalase level in the tissue homogenate was estimated according to the 
method of Sinha (1972) with minor modification. Briefly, add 100 µl of tissue 
homogenate to 300 µl of 50 mM phosphate buffer pH-7. Then, 100 µl of 200mM 
H2O2 was added to the mixture, mix well and placed it in room temperature for 30 
sec. Immediately, after 30 secs, add 500 µl of 1.5% potassium dichromate / acetic acid 
(weight/volume). The mixture was kept in boiling water bath for 10 minutes and 
cooled. The absorbance was read at 590 nm against blank using spectrophotometer. 
The different concentration of H2O2 (1-50 µM) was used for construct the standard 
graph and The catalase activity was calculated from the standard graph of H2O2 (1-50 
µM) and results were expressed as µmole of H2O2 consumed/ mg of protein/ minute.  
 
Table no. 4.1.4.3.a   Effect on Siddha Preparation NVOK  on Haemoglobin level 
Groups Haemoglobin (g/dl) 
Group I 13.85 ± 0.34 
Group II 10.95 ± 0.24 
Group III 12.83 ± 0.30 
Group IV 12.92 ± 0.31 
Group V 13.02 ± 0.33 
Group VI 13.24 ± 0.36 
 
Table no. 4.1.4.3.b Effect on Siddha Preparation NVOK  on RBC level 
Groups RBC (106/µL) 
Group I 7.89 ± 0.17 
Group II 6.74 ± 0.09 
Group III 8.12 ± 0.13 
Group IV 7.62 ± 0.12 
Group V 7.56 ± 0.15 
Group VI 7.77 ± 0.16 
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Table No 4.1.4.3.c Effect of Nannari ver ooral kudineer on WBC level  
Groups WBC (106/ml) 
Group I 7.32 ± 0.24 
Group II 3.48 ±0.12 
Group III 6.56 ± 0.19 
Group IV 6.92 ± 0.21 
Group V 7.08 ± 0.22 
Group VI 6.82 ± 0.20 
 
Table 4.1.4.3.d Effect of Nannari ver ooral kudineer on Platelets level  
Groups 
Platelets 
count (103/µl) 
Group I 842.44 ± 10.55 
Group II 562.94 ± 6.35 
Group III 831.13 ± 9.66 
Group IV 792.24 ± 8.28 
Group V 806.28 ± 8.48 
Group VI 803.45 ± 7.88 
 
Table no: 4.1.4.3.e Effect of Siddha Preparation Nannari ver ooral kudineer  on 
enzymatic and non-enzymatic antioxidant status of liver tissue  
GROUPS 
Catalase 
U/mg 
SOD 
U/mg 
Glutathione 
U/mg 
MDA 
ηM/mg of 
protein 
PCO ηM/mg 
of protein 
Group I 4.97±0.38 63.28±3.82 36.64±1.40 7.38±0.42 3.22±0.17 
Group II 1.34±0.22 40.25±2.62 20.52±1.08 14.82±0.88 6.54±0.30 
Group III 3.88±0.34 56.25±2.88 32.45±1.32 12.62±0.68 5.42±0.21 
Group IV 3.63±0.29 56.62±2.98 30.28±1.12 12.82±0.75 5.68±0.24 
Group V 4.07±0.33 59.32±3.15 33.57±1.40 13.35±0.79 5.92±0.28 
Group VI 4.20±0.35 61.22±3.28 33.82±1.42 13.82±0.84 6.12±0.32 
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The protective effect of Siddha Preparation Nannari ver ooral kudineer  on 
hematopoietic function against CYP induced immune-toxicity was evaluated by 
counting the level of hematological parameters like (Haemoglobin) Hb, RBC, WBC 
and platelet cells. The results of hematological analysis showed that the level of Hb, 
RBC, WBC and platelet cells were significantly reduced in negative control group of 
animals (G2- CYP alone treated) when compared to normal control group of animals 
(G1-Saline alone) (P<0.01) However, these levels were raised significantly in Siddha 
Preparation Nannari ver ooral kudineer  treated group of animals (G4 =50 (mg/kg 
b.w.), and G5 = 100 (mg/kg b.w.) in a dose dependent manner. 
Myelo suppression is the process of decreasing the production of immune 
cells (leukocytes), oxygen carrying cells (erythrocytes) and the cells responsible for 
blood clot (thrombocytes) (Urabe 2003). The results of this study showed that the 
groups treated with Siddha Preparation Nannari ver ooral kudineer  have improved 
the production of hematopoietic cells like RBC, WBC, platelets and hemoglobin. The 
hematological results reveal that the  Nannari ver ooral kudineer has protective 
effect against CYP induced myelo suppression. 
The cell mediated immune response was determined by delayed type 
hypersensitivity reaction(DTH) by measuring their footpad thickness. The group of 
animals treated with Nannari ver ooral kudineer alone (G3) showed 33% higher 
footpad volume than the control group. In this study, Nannari ver ooral kudineer has 
enhanced the cell mediated immune response through the activation of T-cell. 
 The phagocytic test is used to evaluate the non-specific immunity of the 
system. The phagocytic index is calculated from the rate of clearance of colloidal 
carbon particles from the circulatory system. The results carbon clearance test 
indicates that Siddha Preparation Nannari ver ooral kudineer  can enhance non-
specific immune response against CYP induced immunosuppression  
The weight index of organs like spleen, liver, kidney and heart reflects the 
health of the organism. The toxic metabolite produced from CYP is initially 
metabolized in liver and produces toxic metabolite which is further transferred to 
other organs. The results of organ weight index showed that the suppressed health due 
to CYP induced oxidative stress have recovered to normal after Siddha Preparation 
Nannari ver ooral kudineer  treatment.  
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The non-enzymatic antioxidant status plays a major role in maintaining the 
innate antioxidant status. Reduced glutathione level is a suitable indicator for overall 
antioxidant defense which maintains alpha-tocopherol and ascorbic acid  and is also a 
coenzyme for glutathione S-o  transferases and glutathione peroxidases. Nannari ver 
ooral kudineer treatment  on cyclophosphamide-treated intoxicated group of animals 
(G4 and G5) directly decreased the glutathione level significantly based on the dose 
concentration in liver organs. 
Superoxide dismutase (SOD) and catalase (CAT) maintain the enzymatic 
antioxidant status of tissue. The Siddha Preparation Nannari ver ooral kudineer  
treatment to animal (G4 and G5) significantly restored the decreased CAT level to an 
equal or above the CAT levels of normal control group of animals in a dose-
dependent manner. The CAT levels in liver of Siddha Preparation Nannari ver ooral 
kudineer  alone treated group of animals (G3) was found high by 12.8 % than that 
normal control group of animals (G1).  
The level of SOD significantly increased upon the dose dependent manner 
treatment with Siddha Preparation Nannari ver ooral kudineer  and attained the level 
of normal control group of animals at the concentration of 100mg/kg. in liver tissues 
showed 22% higher SOD level than the normal control group of animals (G1).  
The important markers of macromolecular damage is due to oxidative stress 
by lipid and protein damage which produce lipid peroxide (MDA) and carbonyl 
protein (PCO). The increase levels of MDA and PCO indicate that toxic metabolite 
produced from CYP induced oxidative stress damage the lipids and proteins present in 
the organ tissue. CYP treatment significantly elevated the levels of macromolecule 
damage (MDA and PCO) and decrease the levels of enzymatic (SOD and CAT), non-
enzymatic (GSH) antioxidant status in Liver. At the same time, Siddha Preparation 
Nannari ver ooral kudineer  treatment at the concentration of 100mg/kg b.w. reverse 
the effect of CYP induced damage via increasing CAT, SOD and GSH levels and thus 
protecting macromolecular damage and decrease MDA and PCO level. The 
morphological analysis also supports above study and shows the ability of Siddha 
Preparation Nannari ver ooral kudineer  to repair the damage caused by CYP induced 
oxidative stress.  
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DISCUSSION 
According to above Table no 4.1.4.3 (1-5) In this study, CYP is given to the 
wistar albino rats to suppress the immune system and induce oxidative stress. The 
cyclophosphamide effect is expected to reduce the activity of hematological 
parameters, cell mediated immune responses and macrophage production. Moreover, 
CYP impaired the organs through its toxic metabolites and caused oxidative stress. 
The effect of Siddha Preparation Nannari ver ooral kudineer on CYP induced 
immune-toxicity was examined through myelo suppression, immune suppression and 
oxidative damage.  
 
4.1.5. Toxicity study of Nannari ver ooral kudineer 
Acute toxicity: 
Female Wister albino rats weighing 180 ± 20 g were used in acute 
toxicity study. The total no: of 18 animals were divided into three groups of six 
animals in this study. 
 The Group I animals were administered with a single daily dose of 0.5 ml of 
Tween 80 orally for 15 days. 
 In Group II are administered with (300 mg.kg-1b.w.NVOK ) once a day for 
15 days.  
 The Group III are fed 2000 mg.kg-1b.w. once daily for 15 days for acute 
toxicity studies. 
HPE revealed no acute toxic symptoms were observed after 15th day All test animals 
were subjected to gross necropsy. 
Table. 4.1.5.a Acute toxicity study of Nannari ver Ooral kudineer  
 Dose 
(mg.kg-1) 
Sign of Toxicity 
(ST.NB-1) 
Mortality 
(D.S-1) 
Group I 0 0/3 0/3 
Group II 300 0/3 0/3 
Group III 2000 0/3 0/3 
 
Table.1 showed ,the acute toxicity of Nannari Ver Ooral kudineer on experimental 
rats were tested using OECD -423 guidelines, where ST-sign of toxicity ,NB- normal 
behaviour, D- died, S-survive. Values are expressed as number of animals (n=3).  
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RESULTS 
• The acute toxicity of Nannari ver Ooral kudineer has showed no mortality or 
morbidity in animals through the 15-days period following single oral 
administration at all selected dose levels of the NVOK (Table- 4.1.5.a). 
• The morphological characteristics and physical appearance of all animals 
seems to normal. The physical appearance and motor nervous system was 
normal.  
• On comparison, Group I ,II and III showed no toxic effects for the doses upto 
2000/kg/bw. 
 
 Sub-acute toxicity: 
The sub acute toxicity were performed in Male and female Wistar rats 
weighing 180 ± 10 g. The animals were divided into five groups of six animals each. 
The administration of dose is calculated based on the body weight of the animal. 
• The animals in Group I were administered with a single daily dose of 0.5 ml of 
Tween 80 orally for 20 days.  
• The animals in Group II were administered with 50 mg.kg-1 b.w. of the 
NVOK once in daily for 20 days. 
• The animals in Group III were administered with 100 mg.kg-1 b.w. of the 
NVOK orally once daily for 20 days. 
• The animals in Group IV and V were administered 200 and 400 mg.kg-1 b.w. 
once in daily for 20 days. 
The animals were weighed during every five days starting from 
commencement of the study to record the weight variations. At the end of the 
treatment, blood samples were taken for biochemical analysis. The serum plasma was 
analyzed for 
 Total cholesterol 
 Total triglyceride 
 HDL-cholesterol levels 
 LDL-cholesterol 
 Plasma glucose 
 Alanine aminotransferase (ALT) &Aspartate aminotransferase (AST) 
 Creatinine and urea level. 
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Effect of Nannari ver Ooral kudineer(NVOK) on internal organs 
According table no 4.1.5.b. no toxic effects found in kidney, heart, liver and 
brain of the rats were observed. From the study it was clear that, significant (p<0.01) 
changes in the weights of various organs of the animals with higher doses of NVOK 
(400 mg.kg-1 bwt). The group I was compared with other group II, III, IV, and V.  
 
Table: 4.1.5.b The effects of NVOK on kidney, heart, liver and brain of the rats 
Treatment Heart Kidney (gms)   Liver (gms) Brain (gms) 
Control 0.35 ± 0.05 0.65± 0.03 3.33± 0.05 0.68± 0.06 
NVOK  50  
mg.kg-1 
0.36± 0.02 0.81± 0.03 3.45± 0.03 0.71± 0.4 
NVOK   
100 mg.kg-1 
0.37± 0.06 0.79± 0.04 3.76±0.02 0.69± 0.3 
NVOK 200  
mg.kg-1 
0.36± 0.04 0.74± 0.02 3.65± 0.02 0.76± 0.06 
NVOK 400  
mg.kg-1 
0.35± 0.03 0.75± 0.03 3.87± 0.03 0.78± 0.06 
The values are expressed as mean ± S.E.M. n=6. The results of group I were 
compared with other groups such as II, III, IV, and V. The statistical analysis was 
carried out using one way ANOVA  method, where **P<0.01. 
 
Effect of biochemical profiles of rats 
Table no 4.1.5.c.The effect of NVOK on biochemical parameters 
Treatment 
Glucose 
(mg.dl-1) 
Cholesterol 
(mg.dl-1) 
Triglyceride 
(mg.dl-1) 
HDL 
(mg.dl-1) 
LDL 
(mg.dl-1) 
Control 94.65± 0.62 39.62± 0.56 28.25± 0.45 135.25± 0.55 83.15±1.72 
NVOK 50 
 mg.kg-1 
92.50± 0.56 25.85± 0.25* 13.22± 0.23* 175.28± 0.65* 71.59±1.28 
NVOK 100 
 mg.kg-1 
89.45± 0.47 26.74± 0.26* 15.42± 0.28* 165.18±0.78* 69.84±1.10 
NVOK 200  
mg.kg-1 
90.25± 0.55** 33.18± 0.30 17.84± 0.38* 184.30± 0.84* 48.60±1.30 
NVOK 400 
 mg.kg-1 
86.25± 0.45** 32.78± 0.28 19.28± 0.34* 182.2± 0.85* 46.50±0.84 
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Above Table no 4.1.5.c Showed  that nannari ver ooral kudineer has significantly 
decreased (p<0.05)  the plasma glucose level in treated rats especially at higher dose 
(400 mg.kg-1) compared with control groups. **P<0.01 *P<0.05. Significant 
decrease (p<0.05) in the plasma total cholesterol (TC), triglyceride (TG) and LDL-
cholesterol levels were also noted. There was no evidence of severe toxicity 
associated with the administration of higher concentration of NVOK. 
 
Change noted in the hepatic enzymes: 
In table.4.1.5.d.comparison of AST, ALT, ALP, TP and Albumin values  
between Group I and  groups II, III, IV, and V were demonstrated.  
Table. 4.1.5.d The effects of NVOK on hepatic enzymes in rats. 
Treatment 
AST 
(IU.l-1) 
ALT 
(IU.l-1) 
ALP 
(IU.l-1) 
TP 
(g.l-1) 
ALBUMIN 
(g.l-1) 
Control 328.5±12.0 70.5± 3.18 253.58± 8.80 69.85± 3.32 37.15±2.35 
NVOK 50 
mg.kg-1 
317.0±9.50 68.5±2.20** 266.10±2.75** 70.30± 2.32 34.30±2.65 
NVOK 100 
mg.kg-1 
318.3±7.20 66.1± 3.15** 260.18±6.70** 80.15± 2.82 36.30±3.05 
NVOK 200 
mg.kg-1 
313.4±7.95 61.4± 2.90 265.00± 5.20 69.25± 3.32 38.20±2.75 
NVOK 400  
mg.kg-1 
323.2±8.20 63.3± 3.52 269.40± 4.40 74.05± 2.58 37.48±2.70 
 
Effect of Nannari Ver Ooral Kudineer on haematological parameters in rats: 
From the study it was evident that, a significant increase (p<0.01) were 
observed in the hemoglobin contents and RBC count in the group treated with 200 
mg.kg-1 / body weight. There was no significant change in the calcium level in all the 
treated animals compared to the control. 
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Table. 4.1.5.e. The effect of Nannari Ver Ooral Kudineer on haematological 
parameters  & calcium in rats  
Treatment 
Haemoglobin 
(mg.dl-1) 
RBC 
(106 /mm3) 
WBC 
(106 /mm3) 
Calcium 
(mg.dl-1) 
Control 11.3± 0.25 9.15± 0.02 11.45± 0.05 9.44 ±0.02 
NVOK 50 
mg.kg-1 
12.5± 0.26* 9.50± 0.04* 9.55± 0.01* 9.20 ±0.02 
NVOK 100 
mg.kg-1 
12.3± 0.15* 9.55± 0.02* 8.35± 0.32* 9.26 ±0.20 
NVOK 200 
mg.kg-1 
10.7± 0.20* 8.30± 0.12* 11.45± 0.03* 9.61 ±0.13 
NVOK 400 
mg.kg-1 
11.5± 0.35* 8.48± 0.45* 10.55± 0.13* 9.75 ±0.02 
 
Effect of Nannari ver Ooral kudineer on body weight in rats: 
The effect of NVOK was observed for their effect on the body weight changes 
was observed ,significant increased (p<0.05) in body weight. The results are described 
in Table. 4.1.5.f The values are expressed as Mean ± S.E.M. n=6. The results of 
group I were compared with other group II, III, IV, and V ( **P<0.01 *P<0.05). 
 
Table. 4.1.5.f.The effects of NVOK on body weight changes in rats 
Treatment Day1 Day 5 Day 10 Day 20 
Control 187.15±6.8 189.45 ±6.20 198.15 ±6.35 196.75±6.60 
NVOK 50 
mg.kg-1 
196.30 ±6.4 
 
195.30 ±6.30 
 
200.25 ±6.70 
 
198.35±6.76* 
NVOK 100 
mg.kg-1 
188.35 ±5.7 191.30 ±6.40 198.55 ±7.10 197.40±6.36* 
 
NVOK 200 
mg.kg-1 
197.30 ±7.2 200.15±6.50 200.90 ±7.20** 206.50±7.30** 
NVOK 400  
mg.kg-1      
187.65 ± 6.05 194.15 ±5.60                    197.60 ±6.35**                   207.63±7.42** 
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DISCUSSION 
In acute toxicity, the limit dose of 2000 mg/ kg (NVOK) did not result in 
mortality or any clinical sign of acute toxicity in animals in the short-term (48 hours) 
and longterm (14 days) observatory periods, suggesting that no toxic effects upto 
2000 mg/kg in rats.  
Sub acute toxicity study showed that the extract did not affect the normal 
growth of the animals as evidenced by comparing the body weight gain in both 
control and treated animals over the 28-day treatment periods. There were no 
significant changes in liver enzymes (ALT,AST,ALP and IP) .The significantly 
increased in the level of RBC,WBC  and hemoglobin was found in treatment with 
Nannari ver Ooral kudineer (400mg.kg-1). The extract caused no undesirable effect 
on the all organ of the animals making it safe for consumption by human health and it 
was non hemotoxic. 
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4.2 Clinical study: 
The results were observed regarding the following criteria by clinical trial 
study on 40 patients: Out of forty, 20 In patients and 20 Out patients of both sex. 
The criteria were: 
1. Sex Distribution 
2. Age Distribution 
3. Kaalam 
4. Constitution of body 
5. Gunam 
6. Religion 
7. Paruva Kaalam 
8. Thinai 
9. Socio – Economical status 
10. Food habits 
11. Family History 
12. Occupation 
13. Clinical Manifestation 
14. Duration of Illness 
15. Kanmenthiriyam 
16. Gnanendrium 
17. Condition of Mukkutram 
a). Condition of Vatham 
b). Condition of Pitham  
c). Condition of Kapham 
18. Involvement of Udal Kattugal 
19. Conditions of Envagai Thervugal 
20. Neer kuri 
21. Nei kuri 
22. Assessment of outcome 
23. Gradation of results 
24. Laboratory Investigations 
a). Out patients b). In patients 
25. Diseases activity pain score 
a). Out patients b). In patients 
26. Case summary   
a). Out patients b). In patients 
 1.SEX DISTRIBUTION:
Table-1 Illustrates the Distribution of Sex and its percentage.
TABLE
Sl. 
No. 
Sex 
1. Male 
2. Female 
 Total 
 
Among 20 Out patients 25% were Male and 75% were Female. 
Among 20 In patients, 15% were Male and 85% were Female.
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-1 DISTRIBUTION OF SEX 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage
(%)
5 25% 3 15%
15 75% 17 85%
20 100% 20 100%
 
 
-1 DISTRIBUTION OF SEX 
No. Of Cases
In Patients (IP)
3
17 Male
Female
 
 
 
 
 
 
 2.AGE DISTRIBUTION:
Table-2 Illustrates the Distribution of Age and its percentage.
TABLE
Sl. 
No. 
Age group in 
years
1. 11 to 20
2. 21 to 30
3. 31 to 40
4. 41 to 50
 Total
 
From the above table it is observed that the highest incidence of Vali Azhal 
Keel Vayu in Out patients is among the age group of 41 to 50 with 50% and 31 to 40 
with 35%, 15% were in the age group of 21 to 30 years. Among 20 
were in the age group 21 to 30 years , 05% were in the age group of 31 to 40 years , 
85% with the highest incidence in the age group of 41 to 50
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-2 DISTRIBUTION OF AGE 
 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage
(%)
 0 0% 0 0%
 3 15% 2 10%
 7 35% 1 5%
 10 50% 17 85%
 20 100% 20 100%
In 
 years. 
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3.KAALAM DISTRIBUTION:
Table-3 Illustrates the Distribution of Kaalam
TABLE
Sl. 
No. 
Kaalam
1. Vatham
2. Pitham
3. Kapham
 Total 
 
Among 20 Out patients, 20% were affected in Vatha Kaalam and 80% were affected 
in Pitha Kaalam. Among 20 In patients, 90% were affected in Pitha Kaalam and 10% 
were affected in Vatha Kaalam.
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 and its percentage. 
-3 DISTRIBUTION OF KAALAM 
 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage
(%)
 4 20% 2 10%
 16 80% 18 90%
 0 0% 0 
20 100% 20 100%
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 4.CONSTITUTION OF
Table-4 Illustrates the Distribution of Constitution Body and its percentage.
TABLE-4 DISTRIBUTION OF CONSTITUTION OF BODY
Sl. 
No. 
Constitution 
of body 
1. Vatham 
2. Vatha Pitham 
3. Vatha Kapham 
4. Pitham 
5. Pitha Vatham 
6. Pitha Kapham 
7. Kapham 
8. Kaba Vatham 
9. Kaba Pitham 
 Total 
 
Vatha Pitha Thegi register high incidence of Vali Azhal Keel Vayu with 80% OP and 
75% IP. Remaining Pitha Vatha Thegi of 20% OP and 25% IP.
 
FIGURE-4 DISTRIBUTION OF CONSTITUTION OF BODY
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 BODY: 
 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage (%) No. of 
Cases 
Percentage 
0 0% 0 
16 80% 15 
0 0% 0 
0 0% 0 
4 20% 5 
0 0% 0 
0 0% 0 
0 0% 0 
0 0% 0 
20 100% 20 
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 5. GUNAM: 
Table-5 Illustrates the Distribution of Gunam and its percentage.
TABLE
Sl. 
No. 
Gunam
1. Sathuva Gunam
2. Rajo Gunam
3. Thamasa Gunam
 Total 
 
Among 20 Out patients, 5% were Sathuva Gunam, 70% were Rajo gunam and 
25% were Thamasa gunam. 
Among 20 In patients, 80% were Rajo gunam and 20% were Thamasa gunam.
FIGURE
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-5 DISTRIBUTION OF GUNAM 
 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage 
 1 5% 0 
 14 70% 16 
 5 25% 4 
20 100% 20 
 
 
 -5     DISTRIBUTION OF GUNAM 
No. of Cases
In Patients (IP)
0
16
4
Sathuva Gunam Rajo Gunam Thamasa Gunam
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 6. RELIGION: 
Table-6 Illustrates the Distribution of Religion and its percentage.
TABLE
Sl. 
No. 
Religion
1. Hindu 
2. Christian 
3. Muslim 
 Total 
 
Among 20 Out patients, 75% were Hindus, 15% were Christians.10% were 
Muslims. Among 20 In patients, 80% were Hindus,15% were Christians 
Muslims . 
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-6 DISTRIBUTION OF RELIGION 
 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage 
15 75% 16 
3 15% 3 
2 10% 1 
20 100% 20 
-6 DISTRIBUTION OF RELIGION 
No. of Cases
In Patients (IP)
16
3
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(%) 
80% 
15% 
5% 
100% 
and 5% were 
Muslim
 7. PARUVA KAALAM:
Table-7 Illustrates the Distribution of Paruva Kaalam and its percentage.
TABLE-7 DISTRIBUTION OF PARUVA KAALAM
Sl. 
No. 
Paruva Kaalam
1. Elavenil Kaalam
2. Muthuvenil Kaalam
3. Kaar Kaalam 
4. Koothir Kaalam
5. Munpani Kaalam
6. Pinpani Kaalam
 Total 
 
Among 20 Out patients, 05% of cases were in Elavenil Kaalam, 30% of cases 
were in Muthuvenil Kaalam ,40% of cases were in Kaar Kaalam ,05% of cases were 
in Koothir Kaalam, 15% of cases were in 
Pinpani Kalam. 
Among 20 In patients, 05% of cases were in Elavenil Kaalam, 15% of cases 
were in Muthuvenil Kaalam ,20% of cases were in Kaar Kaalam ,10% of cases were 
in Koothir Kaalam, 25% of cases were in Munpani K
Pinpani Kalam. 
 
FIGURE-7 DISTRIBUTION OF PARUVA KAALAM
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Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage 
 1 5% 1 
 6 30% 3 
8 40% 4 
 1 5% 2 
 3 15% 5 
 1 5% 5 
20 100% 20 100%
Munpani Kaalam and 05% of cases were in 
aalam and 25% of cases were in 
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 8. THINAI: 
Table-8 Illustrates the Distribution of Thinai and its percentage.
TABLE
Sl. 
No. 
Thinai 
1. Kurinji 
2. Mullai 
3. Marutham 
4. Neithal 
5. Paalai 
 Total 
 
Among 20 Out patients, 5% were from 
were in Marutham  and  5% were in Neithal.
Among 20 In patients, 70% were in Marutham , 20% were in Neithal ,10% 
were in Mullai,  
FIGURE
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-8 DISTRIBUTION OF THINAI 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage 
(%)
1 5% 0 0%
3 15% 2 10%
15 75% 14 70%
1 5% 4 20%
0 0% 0 0%
20 100% 20 100%
Kurinji, 15% were from Mullai, 75% 
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9. SOCIO - ECONOMICAL
Table-9 Illustrates the Socio 
TABLE
Sl. 
No. 
Socio – Economical Status
1. Low income class
2. Middle income class
3. High income class
 Total 
 
Among 20 Out patients, 15% were in Low income class, 60% were in Middle 
income class and 25% were in High income class. Among 20 In
in Low income class, 50% were in Middle income class and 5% were in High income 
class. 
FIGURE
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 STATUS: 
– Economical Status of patients and its percentage.
-9 SOCIO – ECONOMICAL STATUS 
 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage
 3 15% 9 
 12 60% 10 
 5 25% 1 
20 100% 20 
 patients, 45% were 
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 10. FOOD HABITS: 
Table-10 Illustrates the Distribution of
Sl. 
No. 
Food Habits
1. Vegetarian diet 
2. Non – Vegetarian diet
 
 Total 
 
Among 20 Out patients, 35% were Vegetarian and 65% were non 
Among 20 In patients, 25% were vegetarian and 75% were non 
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 diet among the patients and its percentage.
TABLE-10 FOOD HABITS 
 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage
(%)
7 35% 5 25%
 13 65% 15 75%
20 100% 20 100%
– 
FIGURE-10  FOOD HABITS 
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vegetarian. 
 11. FAMILY HISTORY:
Table-11 Illustrates the Family History and its percentage.
Sl. 
No. 
Family History
1. Positive 
2. Negative 
 
 Total 
 
Among 20 Out patients, 15% have positive Family History and 85% don’t 
have any positive Family History. Among 20 In patients, 25% have positive Family
History and 75% don’t have any positive Family History.
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TABLE-11 FAMILY HISTORY 
 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage
(%)
3 15% 5 25%
17 85% 15 75%
20 100% 20 100%
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 12. OCCUPATION: 
Table-12 Illustrates the Occupation and its percentage.
Sl. 
No. 
Occupation 
1. Agricultural labours
2. Coolie 
3. House wife 
4. Watchman 
5. Driver 
6. Beedi Worker 
7. Business 
8. Sales Women 
9. Teacher 
 
 Total 
 
Among 20 Out patients, 15% Agricultural labours, 50% House Wife,  5% 
Driver, 1 5% Beedi worker, 5% Business and  10% Teacher.
Among 20 In patients, 25% Agricultural labours, 15% Coolie, 45% House 
Wife,5% Watchman, and 10% Sales women were observed
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TABLE-12 OCCUPATION 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
 3 15% 5 
0 0% 3 
10 50% 9 
0 0% 1 
1 5% 0 
3 15% 0 
1 5% 0 
0 0% 2 
2 10% 0 
20 100% 20 
 
.    
FIGURE-12 OCCUPATION 
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13.CLINICAL MANIFESTATION: 
Table-13 Illustrates the Clinical Manifestation and its percentage. 
TABLE-13 CLINICAL MANIFESTATION 
Sl. 
No. 
Symptoms 
Out Patients (OP) In Patients (IP) 
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage 
(%) 
1. Arthritis involving 
more than 3 joints 20 100% 20 100% 
2. Severe pain and 
swelling 
20 100% 20 100% 
3. Symmetrical joint 
involvement 
20 100% 20 100% 
4. Morning stiffness 20 100% 20 100% 
5. Anorexia 6 30% 4 20% 
6. Rheumatoid nodules 2 10% 3 15% 
7. Depression 10 50% 9 45% 
 
Among 20 Out patients, 100% cases have arthritis involving more than 3 
joints, severe pain and swelling, symmetrical joint involvement,100% have morning 
stiffness , 50% have depression, 30% have Anorexia, 10% have Rheumatoid nodules. 
Among 20 In patients, 100% cases have arthritis involving more than 3 joints, severe 
pain and swelling, symmetrical joint involvement,100% have morning stiffness, 
45%have depression, 15% have rheumatoid nodules, 20% have anorexia. 
 FIGURE
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 14. DURATION OF ILLNESS:
Table-14 Illustrates the Duration of Illness and its percentage.
TABLE
Sl. 
No. 
Duration of illness
1. Below 1 year 
2. 1 to 2 years 
3. 2 to 3 years 
4. 3 to 4 years 
5. Above 4 years 
 Total 
 
Among 20 Out patients, Duration of Illness was 20% below 1 year, 30% in 1
to 2 years ,10% in 2 to 3 years, 5% in 3 to 4 years and 35% in above 4 years. 
Among 20 In patients,
2 years, 25% in 2 to 3 years and 
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-14 DURATION OF ILLNESS 
 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage 
4 20% 7 
6 30% 2 
2 10% 5 
1 5% 2 
7 35% 4 
20 100% 20 100%
  Duration of Illness was 35% below 1 year, 10% in 1 to 
  10% in 3to 4 years,20% above 4 year. 
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 15. KANMENTHIRIYAM:
Table-15 Illustrates the Kanmenthiriyam and its percentage.
TABLE
Sl. 
No. 
Kanmenthiriyam
1. Kai 
2. Kaal 
3. Vai 
4. Eruvai 
5. Karuvai 
 
Among 20 Out patients, 100% cases were affected in Kai, Kaal, 20% cases 
were affected in Eruvai. Among 20 In patients, 100% cases were affected in Kai, 
Kaal, 25% cases were affected in
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-15 KANMENTHIRIYAM 
 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
20 100% 20 
20 100% 20 
0 0% 0 
4 20% 5 
0 0% 0 
 Eruvai. 
 
-15 KANMENTHIRIYAM 
Kaal Vai Eruvai Karuvai
0
4
0
20
0
5
0
Out Patients (OP) No. of 
Cases
In Patients (IP) No. of 
Cases
 
Percentage 
(%) 
100% 
100% 
0% 
25% 
0% 
 
 16.GNANENDRIUM 
Table-16 Illustrates the Gnanendrium and its
Sl. 
No. 
Gnanendrium
1. Mei 
2. Vaai 
3. Kan 
4. Mookku 
5. Sevi 
 
Among 20 Out patients, 100% of the patients were affected in Mei, 5% of the
patients were affected in kan.
Among 20 In patients, 100% of the patients were affected in Mei, 10% of the
patients were affected in kan.
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 percentage. 
TABLE-16 GNANENDRIUM 
 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage 
(%)
20 100% 20 100%
0% 0% 0% 0%
1 5% 2 10%
0 0% 0 0%
0 0% 0 0%
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17.CONDITION OF MUKKUTRAM: 
17(a) Condition of Vatham. 
Table-17 Illustrates the Condition of Vatham and its percentage. 
TABLE-17 (a) CONDITION OF VATHAM 
Sl. 
No. 
Condition of 
Vatham 
Out Patients (OP) In Patients (IP) 
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage   
(%) 
1. Piraanan 0 0% 0 0% 
2. Abaanan 4 20% 5 25% 
3. Viyaanan 20 100% 20 100% 
4. Uthaanan 0 0% 0 0% 
5. Samaanan 20 100% 20 100% 
6. Naagan 0 0% 0 0% 
7. Koorman 1 5% 2 10% 
8. Kirukaran 5 25% 3 15% 
9. Devathathan 20 100% 20 100% 
10. Dhananjayan 0 0% 0 0% 
 
Viyaanan, Samaanan, were affected in 100% of both Out patients and In 
patients. Abaanan was affected in 20% of Out patients, and 25% of the In patients, 
Kirugaran was affected in 25% of Out Patients, and 15% of In patients. Devathathan 
was affected in 100% of Out patients, and 100% of In patients. Koorman was affected 
in 5% of Out patients and 10% of In patients, 
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-17 (a) CONDITION OF VATHAM 
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 17(b). CONDITION OF PITHAM
Table-17 (b) Illustrates the Condition of Pitham and its percentage.
TABLE
Sl. 
No. 
Pitham 
1. Anala Pitham 
2. Ranjagam 
3. Sathigam 
4. Prasagam 
5. Aalosagam 
 
Among 20 Out patients, 25% affected in Anala Pitham
Pitham and 100% in Sathiga Pitham, 5% in Aalosagapitham. Among 20 In patients, 
15% affected in Anala Pitham, 75% in Ranjaga Pitham and 100% in Sathiga Pitham, 
10% in Aalosagapitham. 
FIGURE
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-17 (b) CONDITION OF PITHAM 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage 
(%) 
5 25% 3 15%
10 50% 15 75%
20 100% 20 100%
0 0% 0 0%
1 5% 2 10%
, 50% in Ranjaga 
 
-17 (b) CONDITION OF PITHAM 
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 17 (c) CONDITION OF KAPHAM
Table-17 (c) Illustrates the Condition of Kapham and its percentage.
TABLE
Sl. 
No. 
Kapham 
1. Avalambagam 
2. Kilethagam 
3. Pothagam 
4. Tharpagam 
5. Santhigam 
 
Kilethagam was affected in 25% of Out patients and 15% of In patients.
Santhigam was affected in 100% of both Out
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-17 (c) CONDITION OF KAPHAM 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage  
(%) 
No. of 
Cases 
Percentage 
0 0% 0 
5 25% 3 
0 0% 0 
0 0% 0 
20 100% 20 
 patients and In patients.
-17 (c) CONDITION OF KAPHAM 
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 18. INVOLVEMENT OF UDAL KATTUGAL 
Table-18 Illustrates the involvement of Udal Kattugal (or) Udal Thathukal and its 
percentage. 
TABLE-18
Sl. 
No. 
Udal Kattugal 
1. Saaram 
2. Senneer 
3. Oon 
4. Kozhuppu 
5. Enbu 
6. Moolai 
7. Sukkilam / 
Suronitham 
 
Among 20 Out patients and In patients Saaram, Enbu,Kozhuppu, Moolai were 
affected in 100% of the cases. senneer was affected in 50% of OP and 75% of IP.
 
FIGURE-18 INVOLVEMENT OF UDAL KATTUGAL
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 INVOLVEMENT OF UDAL KATTUGAL 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage
20 100% 20 
10 50% 15 
0 0% 0 
20 100% 20 
20 100% 20 
20 100% 20 
0 0% 0 
0
20 20 20
0
15
0
20 20 20
In Patients (IP) No. of  Cases
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100% 
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19.CONDITIONS OF ENVAGAI THERVUGAL 
Table-19 Illustrates the conditions of Envagai Thervugal and its percentage. 
TABLE-19 CONDITION OF ENVAGAI THERVUGAL 
Sl. 
No. 
Envagai Thervugal Out Patients (OP) In Patients (IP) 
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage 
(%) 
1. Naadi (Thontha Naadi) 20 100% 20 100% 
 1). Vatha Pitham 16 80% 15 75% 
 2). Vatha Kapham 0 0% 0 0% 
 3). Pitha Vatham 4 20% 5 25% 
 4). Pitha Kapham 0 0% 0 0% 
 5). Kapha Vatham 0 0% 0 0% 
 6). Kapha Pitham 0 0% 0 0% 
2. Sparisam 20 100% 20 100% 
3. Naa 0 0% 0 0% 
4. Niram 0 0% 0 0% 
5. Mozhi 0 0% 0 0% 
6. Vizhi 1 5% 2 10% 
7. Malam 4 20% 5 25% 
8. Moothiram 0 0% 0 0% 
 
Among 20 Out patients, 5 % were affected in Vizhi, 20% were affected in 
Malam, 100% was affected in Sparisam, Naadi-80% with Vatha Pitham, 20% with 
Pitha Vatham . Among 20 In patients, 10% were affected in Vizhi, 25% was affected 
in Malam, 100% was affected in Sparisam, Naadi-75% with Vatha Pitham , and 25% 
with Pitha Vatham. 
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 20.NEER KURI 
Table-20 Illustrates the Neer 
Sl. 
No. 
Neer kuri 
No.
1. Niram 
2. Manam 
3. Edai 
4. Nurai 
5. Enjal 
 
Niram was affected in 25% of Out patients and 30% of In patients. Nurai was 
affected in 5% of Out patients and 10% of In patients.
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kuri condition and its percentage. 
TABLE-20 NEER KURI 
Out Patients (OP) In Patients (IP)
 of  Cases 
Percentage 
(%) No. of Cases 
Percentage
5 25% 6 
0 0% 0 
0 0% 0 
1 5% 2 
0 0% 0 
 
FIGURE – 20  NEER KURI 
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 21.NEI KURI 
Table-21 Illustrates the Nei Kuri conditions and its percentage.
Sl. 
No. 
Nei Kuri 
1. Vatha Neer / 
spreading like snake
2. Pitha Neer / spreading
like ring 
3. Kapha Neer / 
spreading like pearl
4. Thontha Neer / 
Asthiya Neikurigal
 
Among 20 Out patients, 80% had Vatha Neer, 20% had Pitha neer. Among 20 
In patients, 75% had Vatha Neer, 25% had Pitha 
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TABLE-21 NEI KURI 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage
 
16 80% 15 
 
4 20% 5 
 
0 0% 0 
 
0 0% 0 
Neer. 
FIGURE-21  NEI KURI 
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22.ASSESSMENT OF OUTCOME: 
Table-22 Illustrates the Assessment of Outcome and its percentage. 
 
TABLE-22 ASSESSMENT OF OUTCOME 
Sl. 
No. 
Assessment 
of     
Outcome 
Before Treatment After Treatment 
Out Patients 
(OP) In Patients (IP) 
Out Patients 
(OP) InPatients(IP) 
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage 
(%) 
1. Low 0 0% 0 0% 11 55% 12 60% 
2. Moderate 0 0% 0 0% 6 30% 6 30% 
3. High 20 100% 20 100% 3 15% 2 10% 
 
Lower disease activity 2.6<DAS28 ≤ 3.2  
Moderate disease activity 3.2<DAS28 ≤ 5.1 
High disease activity DAS28>5.1 
 
Reference: 
Prevoo ML, Van’t Hof MA Kuper HH, Van Leeuwen MA, Van de Putte LB, 
Van Rie / PL (1995). “Modified disease activity scores that include twenty-eightjoints 
counts. Development and validation in a prospective longitudinal study of patients 
with rheumatoid arthritis”. Arthritis Rheum. 38 (1):44-8. 
 
 
 
 
 
 FIGURE
 
Before Treatment: 
Among 20 Out patients, and 20 In patients 100% of cases were with High 
disease activity. 
 
After Treatment: 
Among 20 Out patients, 55% of cases with Low disease activity 30% of cases 
with Moderate disease activity and 15% of cases with High disease activity. Among 
20 In patients, 60% of cases with Low disease activity, 30% of cases with Moderate 
disease activity and 10% of cases with High disease activity.
        
 
 
 
 
 
 
 
 
 
 
 
0
5
10
15
20
NO OF 
CASES
BEFORE 
TREATMENT 
OP CASES
TREATMENT 
0 0
20
113 
 
 -22 ASSESSMENT OF OUTCOME 
 
NO OF 
CASES
NO OF 
CASES
NO OF 
CASES
AFTER 
IP CASES
AFTER 
TREATMENT  
OP CASES
AFTER 
TREATMENT 
IP CASES
0
11 12
0
6 6
20
3 2
LOW MODERATE
 
HIGH
 23.  GRADATION OF RESULTS:
Table-23 Illustrates the Gradation of results and its percentage.
TABLE
Sl. 
No. 
Results 
1. Good response 
2. Moderate response
3. Poor response 
 
 Total 
 
Among 20 Out patients, 55% of cases showed Good response, 30% of cases
showed Moderate response and 15% of cases showed Poor
Among 20 In patients, 60% of cases showed Good response, 30% of cases
showed Moderate response and 10% of cases showed Poor
                                       
FIGURE
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-23 GRADATION OF RESULTS 
Out Patients (OP) In Patients (IP)
No. of 
Cases 
Percentage 
(%) 
No. of 
Cases 
Percentage
(%) 
11 55% 12 60% 
 6 30% 6 30% 
3 15% 2 10% 
20 100% 20 100%
 response. 
 response. 
-23 GRADATION OF RESULTS 
Moderate Response Poor Response
30%
15%
60%
30%
10%
Out Patients (OP) Percentage (%)
In Patients (IP) Percentage (%)
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TABLE-24(a) 
i) LABORATORY INVESTIGATION OF OUT PATIENTS 
 
SL. 
NO 
OP. 
NO 
                    HAEMATOLOGICAL REPORT                     URINE   ANALYSIS 
BEFORE TREATMENT  AFTER TREATMENT BEFORE TREATMENT  AFTER TREATMENT 
TC DC ESR 
(1hr) 
Hb 
gms   
% 
TC 
 
DC ESR 
(1hr) 
Hb 
gms 
% 
Alb Sug Dep – 
Epi cells/ 
Pus cells 
Alb Sug Dep – 
Epi cells/ 
Pus cells 
P L E P L E 
1. 50264 6000 63 35 2 70 10.7 6500 66 32 2 25 11.1 NIL NIL NAD NIL NIL NAD 
2. 50813 7300 70 27 3 30 12.4 7100 73 25 2 8 12.9 NIL NIL NAD NIL NIL NAD 
3. 51145 9600 68 27 5 53 10.5 7500 69 28 3 10 10.9 TRACE NIL 3-8  pus cells NAD NIL 1-2  pus cells 
4. 51887 8800 66 30 4 28 8.2 9600 71 27 2 7 11.9 TRACE NIL 10-15pus cells NIL NIL 1-2 pus cells 
5. 53806 9300 69 26 5 52 11.1 9500 72 25 3 25 11.0 NIL NIL NAD NIL NIL NAD 
6 56271 7400 69 29 2 35 13.5 7300 73 26 1 10 11.8 NIL NIL NAD NIL NIL NAD 
7. 60797 7400 65 29 6 45 12.0 7000 60 38 2 8 12.8 NIL NIL NIL NAD NIL NIL 
8. 70311 7900 78 19 3 50 9.4 7500 64 33 3 9 9.5 NIL NIL 1-2  epi.cells NIL NIL NAD 
9. 71246 8900 68 28 4 40 11.4 8700 70 27 3 17 11.3 NIL NIL NAD NIL NIL NAD 
10. 74409 7800 58 36 6 26 12.8 7900 66 32 2 6 13.2 NIL NIL NAD NIL NIL NAD 
11 74892 7300 56 38 6 80 10.5 7400 64 32 4 42 11.8 TRACE NIL 2-3 epi .cells NIL NIL NAD 
12. 75542 9900 67 30 3 50 12.7 9700 70 28 2 9 12.6 NIL NIL Few pus cells NIL NIL NAD 
13. 75545 7600 64 33 3 45 6.8 7800 67 31 2 7 7.0 NIL NIL NAD NIL NIL NAD 
14 75662 7300 57 40 3 58 12.1 7800 60 36 4 22 13.0 NIL NIL NAD NIL NIL NAD 
15. 77398 6000 58 40 2 50 13.8 6400 68 30 2 9 14.3 NIL NIL NAD NIL NIL NAD 
16. 95880 8600 66 31 3 44 14.3 8500 71 27 2 8 13.9 NIL NIL Few  pus cells NIL NIL NAD 
17 9175 8500 62 31 7 38 9.7 8300 68 28 4 7 10.6 NIL NIL NAD NIL NIL NAD 
18 14488 6800 60 36 4 65 10.9 5400 68 29 3 27 12.8 NIL NIL NAD NIL NIL NAD 
19 16486 8900 63 29 8 55 10.4 8600 70 27 3 19 11.4 NIL NIL NAD NIL NIL NAD 
20 40744 7800 68 28 4 62 11.4 7600 72 25 3 24 11.2 NIL NIL 1-2 puscells NIL NIL NAD 
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TABLE-24(a) 
ii). LABORATORY INVESTIGATION (OUT PATIENTS) 
 
SI 
NO 
OP 
NO 
BEFORE TREATMENT AFTER TREATMENT 
Blood 
sugar(R) 
Blood 
Urea 
Serum 
cholestrol 
Serum 
creatinine 
Blood 
sugar(R) 
Blood 
Urea 
Serum 
cholesterol 
Serum 
creatinine 
1 50264 97 25 179 0.6 74 21 156 0.7 
2 50813 84 25 213 1.0 66 30 180 0.8 
3 51145 74 16 291 0.8 84 16 140 0.7 
4 51887 123 10 169 0.6 87 28 143 0.6 
5 53806 138 20 200 0.5 125 23 187 0.6 
6 56271 85 27 157 0.9 76 24 130 0.8 
7 60797 109 27 169 0.7 89 24 161 0.5 
8 70311 122 14 186 0.7 82 20 179 0.8 
9 71246 160 24 187 0.5 98 25 156 0.7 
10 74409 98 24 131 1.0 72 26 124 0.8 
11 74892 130 26 187 0.9 119 24 196 1.0 
12 75542 182 28 170 0.8 154 26 148 0.9 
13 75545 104 26 167 0.5 94 25 156 0.7 
14 75662 250 24 196 1.0 208 20 180 0.9 
15 77398 86 32 168 0.8 92 34 155 0.6 
16 95880 64 15 166 1.0 67 23 148 0.9 
17 9175 90 16 171 0.6 92 21 136 0.5 
18 14488 108 25 148 0.6 100 23 140 0.6 
19 16486 135 18 167 0.7 84 22 178 0.5 
20 40744 102 20 201 0.8 96 26 160 0.7 
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Table-24(a) 
iii). LABORATORY INVESTIGATIONS (OUT PATIENTS) 
SI 
NO 
OP  
NO 
BEFORE TREATMENT AFTER TREATMENT 
RA 
Factor 
(IU/ml) 
ASO 
Titre 
(IU/ml) 
CRP 
(mg/dl) 
Anti –CCP 
(U/ml) 
RA  
Factor 
(IU/ml) 
ASO 
Titre 
(IU/ml) 
CRP 
(mg/dl) 
Anti –CCP 
(IU/ml) 
1. 50264 152.0 97.5 8.0 - 145 85.4 7.2 - 
2. 50813 45 90.4 5.3 - 42.0 78.8 4.7 - 
3. 51145 85.1 182 6.3 - 73.8 167.3 5.9 - 
4. 51887 40.0 78.4 4.9 - 36.7 66.8 3.5 - 
5. 53806 76.2 95.8 53.56 - 72.6 91.5 50.4 - 
6 56271 22.4 69.3 4.0 - 17.5 54 2.9 - 
7. 60797 52.0 114.7 6.8 26.9 48.2 103 5.7 24.3 
8. 70311 35.7 135 3.5 - 26.8 124.5 2.6 - 
9. 71246 63.6 65 6.2 - 58.3 61 5.7 - 
10. 74409 25.9 63.5 4.2 - 20.4 57 3.9 - 
11 74892 180 240 28.0 40.73 175.3 233.6 6.2 39.16 
12. 75542 65.5 172 5.3 - 59.4 165 4.5 - 
13. 75545 30.0 83.7 2.6 - 26.2 62 1.8 - 
14 75662 68.9 54 36.0 73.18 61.5 46 27.3 72.4 
15. 77398 39.25 70.6 6.7 - 34.4 58.2 5,4 - 
16. 95880 40.0 124 5.9 - 32.9 113 4.3 - 
17 9175 30.9 115 3.7 - 26.3 102 2.5 - 
18 14488 52.0 153 9.6 - 47.6 147.2 9.1 - 
19 16486 101.7 88.5 5.9 - 70.4 74 4.8 - 
20 40744 163.7 140.7 6.9 - 157.5 126.4 5.7 - 
Reference range: 
Rheumatoid factor  : Upto 20 IU/ml  ASO titre : Upto 200 IU/ml 
CRP  : Upto 6 mg/dl    Anti –CCP  : Upto 20 U/ml 
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TABLE-24 (b)  i). LABORATORY INVESTIGATION OF IN PATIENTS 
SI. 
 
NO 
IP 
 
NO 
HAEMATOLOGICAL REPORT 
 
URINE   ANALYSIS 
BEFORE TREATMENT AFTER TREATMENT BEFORE TREATMENT AFTER TREATMENT 
 
TC 
DC 
ESR 
(1hr) 
Hb 
gms   
% 
TC 
 
DC 
ESR 
(1hr) 
Hb 
gms   
% 
Alb Sug 
Dep – 
Epi cells/ 
Pus cells 
Alb Sug 
Dep – 
Epi cells/ 
Pus cells 
P L E P L E 
1. 1681 6500 62 31 7 70 10.7 6700 68 29 3 55 10.9 NIL NIL 1-2pus cells NIL NIL NAD 
2. 1732 6900 65 30 5 26 11.1 7300 70 28 2 9 11.8 NIL NIL NAD NIL NIL NAD 
3. 1761 6700 65 31 4 30 12.0 7800 59 38 3 11 14.7 NIL NIL NAD NIL NIL NAD 
4. 2242 7800 60 36 4 30 10.6 7000 71 26 3 8 11.1 NIL NIL Few puscells NIL NIL NAD 
5. 2246 9900 78 19 3 24 9.4 9800 74 25 1 7 11.5 NIL NIL NAD NIL NIL NAD 
6 2350 8500 50 40 10 52 10.2 8700 57 38 5 15 10.9 NIL NIL NAD NIL NIL NAD 
7. 2550 5900 63 33 4 20 9.0 6000 58 40 2 6 9.3 NIL NIL NAD NIL NIL NAD 
8. 2661 7000 62 36 2 23 10.2 7300 64 35 1 7 10.3 Trace NIL 5-6pus cells NIL NIL 1-3pus cells 
9. 2685 8100 60 35 5 72 9.9 7000 65 31 4 40 10.8 NIL NIL NAD NIL NIL NAD 
10. 3189 8000 66 30 4 21 10.6 6200 58 38 4 6 12.1 NIL NIL NAD NIL NIL NAD 
11 183 10600 77 15 8 28 12.1 10500 69 28 3 8 12.0 NIL NIL NAD NIL NIL NAD 
12. 255 11200 72 25 3 23 11.2 8700 70 28 2 9 12.5 NIL NIL 1-2 pus cells NIL NIL NAD 
13. 274 8100 70 26 4 20 8.4 7700 69 28 3 9 8.6 NIL NIL NAD NIL NIL NAD 
14 285 7500 62 36 2 39 11.2 7400 64 34 2 12 10.9 NIL NIL Few pus cells NIL NIL NAD 
15. 530 7000 55 40 5 35 10.3 7300 60 37 3 10 10.1 NIL NIL NAD NIL NIL NAD 
16. 537 9600 65 30 5 22 10.8 9400 63 35 2 10 10.6 NIL NIL NAD NIL NIL NAD 
17 542 7300 64 32 4 78 10.3 8600 70 28 2 21 10.9 NIL NIL NAD NIL NIL NAD 
18 617 6000 71 27 2 28 10.6 6400 70 29 1 7 10.5 NIL NIL NAD NIL NIL NAD 
19 651 8400 60 32 8 34 14.0 8600 66 31 3 9 13.8 NIL NIL Few pus cells NIL NIL NAD 
20 1106 9200 67 27 6 90 10.4 6400 66 30 4 24 10.9 NIL NIL NAD NIL NIL NAD 
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Table. 24 (b) 
ii). LABORATORY INVESTIGATION (IN PATIENTS) 
SI 
NO 
IP 
NO 
BEFORE TREATMENT AFTER TREATMENT 
Blood 
sugar(R) 
Blood 
Urea 
Serum 
cholestrol 
Serum 
creatinine 
Blood 
sugar(R) 
Blood 
Urea 
Serum 
cholestrol 
Serum 
creatinine 
1. 1681 85 15 248 0.6 97 21 204 0.7 
2. 1732 88 20 203 0.8 78 32 170 0.8 
3. 1761 102 18 199 0.9 114 25 182 0.8 
4. 2242 129 17 224 0.8 118 21 145 0.7 
5. 2246 82 14 186 0.7 100 38 150 0.6 
6. 2350 88 28 162 0.7 95 25 148 0.8 
7. 2550 118 12 258 0.8 72 23 106 0.9 
8. 2661 175 27 237 0.9 140 28 187 0.7 
9. 2685 94 17 187 0.9 91 28 150 0.7 
10. 3189 100 20 186 0.5 108 31 142 0.6 
11. 183 119 15 195 1.2 110 26 153 0.9 
12. 255 156 21 220 0.4 130 26 203 0.6 
13. 274 111 34 207 1.1 103 24 152 0.9 
14. 285 136 21 204 0.7 118 31 163 0.8 
15. 530 76 25 218 0.9 92 30 180 0.7 
16. 537 128 23 230 0.6 112 28 172 0.9 
17. 542 171 17 161 0.8 126 19 146 0.6 
18. 617 118 19 200 0.7 106 26 139 0.8 
19. 651 94 19 162 0.6 115 34 142 0.7 
20. 1106 125 20 200 0.7 100 18 165 0.6 
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Table 24(b) 
iii). LABORATORY INVESTIGATIONS (IN PATIENTS) 
SI 
NO 
IP 
NO 
BEFORE TREATMENT AFTER TREATMENT 
RA 
Factor 
(IU/ml) 
ASO 
Titre 
(IU/ml) 
CRP 
(mg/dl) 
Anti –CCP 
(IU/ml) 
RA 
Factor 
(IU/ml) 
ASO 
Titre 
(IU/ml) 
CRP 
(mg/dl) 
Anti – CCP 
(IU/ml) 
1. 1681 285 197 12.7 64 292.6 186 12.3 63 
2. 1732 39.2 65.2 4.3 - 30.8 63 2.9 - 
3. 1761 53 72.4 7.1 - 46.7 68.4 6.5 - 
4. 2242 25.9 80.7 3.2 - 19.5 76.4 2.9 - 
5. 2246 22.1 126.4 2.6 - 16.8 118.3 2.4 - 
6 2350 68.29 213.5 20.1 32.40 61.0 176 17.6 30.8 
7. 2550 30.34 138.91 14.6 - 24,5 129.80 13.5 - 
8. 2661 20.0 96.2 2.4 - 16.4 93.0 2.1 - 
9. 2685 449 98 9.7 - 454 94 8.5 - 
10. 3189 26.0 79.6 2.9 - 14.3 71.2 2.0 - 
11 183 24.8 65.4 2.8 - 16.7 60.3 2.3 - 
12. 255 48.0 84.3 4.1 - 45.2 79.8 3.5 - 
13. 274 36.2 107 3.7 - 34.6 102 3.5 - 
14 285 37.3 89.4 3.4 - 34.8 74 2.8 - 
15. 530 30.0 76.7 16.4 - 26.3 62.0 14.7 - 
16. 537 27.6 88.2 3.2 - 23.2 82.4 2.9 - 
17 542 166.0 114.2 56.0 - 160.2 93 53.8 - 
18 617 22.7 65.7 1.9 - 18.3 61.5 1.5 - 
19 651 29.6 76 2.5 - 21.7 72.1 2.3 - 
20 1106 110.3 93.2 5.6 - 95.2 90.8 4.7 - 
Reference range: 
Rheumatoid factor  : Upto 20 IU/ml  ASO titre : Upto 200 IU/ml 
CRP  : Upto 6 mg/dl    Anti –CCP  : Upto 20 U/ml 
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TABLE 25(a) 
DISEASE ACTIVITY PAIN SCORE (OUT PATIENTS) 
SI 
NO 
OP NO 
Before Treatment After Treatment 
TJC 
28 
SJC 
28 
ESR 
mm/hr 
VAS 
DAS 
28 
TJC       
28 
SJC 
28 
ESR 
mm/hr 
VAS 
DAS 
28 
1. 50264 13 11 70 60 6.77 6 4 25 30 4.61 
2. 50813 12 9 30 50 5.87 4 2 8 10 3.11 
3. 51145 17 14 53 60 6.98 8 3 10 20 3.96 
4. 51887 9 8 28 40 5.37 3 2 7 10 2.87 
5. 53806 24 15 52 70 7.58 13 8 25 30 5.48 
6 56271 10 8 35 40 5.62 3 2 10 10 3.12 
7. 60797 11 9 45 50 6.07 4 3 8 10 3.2 
8. 70311 10 8 50 70 6.29 3 2 9 20 3.18 
9. 71246 12 8 40 50 6.02 6 5 17 10 4.12 
10. 74409 12 10 26 40 5.67 3 2 6 10 2.76 
11 74892 26 20 80 80 8.3 17 12 42 40 6.46 
12. 75542 13 8 50 60 6.39 4 2 9 10 3.19 
13. 75545 12 9 45 50 6.15 3 3 7 10 2.96 
14 75662 16 9 58 50 6.62 10 4 22 20 4.77 
15. 77398 14 11 50 60 6.61 4 2 9 10 3.19 
16. 95880 13 8 44 50 6.16 4 2 8 10 3.11 
17 9175 11 9 38 50 5.95 3 2 7 10 2.87 
18 14488 25 18 65 70 7.9 16 10 27 30 5.85 
19 16486 14 13 55 60 6.76 9 6 19 20 4.71 
20 40744 20 15 62 70 7.46 9 7 24 30 5.07 
 
Interpretation: 
Low disease activity  2.6 < DAS 28 ≤ 3.2            
Moderate disease activity 3.2 < DAS 28
 ≤ 5.1    
High disease  activity DAS 28>5.1 
Reference range   ESR 5-15mm / hr.  
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TABLE  25 
(b) DISEASE ACTIVITY PAIN SCORE (IN PATIENTS) 
SI 
NO 
IP 
NO 
Before Treatment After Treatment 
TJC 
28 
SJC 
28 
ESR 
mm/hr 
VAS 
DAS 
28 
TJC       
28 
SJC 
28 
ESR 
mm/hr 
VAS 
DAS 
28 
1. 1681 25 23 70 80 8.25 14 10 55 40 6.35 
2. 1732 12 8 26 50 5.72 4 2 9 10 3.19 
3. 1761 24 8 30 60 6.76 12 5 11 20 4.52 
4. 2242 10 9 30 60 5.84 3 2 8 10 2.96 
5. 2246 12 8 24 60 5.8 3 3 7 20 3.1 
6 2350 13 12 52 70 6.74 6 5 15 20 4.17 
7. 2550 14 7 20 60 5.78 4 3 6 20 3.14 
8. 2661 13 9 23 50 5.76 4 2 7 10 3.02 
9. 2685 27 25 72 90 8.58 15 12 40 50 6.43 
10. 3189 8 7 21 60 5.3 3 2 6 10 2.76 
11 183 10 7 28 60 5.69 4 3 8 10 3.2 
12. 255 9 6 23 50 5.27 3 3 9 10 3.13 
13. 274 12 7 20 60 5.62 3 2 9 20 3.18 
14 285 14 10 39 60 6.39 7 4 12 20 4.06 
15. 530 16 9 35 60 6.41 8 3 10 20 3.96 
16. 537 9 6 22 60 5.38 3 2 10 10 3.12 
17 542 20 15 78 80 7.77 9 7 21 30 4.97 
18 617 8 6 28 50 5.31 4 2 7 10 3.02 
19 651 9 7 34 70 5.88 3 2 9 20 3.18 
20 1106 18 13 90 70 7.52 8 6 24 30 4.92 
 
Interpretation: 
Low disease activity  2.6 < DAS 28 ≤ 3.2            
Moderate disease activity  3.2 < DAS 28 ≤ 5.1    
High disease  activity DAS 28>5.1 
Reference range  ESR 5-15mm / hr   
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TABLE-26 
(a) CASE SUMMARY - OUT PATIENTS 
SI 
NO 
OP 
 
NO 
Name 
Age/ 
Sex 
Occupation 
Duration 
of          
Illness 
DOA DOD 
Total 
Days 
Results 
1. 50264 Eswari 38/F Beedi worker 4 Years 13.6.18 13.7.18 30 Moderate 
2. 50813 Mariyappan 45/M Driver 1 Year 15.6.18 15.7.18 30 Good 
3. 51145 Beaula 35/F Teacher 8 Months 16.6.18 16.7.18 30 Moderate 
4. 51887 Dhanalakshmi 41/F Housewife 
1 ½ 
years 
19.6.18 19.7.18 30 Good 
5. 53806 Kanjana 46/F Housewife 1 Year 26.6.18 26.7.18 30 Poor 
6 56271 Selvi 43/F Housewife 5 Years 5.7.18 5.8.18 30 Good 
7. 60797 Elango 36/M Teacher 
1 ½ 
Years 
21.7.18 21.8.18 30 Good 
8. 70311 Lincy 42/F Housewife 7 Years 24.8.18 24.9.18 30 Good 
9. 71246 Gomathi 38/F Housewife 6 Years 27.8.18 27.9.18 30 Moderate 
10. 74409 Muthulakshmi 28/F Beedi  worker 1 Year 7.9.18 7.10.18 30 Good 
11 74892 Fathima 39/F Beedi  worker 5 Years 8.9.18 8.10.18 30 Poor 
12. 75542 
Joseph 
Thangaraj 39/M Business 5 Months 11.9.18 11.10.18 30 Good 
13. 75545 Maragatham 23/F Housewife 1 Year 11.9.18 11.10.18 30 Good 
14 75662 Indhira 42/F Housewife 8 Months 11.9.18 11.10.18 30 Moderate 
15. 77398 
Bala 
Subramaniaan 
45/M 
Agricultural 
labour 
2 Years 18.9.18 18.10.18 30 Good 
16. 95880 Chella durai 45/M 
Agriculture 
labour 
6 Months 20.11.18 20.12.19 30 Good 
17 9175 Shanmuga Devi 29/F Housewife 4 Years 24.1.19 24.2.19 30 Good 
18 14488 Mydheen Fathu 31/F Housewife 2 Years 8.2.19 10.3.19 30 Poor 
19 16486 Petchiyammal 44/F 
Agricultural 
labour 
3 Years 14.2.19 16.3.19 30 Moderate 
20 40744 Kaaliyammal 42/F Housewife 4 Years 3.5.19 3.6.19 30 Moderate 
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TABLE-26 
(b) CASE SUMMARY - IN PATIENTS 
SI 
NO 
IP NO Name 
Age/ 
Sex 
Occupation 
Duration       
of Illness 
DOA DOD 
Total 
Days Total  
days 
Results 
IP OP 
1. 1681 S.Pappa 47/F Housewife 6 Months 2.7.18 2.8.18 30 - 30 Poor 
2. 1732 Salomi 36/F Coolie 1 Year 6.7.18 6.8.18 30 - 30 Good 
3. 1761 Michealammal 49/F Housewife 2 Years 11.7.18 11.8.18 30 - 30 Moderate 
4. 2242 Ramalakshmi 42/F 
Agricultural 
labour 
5 Months 1.9.18 1.10.18 30 - 30 Good 
5. 2246 C.Madaththi 40/F Coolie 7 Years 1.9.18 1.10.18 30 - 30 Good 
6 2350 Jeyasakthi 26/F Sales women 8 Years 17.9.18 18.10.18 30 - 30 Moderate 
7. 2550 Rathika 28/F Housewife 6 Months 11.10.18 15.11.18 30 - 30 Good 
8. 2661 Poomani 45/F 
Agricultural 
labour 
2 Years 29.10.18 1.12.18 30 - 30 Good 
9. 2685 Lakshmi 42/F 
Agricultural 
labour 
4 Years 2.11.18 28.12.18 25 5 30 Poor 
10. 3189 
Mydeen 
Nachiyar 
40/F Housewife 5 Months 29.12.18 27.1.19 30 - 30 Good 
11 183 Subramanian 45/M 
Agricultural 
labour 
4 Months 29.1.19 1.3.19 30 - 30 Good 
12. 255 R.Pappa 43/F Housewife 2 Years 5.2.19 7.3.19 30 - 30 Good 
13. 274 Pichumani 46/M Watchman 2 Years 7.2.19 9.3.19 30 - 30 Good 
14 285 S.Madaththi 45/F Housewife 5 Months 8.2.19 10.3.19 30 - 30 Moderate 
15. 530 Eswari 43/F 
Agricultural 
labour 
5 Years 1.3.19 3.4.19 30 - 30 Moderate 
16. 537 Jeyalakshmi 47/F Housewife 9 Months 2.3.19 4.4.19 30 - 30 Good 
17 542 Pitchaammal 44/F Sales women 3 Years 2.3.19 3.4.19 30 - 30 Moderate 
18 617 Kuruvammal 40/F Housewife 1 Year 9.3.19 10.4.19 30 - 30 Good 
19 651 Maduraiveeran 47/M Coolie 2 Years 13.3.19 15.4.19 30 - 30 Good 
20 1106 Rejina Mary 41/F Housewife 3 Years 1.5.19 3.6.19 30 - 30 Moderate 
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4.3 Bio –Statistical Analysis: 
                   Statistical analysis has shown DAS 28 score among OP & IP was found to 
be highly significant at P < 0.01 from  Statistical analysis is done using students’s 
Paired ‘t’ test  using SPSS Software.The  results were expressed as Mean, Standard 
Deviation, ‘t’ value and P values < 0.01 was considered as statistically significant. 
 
Out patients - DAS 28 Score  comparison through statistical analysis  
SI. 
No 
Parameters Mean 
Standard 
Deviation 
t value P value Results 
1. Before Treatment 6.5270 0.78874 
22.232 < 0.01 Significant 
2. After  Treatment 3.9295 1.13210 
  
In patients - DAS 28 Score  comparison through statistical analysis  
SI. 
No 
Parameters Mean 
Standard 
Deviation 
t value P value Results 
1. Before Treatment 6.2885 1.00868 
43.819 < 0.01 Significant 
2. After Treatment 3.8190 1.10324 
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CHAPTER-V 
DISCUSSION 
Vali Azhal Keel Vayu, described in Sabapathy manuscript is nearly correlated 
in modern science with Rheumatoid Arthritis (RA). In this clinical trial study totally 
40 patients were selected, 20 were treated as Out patient and 20 were treated as In 
patients with clinical trial drug ‘NANNARI VER OORAL KUDINEER’. 
Professor, Associate Professor, Lecturers of the Department of Pothu 
Maruthuvam had supervised the entire clinical study, its observation and results. 
The observed results were discussed below: 
1.Sex Distribution: 
Among 20 Out patients 25% were Male and 75% were Female. 
Among 20 In patients, 15% were Male and 85% were Female.   
2.Age Distribution: 
It is observed that the highest incidence of Vali Azhal Keel Vayu in Out 
patients is among the age group of 41 to 50 with 50% and 31 to 40 with 35%, 15% 
were in the age group of 21 to 30 years. Among 20 In patients 10% were in the age 
group 21 to 30 years, 5% were in the age group of 31 to 40 years, 85% with the 
highest incidence in the age group of 41 to 50 years. 
 3.  Kaalam: 
Among 20 Out patients, 20% were affected in Vatha Kaalam and 80% were 
affected in Pitha Kaalam. Among 20 In patients, 90% were affected in Pitha Kaalam 
and 10% were affected in Vatha Kaalam. 
 4.  Constitution of body: 
Vatha Pitha Thegi register high incidence of Vali Azhal Keel Vayu  with 80% 
OP and 75% IP. Remaining Pitha Vatha Thegi of 20% OP and 25% IP. 
5. Gunam: 
Among 20 Out patients, 5% were Sathuva Gunam, 70% were Rajo gunam and    
25%  were  Thamasa  gunam .  
Among 20 In patients, 80% were Rajo gunam and 20% were Thamasa gunam. 
6.Religion: 
Among 20 Out patients, 75% were Hindus, 15% were Christians.10% were 
Muslims. Among 20 In patients, 80% were Hindus, 15% were Christians and 5% 
were Muslims . 
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7. Paruva Kaalam: 
Among 20 Out patients, 05% of cases were in Elavenil Kaalam, 30% of cases 
were in Muthuvenil Kaalam, 40% of cases were in Kaar Kaalam ,05% of cases were 
in Koothir Kaalam, 15% of cases were in Munpani Kaalam and 05% of cases were in 
Pinpani Kalam. 
Among 20 In patients, 05% of cases were in Elavenil Kaalam, 15% of cases 
were in Muthuvenil Kaalam ,20% of cases were in Kaar Kaalam, 10% of cases were 
in Koothir Kaalam, 25% of cases were in Munpani Kaalam and 25% of cases were in 
Pinpani Kalam. 
8. Thinai: 
Among 20 Out patients, 5% were from Kurinji, 15% were from Mullai, 75% 
were in Marutham  and  5% were in Neithal. 
Among 20 In patients, 70% were in Marutham, 20% were in Neithal ,10% 
were in Mullai,  
9. Socio – economical status: 
Among 20 Out patients, 15% were in Low income class, 60% were in Middle 
income class and 25% were in High income class. Among 20 In patients, 45% were in 
Low income class, 50% were in Middle income class and 5% were in High income 
class. 
10. Food habits: 
Among 20 Out patients, 35% were Vegetarian and 65% were non – 
vegetarian. 
           Among 20 In patients, 25% were vegetarian and 75% were non – vegetarian 
11. Family History: 
Among 20 Out patients, 15% have positive Family History and 85% don’t 
have any positive Family History. Among 20 In patients, 25% have positive Family 
History and 75% don’t have any positive Family History. 
12. Occupation: 
Among 20 Out patients, 15% Agricultural labours, 50% House Wife, 5%  
Driver, 15% Beedi worker, 5% Business and  10% Teacher. 
Among 20 In patients, 25% Agricultural labours, 15% Coolie, 45% House 
Wife, 5% Watchman, and 10% Sales women were observed. 
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13. Clinical Manifestation: 
Among 20 Out patients, 100% cases have arthritis involving more than 3 
joints, severe pain and swelling, symmetrical joint involvement, 100% have morning 
stiffness , 50% have depression, 30% have Anorexia, 10% have Rheumatoid nodules. 
Among 20 In patients, 100% cases have arthritis involving more than 3 joints, 
severe pain and swelling, symmetrical joint involvement, 100% have morning 
stiffness, 45% have depression, 15% have rheumatoid nodules, 20% have anorexia. 
14. Duration of Illness: 
Among 20 Out patients, Duration of Illness was 20% below 1 year, 30% in 1 
to2 years ,10% in 2 to 3 years, 5% in 3 to 4 years and 35% in above 4 years.  
Among 20 In patients, Duration of Illness was 35% below 1 year, 10% in 1 to 
2 years, 25% in 2 to 3 years and 10% in 3to 4 years,20% above 4 year. 
15. Kanmenthiriyam: 
Among 20 Out patients, 100% cases were affected in Kai, Kaal, 20% cases 
were affected in Eruvai. Among 20 In patients, 100% cases were affected in Kai, 
Kaal, 25% cases were affected in Eruvai. 
16. Gnanendrium: 
Among 20 Out patients, 100% of the patients were affected in Mei, 5% of the 
patients were affected in kan. 
Among 20 In patients, 100% of the patients were affected in Mei, 10% of the 
patients were affected in kan. 
17. Condition of Mukkutram: 
a) Condition of Vatham: 
Viyaanan, Samaanan, were affected in 100% of both Out patients and In 
patients. Abaanan was affected in 20% of Out patients, and 25% of the In patients, 
Kirugaran was affected in 25% of Out Patients, and 15% of In patients. Devathathan 
was affected in 100% of Out patients, and 100% of In patients. Koorman was affected 
in 5% of Out patients and 10% of In patients, 
b) Condition of Pitham: 
Among 20 Out patients, 25% affected in Anala Pitham, 50% in Ranjaga 
Pitham and 100% in Sathiga Pitham, 5% in Aalosaga pitham. Among 20 In patients, 
15% affected in Anala Pitham, 75% in Ranjaga Pitham and 100% in Sathiga Pitham, 
10% in Aalosaga pitham. 
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c) Condition of Kapham: 
Kilethagam was affected in 25% of Out patients and 15% of In  patients. 
Santhigam was affected in 100% of both Out patients and In patients 
18. Involvement of Udal Kattugal: 
Among 20 Out patients and In patients Saaram, Enbu,Kozhuppu, Moolai were 
affected in 100% of the cases. senneer was affected in 50% of OP and 75% of IP. 
19. Conditions of Envagai Thervugal: 
Among 20 Out patients, 5 % were affected in Vizhi, 20% were affected in 
Malam, 100% was affected in Sparisam, Naadi-80% with Vatha Pitham, 20% with 
Pitha Vatham. Among 20 In patients, 10% were affected in Vizhi, 25% was affected 
in Malam, 100% was affected in Sparisam, Naadi-75% with Vatha Pitham, and 25% 
with Pitha Vatham. 
20. Neer kuri: 
Niram was affected in 25% of Out patients and 30% of In patients. Nurai was 
affected in 5% of Out patients and 10% of In patients. 
21. Nei kuri: 
Among 20 Out patients, 80% had Vatha Neer, 20% had Pitha neer. Among 20 
In patients, 75% had Vatha Neer, 25% had Pitha Neer. 
22. Assessment of outcome: 
Before Treatment: 
Among 20 Out patients, and 20 In patients 100% of cases were with High 
disease activity. 
After Treatment: 
Among 20 Out patients, 55% of cases with Low disease activity 30% of cases 
with Moderate disease activity and 15% of cases with High disease activity. Among 
20 In patients, 60% of cases with Low disease activity, 30% of cases with Moderate 
disease activity and 10% of cases with High disease activity. 
Result : 
The before and after treatment mean value of DAS 28  score of Out Patients  
was respectively 6.5270 & 3.9295 ,In patients was 6.2885 & 3.8190. 
The before and after treatment standard deviation of DAS 28  score of Out 
Patients  was  respectively 0.78874 & 1.13210 ,In patients was  1.00868 & 1.10324. 
The ‘t’value of the DAS 28 Score of the OP & IP patients were 22.232,43.819. 
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That all the above details derived from biostatistical analysis showed that DAS 
28 Score is significant (P < 0.01) 
23. Gradation of results: 
Among 20 Out patients, 55% of cases showed Good response, 30% of cases 
showed Moderate response and 15% of cases showed Poor response.  Among 20 In 
patients, 60% of cases showed Good response, 30% of cases showed Moderate 
response and 10% of cases showed Poor response. 
All the 40 patients were treated with the clinical trial medicine  NANNARI 
VER OORAL KUDINEER  for 30 days. Thus, at the end of the result, the clinical 
trial drug showed good clinical improvement of the disease 
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CHAPTER-VI 
SUMMARY 
 
A Prospective open labelled phase II Non- randomized clinical study on 
‘VALI AZHAL KEEL VAYU’ with reference to its aetiology, pathogenesis, clinical 
features, diagnosis, investigations and treatment was conducted at Department of 
Pothu Maruthuvam, Government Siddha Medical College and Hospital, 
Palayamkottai.This clinical study was done on the basis of reference mentioned in 
Sabapathi manuscript in Noinadal, Noi mudhal naadal Thiratu Part-II, Pg.no.623. The 
disease can be correlated with Rhematioid arthritis. 
The trial drug chosen for the clinical study – NANNARI VER OORAL 
KUDINEER (Ref.Gunapadam (Mooligai Vaguppu) K.S.Murugesu Mudaliyar,Pg. 
no.562)  
The literature review of the disease were collected from a number of 
literatures both in Siddha system as well as in modern system of medicine. During the 
study, Out of 40 patients, 20 patients were admitted in the In patients ward and treated 
with trial medicine. Another twenty patients were treated in Out patients facility. 
Routine blood examinations, Urine analysis, other specific investigations and 
radiological investigations were done by modern scientific methods. The same 
methods were considered for diagnosis and further follow up of the patients.Siddha 
diagnosis was made with the aid of Ezhu Udal Kattugal, Envagai Thervugal and other 
important criterias belonging to 96 thathuvams.Since, Vali Azhal Keel Vayu is a 
chronic disease, it requires treatment for minimum thirty days to minimize the severe 
pain, tenderness and swelling with slight disappearance of stiffness. The patient was 
advised to follow up the treatment in Out patient Department. 
From this study, the following datas were collected.  
 Disease was more common in female than male.  
 Maximum incidence was in Pitha Kaalam.  
 Clinically marked reduction in the symptoms along with increased sense of 
well being 
 Decrease in ESR 
 Decrease in the DISEASE ACTIVITY PAIN SCORE OF 28 JOINTS was 
noted. 
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Bio-chemical analysis of NANNARI VER OORAL KUDINEER showed the 
presence of calcium, sulphate, ferrous iron, starch, amino acids and unsaturated 
compound. 
Anti- Microbial test shows   NANNARI VER OORAL KUDINEER  is highly  
sensitive to both gram positive and gram negative bacteria viz Staphylococcus 
aureus, E.coli  and  Klebsiella pneumoniae .           
Phytochemical analysis of NANNARI VER OORAL KUDINER showed the 
presence of flavonoids, carbohydrates, glycosides, phytosterols, alkaloids, tannis, 
proteins and lignin.  
The pharamacological evaluation of NANNARI VER OORAL KUDINEER 
showed significant anti inflammatory, analgesic and Immunomodulatory activity.  No 
toxicity effects were noted during the treatment.  
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CHAPTER-VII 
CONCLUSION 
The Sabapathy Manuscript has mentioned Vali Azhal Keel Vayu  under the 
main heading of keel vayu. Treatment was planned and given on the basis of  
Mukkutra & Suvai theories. In all cases, vitiation of vatha kutram was noticed. The 
trial medicine Nannari ver ooral kudineer has the taste of inippu.  
According to arusuvai theory, Inippu suvai has the ability to neutralize the  
vitiation of Vatham and Pitham. Thus the trial drug acts as effective agent in the 
reduction of pain and swelling.  
In pre-clinical studies, bio-chemical, phytochemical, pharmacological, anti-
microbial and toxicological studies were carried out and obtained relevant results. 
In all cases, considerable improvements were noticed after the trial. Reduction 
in pain and swelling along with improvement in joint flexibility was seen in majority 
of cases. So, I conclude that, NANNARI VER OORAL KUDINEER has improved 
the clinical symptoms of the RA and assured them a better standard of living. 
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ANNEXURE  - I 
PREPARATION AND PROPERTIES OF TRIAL MEDICINE 
ed;dhup Ntu; Cwy;; ; ;; ; ;; ; ; FbePu;P ;P ;P ; 
(Reference;-Gunapadam mooligai vaguppu,Pg.No .562, Dr K.S. Murugesa   
       Mudaliyar) 
ed;dhup  nghJFzk;:; ;; ;; ;   
ryNjhlk; gpj;jkjp jhfk; coiy 
ryNkW rPjkpd;dhH jQ;#-Lyfkjpw;  
nrhd;dkJ Nkfk; Gz;Rukpitna yhnkhopf;Fk; 
nkd;kJu ed;dhup NtH 
  ,jdhy; moy; Neha;> tz;Lfb> Nghk;. NkYk; ePNuw;wk;> 
ePu;Ntl;if>  tha;ePu;r;Rug;gp> Gzu;r;rpapd; #L> ePupopT> fpue;jp> RuNtl;if 
,it jzpAk;. 
TABLE: 1 Details of Hemidesmus Indicus  
Tamil 
Name 
Botanical 
Name 
Family Part 
Used 
Phyto 
chemicals 
Action 
Nannari Hemidesmus 
indicus 
Asclepiadiaceae Root Flavonoids, 
 Steroids,  
Terbinoides, 
Glycosides,  
Tannins,  
Triterbinoids 
Analgesic,  
Anti- Inflammatory, 
Immunomodulatory, 
Anti –Pyretic,  
Diuretic.  
 
PURIFICATION OF RAW DRUGS: 
The roots washed with pure water to remove the impurities and allowed it to 
dry. 
METHODS OF PREPARATION: 
            Fresh roots of Nannari were cleaned and dryed in shade then it made into 
coarse powder.10gms of powder added to 100ml of hot water and waited for one hour 
till the powder infuse and then filtered it. 
Dose           : 90 ml (Thrice a day) 
Duration    : 30 days 
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PREPARATION OF NANNARI VER OORAL KUDINEER 
 
                 
         Dried Roots                                             Kudineer  Chooranam 
 
 
 
 
 
 
 
 
 
 
 
                                            Nannari Ver Ooral Kudineer 
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                ANNEXURE  - II 
                    DEFORMITIES   OBSERVED  IN THE PATIENTS 
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